JP2019505558A - 6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド化合物 - Google Patents
6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド化合物 Download PDFInfo
- Publication number
- JP2019505558A JP2019505558A JP2018544154A JP2018544154A JP2019505558A JP 2019505558 A JP2019505558 A JP 2019505558A JP 2018544154 A JP2018544154 A JP 2018544154A JP 2018544154 A JP2018544154 A JP 2018544154A JP 2019505558 A JP2019505558 A JP 2019505558A
- Authority
- JP
- Japan
- Prior art keywords
- pyrazolo
- dihydro
- oxazine
- carboxamide
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 6,7-Dihydro-5H-pyrazolo [5,1-b] [1,3] oxazine-2-carboxamide compound Chemical class 0.000 title claims description 191
- 150000001875 compounds Chemical class 0.000 claims abstract description 206
- 150000003839 salts Chemical class 0.000 claims abstract description 65
- 238000000034 method Methods 0.000 claims abstract description 43
- 101000988424 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4B Proteins 0.000 claims abstract description 41
- 102100029168 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Human genes 0.000 claims abstract description 41
- 238000011282 treatment Methods 0.000 claims abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 67
- 125000001072 heteroaryl group Chemical group 0.000 claims description 67
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 67
- 108010029485 Protein Isoforms Proteins 0.000 claims description 55
- 102000001708 Protein Isoforms Human genes 0.000 claims description 55
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 49
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 46
- 229910052757 nitrogen Inorganic materials 0.000 claims description 44
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 36
- 125000001424 substituent group Chemical group 0.000 claims description 36
- QMOPFHQOZKALTC-ZETCQYMHSA-N (6S)-3-(4-chloro-2,5-difluorophenyl)-N-cyclopropyl-6-fluoro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound ClC1=CC(=C(C=C1F)C=1C(=NN2C=1OC[C@H](C2)F)C(=O)NC1CC1)F QMOPFHQOZKALTC-ZETCQYMHSA-N 0.000 claims description 32
- 229910052736 halogen Inorganic materials 0.000 claims description 31
- 239000001257 hydrogen Substances 0.000 claims description 30
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- 150000002367 halogens Chemical class 0.000 claims description 29
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 23
- 229910052799 carbon Inorganic materials 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- 125000004043 oxo group Chemical group O=* 0.000 claims description 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 14
- 125000004076 pyridyl group Chemical group 0.000 claims description 13
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 11
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 125000001153 fluoro group Chemical group F* 0.000 claims description 11
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 11
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 10
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 9
- 201000000980 schizophrenia Diseases 0.000 claims description 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 8
- 125000002393 azetidinyl group Chemical group 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 7
- GRFHQTKEAOBDST-NSHDSACASA-N ClC1=CC(=C(C=C1)C=1C(=NN2C=1OC[C@H](C2)F)C(=O)NC1CC1)C Chemical compound ClC1=CC(=C(C=C1)C=1C(=NN2C=1OC[C@H](C2)F)C(=O)NC1CC1)C GRFHQTKEAOBDST-NSHDSACASA-N 0.000 claims description 7
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 7
- 125000001425 triazolyl group Chemical group 0.000 claims description 7
- RQCIGHZUMYJCCJ-UHFFFAOYSA-N 3-(4-cyano-3-fluorophenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound C(#N)C1=C(C=C(C=C1)C=1C(=NN2C=1OCCC2)C(=O)NC1CC1)F RQCIGHZUMYJCCJ-UHFFFAOYSA-N 0.000 claims description 6
- 101001098805 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4A Proteins 0.000 claims description 6
- 102100037092 cAMP-specific 3',5'-cyclic phosphodiesterase 4A Human genes 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 125000002883 imidazolyl group Chemical group 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 6
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 6
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 6
- 208000011117 substance-related disease Diseases 0.000 claims description 6
- KXLPTRRQYABNIU-UHFFFAOYSA-N 3-(4-chloro-2-methylphenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Cc1cc(Cl)ccc1-c1c2OCCCn2nc1C(=O)NC1CC1 KXLPTRRQYABNIU-UHFFFAOYSA-N 0.000 claims description 5
- 101000988423 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4C Proteins 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims description 5
- 102100029169 cAMP-specific 3',5'-cyclic phosphodiesterase 4C Human genes 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 125000002971 oxazolyl group Chemical group 0.000 claims description 5
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims description 4
- RQKJDWFZSBVQSW-UHFFFAOYSA-N 3-(4-chloro-2-methylphenyl)-N-cyclopropyl-6,6-difluoro-5,7-dihydropyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Cc1cc(Cl)ccc1-c1c2OCC(F)(F)Cn2nc1C(=O)NC1CC1 RQKJDWFZSBVQSW-UHFFFAOYSA-N 0.000 claims description 4
- GYVJFOZZFFIUSZ-UHFFFAOYSA-N 3-(4-chlorophenyl)-N-cyclopropyl-5-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound CC1CCn2nc(C(=O)NC3CC3)c(c2O1)-c1ccc(Cl)cc1 GYVJFOZZFFIUSZ-UHFFFAOYSA-N 0.000 claims description 4
- ZTEOJNWIHZBBMB-UHFFFAOYSA-N 3-(4-chlorophenyl)-N-cyclopropyl-7-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound CC1CCOc2c(c(nn12)C(=O)NC1CC1)-c1ccc(Cl)cc1 ZTEOJNWIHZBBMB-UHFFFAOYSA-N 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- BLUWLSQGJDRYLP-UHFFFAOYSA-N azetidin-1-yl-[3-(4-chloro-2-methylphenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound Cc1cc(Cl)ccc1-c1c2OCCCn2nc1C(=O)N1CCC1 BLUWLSQGJDRYLP-UHFFFAOYSA-N 0.000 claims description 4
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 150000003857 carboxamides Chemical class 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- MJHYQMWSWMXYQH-UHFFFAOYSA-N 3-(4-cyano-5-fluoro-2-methylphenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound C(#N)C1=CC(=C(C=C1F)C=1C(=NN2C=1OCCC2)C(=O)NC1CC1)C MJHYQMWSWMXYQH-UHFFFAOYSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- HGOQXTQGKPHGEY-UHFFFAOYSA-N azetidin-1-yl-[3-(4-chloro-2,3-difluorophenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound N1(CCC1)C(=O)C1=NN2C(OCCC2)=C1C1=C(C(=C(C=C1)Cl)F)F HGOQXTQGKPHGEY-UHFFFAOYSA-N 0.000 claims description 3
- LTQPXIUEDFTWNR-UHFFFAOYSA-N azetidin-1-yl-[3-(4-chloro-2,5-difluorophenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound N1(CCC1)C(=O)C1=NN2C(OCCC2)=C1C1=C(C=C(C(=C1)F)Cl)F LTQPXIUEDFTWNR-UHFFFAOYSA-N 0.000 claims description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 3
- 125000001041 indolyl group Chemical group 0.000 claims description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- CICKNGAWODWCEX-NSHDSACASA-N (6S)-3-(4-cyano-5-fluoro-2-methylphenyl)-N-cyclopropyl-6-fluoro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Cc1cc(C#N)c(F)cc1-c1c(nn2C[C@H](F)COc12)C(=O)NC1CC1 CICKNGAWODWCEX-NSHDSACASA-N 0.000 claims 2
- HXVNESZNUYSKMT-UHFFFAOYSA-N 4-[2-(azetidine-1-carbonyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl]-2-fluoro-5-methylbenzonitrile Chemical compound Cc1cc(C#N)c(F)cc1-c1c2OCCCn2nc1C(=O)N1CCC1 HXVNESZNUYSKMT-UHFFFAOYSA-N 0.000 claims 2
- DJQNRDCGWWXDHA-SECBINFHSA-N (6R)-3-(4-chloro-5-fluoro-2-methylphenyl)-N-cyclopropyl-6-fluoro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Cc1cc(Cl)c(F)cc1-c1c(nn2C[C@@H](F)COc12)C(=O)NC1CC1 DJQNRDCGWWXDHA-SECBINFHSA-N 0.000 claims 1
- NXQIEDDZYQXLGS-LLVKDONJSA-N (6R)-3-(4-chlorophenyl)-N-cyclopropyl-6-fluoro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound F[C@H]1COc2c(c(nn2C1)C(=O)NC1CC1)-c1ccc(Cl)cc1 NXQIEDDZYQXLGS-LLVKDONJSA-N 0.000 claims 1
- CICKNGAWODWCEX-LLVKDONJSA-N (6R)-3-(4-cyano-5-fluoro-2-methylphenyl)-N-cyclopropyl-6-fluoro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Cc1cc(C#N)c(F)cc1-c1c(nn2C[C@@H](F)COc12)C(=O)NC1CC1 CICKNGAWODWCEX-LLVKDONJSA-N 0.000 claims 1
- NXQIEDDZYQXLGS-NSHDSACASA-N (6S)-3-(4-chlorophenyl)-N-cyclopropyl-6-fluoro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound F[C@@H]1COc2c(c(nn2C1)C(=O)NC1CC1)-c1ccc(Cl)cc1 NXQIEDDZYQXLGS-NSHDSACASA-N 0.000 claims 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 claims 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 claims 1
- PHRSCPGZAINQTD-UHFFFAOYSA-N 2H-1,3-oxazine-2-carboxamide Chemical compound O1C(N=CC=C1)C(=O)N PHRSCPGZAINQTD-UHFFFAOYSA-N 0.000 claims 1
- LGFLTCBFNXDCLY-UHFFFAOYSA-N 3-(3-chloro-4-fluorophenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Fc1ccc(cc1Cl)-c1c2OCCCn2nc1C(=O)NC1CC1 LGFLTCBFNXDCLY-UHFFFAOYSA-N 0.000 claims 1
- GBWMEFKBLUNZIM-UHFFFAOYSA-N 3-(3-chlorophenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Clc1cccc(c1)-c1c2OCCCn2nc1C(=O)NC1CC1 GBWMEFKBLUNZIM-UHFFFAOYSA-N 0.000 claims 1
- FGOAWTXGIORNAM-UHFFFAOYSA-N 3-(4-chloro-2,3-difluorophenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Fc1c(Cl)ccc(-c2c3OCCCn3nc2C(=O)NC2CC2)c1F FGOAWTXGIORNAM-UHFFFAOYSA-N 0.000 claims 1
- WYSBJUKHVQZOHC-UHFFFAOYSA-N 3-(4-chloro-2,5-difluorophenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Fc1cc(-c2c3OCCCn3nc2C(=O)NC2CC2)c(F)cc1Cl WYSBJUKHVQZOHC-UHFFFAOYSA-N 0.000 claims 1
- MYPOVEUFNMJGML-UHFFFAOYSA-N 3-(4-chloro-2,5-difluorophenyl)-N-ethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound CCNC(=O)c1nn2CCCOc2c1-c1cc(F)c(Cl)cc1F MYPOVEUFNMJGML-UHFFFAOYSA-N 0.000 claims 1
- IFCNLIRUYVNPKA-UHFFFAOYSA-N 3-(4-chloro-2-fluorophenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Fc1cc(Cl)ccc1-c1c2OCCCn2nc1C(=O)NC1CC1 IFCNLIRUYVNPKA-UHFFFAOYSA-N 0.000 claims 1
- GRFHQTKEAOBDST-UHFFFAOYSA-N 3-(4-chloro-2-methylphenyl)-N-cyclopropyl-6-fluoro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Cc1cc(Cl)ccc1-c1c(nn2CC(F)COc12)C(=O)NC1CC1 GRFHQTKEAOBDST-UHFFFAOYSA-N 0.000 claims 1
- ZDSSYIMMEPTDEO-UHFFFAOYSA-N 3-(4-chloro-3,5-difluorophenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Fc1cc(cc(F)c1Cl)-c1c2OCCCn2nc1C(=O)NC1CC1 ZDSSYIMMEPTDEO-UHFFFAOYSA-N 0.000 claims 1
- TWKMZYIUVKFGDK-UHFFFAOYSA-N 3-(4-chloro-3-fluorophenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Fc1cc(ccc1Cl)-c1c2OCCCn2nc1C(=O)NC1CC1 TWKMZYIUVKFGDK-UHFFFAOYSA-N 0.000 claims 1
- MKFKTQOJJMIDOC-UHFFFAOYSA-N 3-(4-chloro-3-fluorophenyl)-N-cyclopropyl-6-fluoro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound FC1COc2c(c(nn2C1)C(=O)NC1CC1)-c1ccc(Cl)c(F)c1 MKFKTQOJJMIDOC-UHFFFAOYSA-N 0.000 claims 1
- KPTCNORYAGZPTM-UHFFFAOYSA-N 3-(4-chloro-3-fluorophenyl)-N-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound CNC(=O)c1nn2CCCOc2c1-c1ccc(Cl)c(F)c1 KPTCNORYAGZPTM-UHFFFAOYSA-N 0.000 claims 1
- SPFPGSNCBFECSG-UHFFFAOYSA-N 3-(4-chloro-3-fluorophenyl)-N-propan-2-yl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound CC(C)NC(=O)c1nn2CCCOc2c1-c1ccc(Cl)c(F)c1 SPFPGSNCBFECSG-UHFFFAOYSA-N 0.000 claims 1
- AIIYPFJZLRJGEL-UHFFFAOYSA-N 3-(4-chloro-5-fluoro-2-methylphenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Cc1cc(Cl)c(F)cc1-c1c2OCCCn2nc1C(=O)NC1CC1 AIIYPFJZLRJGEL-UHFFFAOYSA-N 0.000 claims 1
- WYVVCFNADZMHEN-UHFFFAOYSA-N 3-(4-chloro-5-fluoro-2-methylphenyl)-N-ethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound CCNC(=O)c1nn2CCCOc2c1-c1cc(F)c(Cl)cc1C WYVVCFNADZMHEN-UHFFFAOYSA-N 0.000 claims 1
- XWLDNGLNMIBYMP-UHFFFAOYSA-N 3-(4-chloro-5-fluoro-2-methylphenyl)-N-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound CNC(=O)c1nn2CCCOc2c1-c1cc(F)c(Cl)cc1C XWLDNGLNMIBYMP-UHFFFAOYSA-N 0.000 claims 1
- NHVPCMGYIPONNR-UHFFFAOYSA-N 3-(4-chlorophenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Clc1ccc(cc1)-c1c2OCCCn2nc1C(=O)NC1CC1 NHVPCMGYIPONNR-UHFFFAOYSA-N 0.000 claims 1
- NXQIEDDZYQXLGS-UHFFFAOYSA-N 3-(4-chlorophenyl)-N-cyclopropyl-6-fluoro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound FC1COc2c(c(nn2C1)C(=O)NC1CC1)-c1ccc(Cl)cc1 NXQIEDDZYQXLGS-UHFFFAOYSA-N 0.000 claims 1
- KEZOJFATBPGWGR-UHFFFAOYSA-N 3-(4-cyano-2,5-difluorophenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Fc1cc(-c2c3OCCCn3nc2C(=O)NC2CC2)c(F)cc1C#N KEZOJFATBPGWGR-UHFFFAOYSA-N 0.000 claims 1
- MGICYBWWARAATG-UHFFFAOYSA-N 3-(4-cyano-2-methylphenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Cc1cc(ccc1-c1c2OCCCn2nc1C(=O)NC1CC1)C#N MGICYBWWARAATG-UHFFFAOYSA-N 0.000 claims 1
- GWWNXYAZKUJVBF-UHFFFAOYSA-N 3-(4-cyano-5-fluoro-2-methylphenyl)-N-ethyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound CCNC(=O)c1nn2CCCOc2c1-c1cc(F)c(cc1C)C#N GWWNXYAZKUJVBF-UHFFFAOYSA-N 0.000 claims 1
- QQMQNXMQOPTOHL-UHFFFAOYSA-N 3-(5-cyano-2-fluorophenyl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Fc1ccc(cc1-c1c2OCCCn2nc1C(=O)NC1CC1)C#N QQMQNXMQOPTOHL-UHFFFAOYSA-N 0.000 claims 1
- WAMLUDBFCUDTPT-UHFFFAOYSA-N 3-(6-cyanopyridin-3-yl)-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound O=C(NC1CC1)c1nn2CCCOc2c1-c1ccc(nc1)C#N WAMLUDBFCUDTPT-UHFFFAOYSA-N 0.000 claims 1
- HIZORNOKOHJTBO-UHFFFAOYSA-N 4-[2-(azetidine-1-carbonyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl]-2,5-difluorobenzonitrile Chemical compound Fc1cc(-c2c3OCCCn3nc2C(=O)N2CCC2)c(F)cc1C#N HIZORNOKOHJTBO-UHFFFAOYSA-N 0.000 claims 1
- JVQZYDGQUZXTDQ-UHFFFAOYSA-N 4-[2-(azetidine-1-carbonyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl]-2,6-difluorobenzonitrile Chemical compound Fc1cc(cc(F)c1C#N)-c1c2OCCCn2nc1C(=O)N1CCC1 JVQZYDGQUZXTDQ-UHFFFAOYSA-N 0.000 claims 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- TUHZURBDZPBKQB-UHFFFAOYSA-N ClC1=CC=C(C=C1)C=1C(=NN2C=1OCC(C2)(F)F)C(=O)NC1CC1 Chemical compound ClC1=CC=C(C=C1)C=1C(=NN2C=1OCC(C2)(F)F)C(=O)NC1CC1 TUHZURBDZPBKQB-UHFFFAOYSA-N 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- XMTOCICLPIPODV-UHFFFAOYSA-N N-cyclopropyl-3-(3,4-dichlorophenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound Clc1ccc(cc1Cl)-c1c2OCCCn2nc1C(=O)NC1CC1 XMTOCICLPIPODV-UHFFFAOYSA-N 0.000 claims 1
- AEPRWSVYIWUKRK-UHFFFAOYSA-N N-cyclopropyl-3-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound O=C(NC1CC1)c1nn2CCCOc2c1-c1ccc2ncnn2c1 AEPRWSVYIWUKRK-UHFFFAOYSA-N 0.000 claims 1
- MYBATSJXBUMOOH-UHFFFAOYSA-N N-cyclopropyl-3-[2-(difluoromethoxy)pyridin-4-yl]-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound FC(F)Oc1cc(ccn1)-c1c(nn2CCCOc12)C(=O)NC1CC1 MYBATSJXBUMOOH-UHFFFAOYSA-N 0.000 claims 1
- ONZFTFUFKHZXEF-UHFFFAOYSA-N N-cyclopropyl-3-pyrazolo[1,5-a]pyridin-6-yl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound O=C(NC1CC1)c1nn2CCCOc2c1-c1ccc2ccnn2c1 ONZFTFUFKHZXEF-UHFFFAOYSA-N 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- OEWWVAVGPPIPRO-UHFFFAOYSA-N azetidin-1-yl-[3-(3,4-dichlorophenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound Clc1ccc(cc1Cl)-c1c(nn2CCCOc12)C(=O)N1CCC1 OEWWVAVGPPIPRO-UHFFFAOYSA-N 0.000 claims 1
- ARADJHAPDWYDIE-UHFFFAOYSA-N azetidin-1-yl-[3-(3,5-difluoro-4-methoxyphenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound COc1c(F)cc(cc1F)-c1c2OCCCn2nc1C(=O)N1CCC1 ARADJHAPDWYDIE-UHFFFAOYSA-N 0.000 claims 1
- CRKMXHLUZCJURN-UHFFFAOYSA-N azetidin-1-yl-[3-(3-chlorophenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound Clc1cccc(c1)-c1c(nn2CCCOc12)C(=O)N1CCC1 CRKMXHLUZCJURN-UHFFFAOYSA-N 0.000 claims 1
- AYWBPURWDSSBNA-UHFFFAOYSA-N azetidin-1-yl-[3-(4-chloro-2-fluorophenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound Fc1cc(Cl)ccc1-c1c2OCCCn2nc1C(=O)N1CCC1 AYWBPURWDSSBNA-UHFFFAOYSA-N 0.000 claims 1
- XUMPDYRHXWOEDT-UHFFFAOYSA-N azetidin-1-yl-[3-(4-chloro-3,5-difluorophenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound Fc1cc(cc(F)c1Cl)-c1c2OCCCn2nc1C(=O)N1CCC1 XUMPDYRHXWOEDT-UHFFFAOYSA-N 0.000 claims 1
- AQWXGANUJJZTGU-UHFFFAOYSA-N azetidin-1-yl-[3-(4-chloro-3-fluorophenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound Fc1cc(ccc1Cl)-c1c2OCCCn2nc1C(=O)N1CCC1 AQWXGANUJJZTGU-UHFFFAOYSA-N 0.000 claims 1
- GUBLWTBQTNDNFO-UHFFFAOYSA-N azetidin-1-yl-[3-(4-chloro-5-fluoro-2-methylphenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound Cc1cc(Cl)c(F)cc1-c1c2OCCCn2nc1C(=O)N1CCC1 GUBLWTBQTNDNFO-UHFFFAOYSA-N 0.000 claims 1
- MONOEYMRTNNARV-UHFFFAOYSA-N azetidin-1-yl-[3-(4-chlorophenyl)-5-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound CC1CCn2nc(C(=O)N3CCC3)c(c2O1)-c1ccc(Cl)cc1 MONOEYMRTNNARV-UHFFFAOYSA-N 0.000 claims 1
- BKTUIOVWODWFPG-UHFFFAOYSA-N azetidin-1-yl-[3-(4-chlorophenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl]methanone Chemical compound Clc1ccc(cc1)-c1c(nn2CCCOc12)C(=O)N1CCC1 BKTUIOVWODWFPG-UHFFFAOYSA-N 0.000 claims 1
- JROPBYGZSRBHDV-UHFFFAOYSA-N oxazine-2-carboxamide Chemical compound NC(=O)N1OC=CC=C1 JROPBYGZSRBHDV-UHFFFAOYSA-N 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 21
- 239000000126 substance Substances 0.000 abstract description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 103
- 239000000203 mixture Substances 0.000 description 59
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 57
- 208000035475 disorder Diseases 0.000 description 57
- 239000000047 product Substances 0.000 description 50
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- 238000005481 NMR spectroscopy Methods 0.000 description 48
- 238000003786 synthesis reaction Methods 0.000 description 47
- 239000000243 solution Substances 0.000 description 46
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 45
- 230000015572 biosynthetic process Effects 0.000 description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 42
- 239000007787 solid Substances 0.000 description 40
- 101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 description 34
- 102100029170 cAMP-specific 3',5'-cyclic phosphodiesterase 4D Human genes 0.000 description 34
- 239000011541 reaction mixture Substances 0.000 description 34
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 28
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- 239000003814 drug Substances 0.000 description 25
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 25
- 239000000460 chlorine Substances 0.000 description 24
- 239000011780 sodium chloride Substances 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 21
- 125000006413 ring segment Chemical group 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- 229920006395 saturated elastomer Polymers 0.000 description 19
- 210000003169 central nervous system Anatomy 0.000 description 18
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 17
- 229910052801 chlorine Inorganic materials 0.000 description 17
- 239000012044 organic layer Substances 0.000 description 17
- 238000000746 purification Methods 0.000 description 17
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 16
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 16
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 16
- 239000002253 acid Substances 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 125000005842 heteroatom Chemical group 0.000 description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 15
- 238000010898 silica gel chromatography Methods 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 13
- 230000003542 behavioural effect Effects 0.000 description 13
- 239000000872 buffer Substances 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 229910052740 iodine Inorganic materials 0.000 description 13
- 230000036407 pain Effects 0.000 description 13
- 239000003208 petroleum Substances 0.000 description 13
- 229910052717 sulfur Inorganic materials 0.000 description 13
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
- 241000238631 Hexapoda Species 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 125000004429 atom Chemical group 0.000 description 12
- 235000011187 glycerol Nutrition 0.000 description 12
- 229960005150 glycerol Drugs 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 229910052938 sodium sulfate Inorganic materials 0.000 description 12
- 235000011152 sodium sulphate Nutrition 0.000 description 12
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 11
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
- 229910052796 boron Inorganic materials 0.000 description 11
- 239000002552 dosage form Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 239000001301 oxygen Chemical group 0.000 description 11
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 11
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 10
- 229920000936 Agarose Polymers 0.000 description 10
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 10
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 10
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 10
- 229910000024 caesium carbonate Inorganic materials 0.000 description 10
- 150000001721 carbon Chemical group 0.000 description 10
- 239000011593 sulfur Chemical group 0.000 description 10
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 9
- 108010044467 Isoenzymes Proteins 0.000 description 9
- NXQGGXCHGDYOHB-UHFFFAOYSA-L [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (II) Substances [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 235000019253 formic acid Nutrition 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 8
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 8
- 208000014094 Dystonic disease Diseases 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 208000010877 cognitive disease Diseases 0.000 description 8
- 208000010118 dystonia Diseases 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 208000011580 syndromic disease Diseases 0.000 description 8
- 208000023275 Autoimmune disease Diseases 0.000 description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 150000001408 amides Chemical group 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 230000001363 autoimmune Effects 0.000 description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 7
- 239000001110 calcium chloride Substances 0.000 description 7
- 229910001628 calcium chloride Inorganic materials 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 208000027866 inflammatory disease Diseases 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 230000009885 systemic effect Effects 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- 238000011537 Coomassie blue staining Methods 0.000 description 6
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000003176 neuroleptic agent Substances 0.000 description 6
- 230000000701 neuroleptic effect Effects 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 208000020016 psychiatric disease Diseases 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
- 208000028698 Cognitive impairment Diseases 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 5
- 210000004227 basal ganglia Anatomy 0.000 description 5
- 230000004064 dysfunction Effects 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 229940093915 gynecological organic acid Drugs 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 230000003340 mental effect Effects 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 230000036651 mood Effects 0.000 description 5
- 235000005985 organic acids Nutrition 0.000 description 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 229950005741 rolipram Drugs 0.000 description 5
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 5
- 229940076279 serotonin Drugs 0.000 description 5
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 208000016686 tic disease Diseases 0.000 description 5
- YCYMCMYLORLIJX-SNVBAGLBSA-N (2r)-2-propyloctanoic acid Chemical compound CCCCCC[C@H](C(O)=O)CCC YCYMCMYLORLIJX-SNVBAGLBSA-N 0.000 description 4
- SRXXSLUUAWHGBZ-UHFFFAOYSA-N (4-chloro-2-methylphenyl)boronic acid Chemical compound CC1=CC(Cl)=CC=C1B(O)O SRXXSLUUAWHGBZ-UHFFFAOYSA-N 0.000 description 4
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 4
- MHNSPTUQQIYJOT-SJDTYFKWSA-N Doxepin Hydrochloride Chemical compound Cl.C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 MHNSPTUQQIYJOT-SJDTYFKWSA-N 0.000 description 4
- 208000012661 Dyskinesia Diseases 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 4
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 206010044565 Tremor Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 4
- IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 150000001602 bicycloalkyls Chemical group 0.000 description 4
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- LWJQNZGEBBWCFP-YFKPBYRVSA-N ethyl (6S)-3-bromo-6-fluoro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxylate Chemical compound BrC=1C(=NN2C=1OC[C@H](C2)F)C(=O)OCC LWJQNZGEBBWCFP-YFKPBYRVSA-N 0.000 description 4
- SNSXVLPZBPAQGM-LURJTMIESA-N ethyl (6S)-6-fluoro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxylate Chemical compound F[C@H]1CN2C(OC1)=CC(=N2)C(=O)OCC SNSXVLPZBPAQGM-LURJTMIESA-N 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 description 4
- 208000030159 metabolic disease Diseases 0.000 description 4
- 239000006199 nebulizer Substances 0.000 description 4
- 208000004296 neuralgia Diseases 0.000 description 4
- 208000021722 neuropathic pain Diseases 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 229940044601 receptor agonist Drugs 0.000 description 4
- 239000000018 receptor agonist Substances 0.000 description 4
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 3
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 3
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 3
- ABXZXEUBAMIABP-UHFFFAOYSA-N 3-(4-chlorophenyl)-5-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxylic acid Chemical compound ClC1=CC=C(C=C1)C=1C(=NN2C=1OC(CC2)C)C(=O)O ABXZXEUBAMIABP-UHFFFAOYSA-N 0.000 description 3
- FFZHUOCVOJTVHG-UHFFFAOYSA-N 3-(4-chlorophenyl)-7-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxylic acid Chemical compound ClC1=CC=C(C=C1)C=1C(=NN2C=1OCCC2C)C(=O)O FFZHUOCVOJTVHG-UHFFFAOYSA-N 0.000 description 3
- OWMODOCZTPAZCG-UHFFFAOYSA-N 3-bromo-N-cyclopropyl-6,6-difluoro-5,7-dihydropyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound FC1(F)COc2c(Br)c(nn2C1)C(=O)NC1CC1 OWMODOCZTPAZCG-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 3
- 208000020706 Autistic disease Diseases 0.000 description 3
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 3
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 3
- 206010006550 Bulimia nervosa Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 208000020401 Depressive disease Diseases 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 201000011240 Frontotemporal dementia Diseases 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 description 3
- 108010005716 Interferon beta-1a Proteins 0.000 description 3
- 108010005714 Interferon beta-1b Proteins 0.000 description 3
- NYMGNSNKLVNMIA-UHFFFAOYSA-N Iproniazid Chemical compound CC(C)NNC(=O)C1=CC=NC=C1 NYMGNSNKLVNMIA-UHFFFAOYSA-N 0.000 description 3
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 3
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 3
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 3
- 208000016285 Movement disease Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 108090000028 Neprilysin Proteins 0.000 description 3
- 102000003729 Neprilysin Human genes 0.000 description 3
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 3
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 206010034010 Parkinsonism Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 3
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 3
- 229960001164 apremilast Drugs 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 3
- 229960001058 bupropion Drugs 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 3
- 229960001076 chlorpromazine Drugs 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 238000013480 data collection Methods 0.000 description 3
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 235000014632 disordered eating Nutrition 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- LZWLLMFYVGUUAL-UHFFFAOYSA-L ditert-butyl(cyclopenta-1,3-dien-1-yl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.CC(C)(C)P(C(C)(C)C)C1=CC=C[CH-]1.CC(C)(C)P(C(C)(C)C)C1=CC=C[CH-]1 LZWLLMFYVGUUAL-UHFFFAOYSA-L 0.000 description 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 3
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 230000002996 emotional effect Effects 0.000 description 3
- LWJQNZGEBBWCFP-RXMQYKEDSA-N ethyl (6R)-3-bromo-6-fluoro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxylate Chemical compound BrC=1C(=NN2C=1OC[C@@H](C2)F)C(=O)OCC LWJQNZGEBBWCFP-RXMQYKEDSA-N 0.000 description 3
- SNSXVLPZBPAQGM-ZCFIWIBFSA-N ethyl (6R)-6-fluoro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxylate Chemical compound F[C@@H]1CN2C(OC1)=CC(=N2)C(=O)OCC SNSXVLPZBPAQGM-ZCFIWIBFSA-N 0.000 description 3
- MTPVDOWFOIXMFF-UHFFFAOYSA-N ethyl 3-bromo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxylate Chemical compound BrC=1C(=NN2C=1OCCC2)C(=O)OCC MTPVDOWFOIXMFF-UHFFFAOYSA-N 0.000 description 3
- KUCKYUCTIZRRJQ-UHFFFAOYSA-N ethyl 5-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxylate Chemical compound CCOC(=O)c1cc2OC(C)CCn2n1 KUCKYUCTIZRRJQ-UHFFFAOYSA-N 0.000 description 3
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 3
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 3
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 3
- QORVDGQLPPAFRS-XPSHAMGMSA-N galantamine hydrobromide Chemical compound Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 description 3
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 229960002491 ibudilast Drugs 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 3
- 208000024714 major depressive disease Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- VUYVXCJTTQJVKJ-UHFFFAOYSA-L palladium(2+);tricyclohexylphosphane;dichloride Chemical compound Cl[Pd]Cl.C1CCCCC1P(C1CCCCC1)C1CCCCC1.C1CCCCC1P(C1CCCCC1)C1CCCCC1 VUYVXCJTTQJVKJ-UHFFFAOYSA-L 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- IBALRBWGSVJPAP-HEHNFIMWSA-N progabide Chemical compound C=1C(F)=CC=C(O)C=1C(=N/CCCC(=O)N)/C1=CC=C(Cl)C=C1 IBALRBWGSVJPAP-HEHNFIMWSA-N 0.000 description 3
- 229960002752 progabide Drugs 0.000 description 3
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- HUCSPLIDQQOHMN-UHFFFAOYSA-N pyrazolo[3,4-e]oxazine Chemical group C1=NOC2=CN=NC2=C1 HUCSPLIDQQOHMN-UHFFFAOYSA-N 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 229960002586 roflumilast Drugs 0.000 description 3
- 238000002821 scintillation proximity assay Methods 0.000 description 3
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 238000004808 supercritical fluid chromatography Methods 0.000 description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- 229960000744 vinpocetine Drugs 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 3
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical group C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- GTWLIQOLGOZTLF-UHFFFAOYSA-N 2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b]indole;dihydrochloride Chemical compound Cl.Cl.C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 GTWLIQOLGOZTLF-UHFFFAOYSA-N 0.000 description 2
- YBAWYTYNMZWMMJ-UHFFFAOYSA-N 2-(6-fluoro-1h-indol-3-yl)-n-[[3-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]ethanamine Chemical compound FC(F)C(F)(F)COC1=CC=CC(CNCCC=2C3=CC=C(F)C=C3NC=2)=C1 YBAWYTYNMZWMMJ-UHFFFAOYSA-N 0.000 description 2
- XILIYVSXLSWUAI-UHFFFAOYSA-N 2-(diethylamino)ethyl n'-phenylcarbamimidothioate;dihydrobromide Chemical compound Br.Br.CCN(CC)CCSC(N)=NC1=CC=CC=C1 XILIYVSXLSWUAI-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 2
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 2
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- IOSAAWHGJUZBOG-UHFFFAOYSA-N 3-(6-amino-9h-purin-9-yl)nonan-2-ol Chemical compound N1=CN=C2N(C(C(C)O)CCCCCC)C=NC2=C1N IOSAAWHGJUZBOG-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Aminopropanesulfonate Chemical compound NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 description 2
- UWNCBPJTDSGSBL-UHFFFAOYSA-N 3-bromo-N-cyclopropyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide Chemical compound BrC=1C(=NN2C=1OCCC2)C(=O)NC1CC1 UWNCBPJTDSGSBL-UHFFFAOYSA-N 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- DWOZNANUEDYIOF-UHFFFAOYSA-L 4-ditert-butylphosphanyl-n,n-dimethylaniline;dichloropalladium Chemical compound Cl[Pd]Cl.CN(C)C1=CC=C(P(C(C)(C)C)C(C)(C)C)C=C1.CN(C)C1=CC=C(P(C(C)(C)C)C(C)(C)C)C=C1 DWOZNANUEDYIOF-UHFFFAOYSA-L 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 2
- IASRYLKZYZPWRV-UHFFFAOYSA-N 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine Chemical class C1CCOC2=CC=NN21 IASRYLKZYZPWRV-UHFFFAOYSA-N 0.000 description 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 2
- XDBHURGONHZNJF-UHFFFAOYSA-N 6-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=C(OCC)C(OCC)=CC=C1C1=NC(C=2N=C(C=CC=2)C(O)=O)=CS1 XDBHURGONHZNJF-UHFFFAOYSA-N 0.000 description 2
- FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo(3.3.1)nonane Chemical compound C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- OVCDSSHSILBFBN-UHFFFAOYSA-N Amodiaquine Chemical compound C1=C(O)C(CN(CC)CC)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 OVCDSSHSILBFBN-UHFFFAOYSA-N 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 208000028185 Angioedema Diseases 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000036640 Asperger disease Diseases 0.000 description 2
- 201000006062 Asperger syndrome Diseases 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 206010003805 Autism Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 2
- 208000032841 Bulimia Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- RZZPDXZPRHQOCG-OJAKKHQRSA-N CDP-choline Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-N 0.000 description 2
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000006378 Catechol O-methyltransferase Human genes 0.000 description 2
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 2
- BIWQNIMLAISTBV-UHFFFAOYSA-N Cc1ccc(B(O)O)cc1 Chemical compound Cc1ccc(B(O)O)cc1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 2
- 206010008748 Chorea Diseases 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- 206010012218 Delirium Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- 208000030814 Eating disease Diseases 0.000 description 2
- VWLHWLSRQJQWRG-UHFFFAOYSA-O Edrophonum Chemical compound CC[N+](C)(C)C1=CC=CC(O)=C1 VWLHWLSRQJQWRG-UHFFFAOYSA-O 0.000 description 2
- 208000027534 Emotional disease Diseases 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 208000001836 Firesetting Behavior Diseases 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 108010072051 Glatiramer Acetate Proteins 0.000 description 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- NZDMFGKECODQRY-UHFFFAOYSA-N Maprotiline hydrochloride Chemical compound Cl.C12=CC=CC=C2C2(CCCNC)C3=CC=CC=C3C1CC2 NZDMFGKECODQRY-UHFFFAOYSA-N 0.000 description 2
- 208000036626 Mental retardation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- RGHAZVBIOOEVQX-UHFFFAOYSA-N Metoprolol succinate Chemical compound OC(=O)CCC(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 RGHAZVBIOOEVQX-UHFFFAOYSA-N 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 102000004230 Neurotrophin 3 Human genes 0.000 description 2
- 108090000742 Neurotrophin 3 Proteins 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 2
- 208000027089 Parkinsonian disease Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 201000009916 Postpartum depression Diseases 0.000 description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 2
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 2
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 206010041250 Social phobia Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 description 2
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 2
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- PBHFNBQPZCRWQP-AZUAARDMSA-N [(3aS,8bR)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-phenylcarbamate Chemical compound CN([C@H]1[C@](C2=C3)(C)CCN1C)C2=CC=C3OC(=O)NC1=CC=CC=C1 PBHFNBQPZCRWQP-AZUAARDMSA-N 0.000 description 2
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 206010069351 acute lung injury Diseases 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 229960001444 amodiaquine Drugs 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 2
- YFGHCGITMMYXAQ-LJQANCHMSA-N armodafinil Chemical compound C=1C=CC=CC=1C([S@](=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-LJQANCHMSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
- 229960002430 atomoxetine Drugs 0.000 description 2
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- HGQULGDOROIPJN-UHFFFAOYSA-N azetidin-1-ium;chloride Chemical compound Cl.C1CNC1 HGQULGDOROIPJN-UHFFFAOYSA-N 0.000 description 2
- NOTGCUCZJNLJOH-UHFFFAOYSA-N azetidin-1-yl-(3-bromo-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl)methanone Chemical compound N1(CCC1)C(=O)C1=NN2C(OCCC2)=C1Br NOTGCUCZJNLJOH-UHFFFAOYSA-N 0.000 description 2
- XJURALZPEJKKOV-CQSZACIVSA-N bay 38-7271 Chemical compound C([C@H](CC1=2)CO)C1=CC=CC=2OC1=CC=CC(OS(=O)(=O)CCCC(F)(F)F)=C1 XJURALZPEJKKOV-CQSZACIVSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
- CPFJLLXFNPCTDW-BWSPSPBFSA-N benzatropine mesylate Chemical compound CS([O-])(=O)=O.O([C@H]1C[C@H]2CC[C@@H](C1)[NH+]2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 CPFJLLXFNPCTDW-BWSPSPBFSA-N 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 2
- XXRMYXBSBOVVBH-UHFFFAOYSA-N bethanechol chloride Chemical compound [Cl-].C[N+](C)(C)CC(C)OC(N)=O XXRMYXBSBOVVBH-UHFFFAOYSA-N 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 229960004596 cabergoline Drugs 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- KPWSJANDNDDRMB-QAQDUYKDSA-N cariprazine Chemical compound C1C[C@@H](NC(=O)N(C)C)CC[C@@H]1CCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 KPWSJANDNDDRMB-QAQDUYKDSA-N 0.000 description 2
- 229960005123 cariprazine Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 208000012601 choreatic disease Diseases 0.000 description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000007278 cognition impairment Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- DWLTUUXCVGVRAV-XWRHUKJGSA-N davunetide Chemical compound N([C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O DWLTUUXCVGVRAV-XWRHUKJGSA-N 0.000 description 2
- 108010042566 davunetide Proteins 0.000 description 2
- 229960002887 deanol Drugs 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940119751 dextroamphetamine sulfate Drugs 0.000 description 2
- 229960001985 dextromethorphan Drugs 0.000 description 2
- 201000011190 diabetic macular edema Diseases 0.000 description 2
- CURUTKGFNZGFSE-UHFFFAOYSA-N dicyclomine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 125000006001 difluoroethyl group Chemical group 0.000 description 2
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 description 2
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 2
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- DKGJFKPIUSHDIT-UHFFFAOYSA-L disodium;propane-1,3-disulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCCS([O-])(=O)=O DKGJFKPIUSHDIT-UHFFFAOYSA-L 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- LBOJYSIDWZQNJS-CVEARBPZSA-N dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 description 2
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 description 2
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 2
- 229960005426 doxepin Drugs 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 229960000394 droperidol Drugs 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 2
- 229950009041 edaravone Drugs 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 230000001667 episodic effect Effects 0.000 description 2
- 229950004685 eprodisate Drugs 0.000 description 2
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 2
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- CHEQJOKYDPAFNB-UHFFFAOYSA-N ethyl 7-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxylate Chemical compound CC1N2C(OCC1)=CC(=N2)C(=O)OCC CHEQJOKYDPAFNB-UHFFFAOYSA-N 0.000 description 2
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
- 210000001263 extrapyramidal tract Anatomy 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 229960001938 fencamfamin Drugs 0.000 description 2
- IKFBPFGUINLYQI-UHFFFAOYSA-N fencamfamin Chemical compound CCNC1C(C2)CCC2C1C1=CC=CC=C1 IKFBPFGUINLYQI-UHFFFAOYSA-N 0.000 description 2
- LZPBLUATTGKZBH-UHFFFAOYSA-L fenoprofen calcium Chemical compound O.O.[Ca+2].[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1.[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 LZPBLUATTGKZBH-UHFFFAOYSA-L 0.000 description 2
- 229960000556 fingolimod Drugs 0.000 description 2
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- RERZNCLIYCABFS-UHFFFAOYSA-N harmaline Chemical compound C1CN=C(C)C2=C1C1=CC=C(OC)C=C1N2 RERZNCLIYCABFS-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 2
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 2
- MNLULKBKWKTZPE-UHFFFAOYSA-N indantadol Chemical compound C1=CC=C2CC(NCC(=O)N)CC2=C1 MNLULKBKWKTZPE-UHFFFAOYSA-N 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940111894 intuniv Drugs 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229940070023 iproniazide Drugs 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 description 2
- 229960004294 lercanidipine Drugs 0.000 description 2
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 229960003907 linezolid Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 208000007903 liver failure Diseases 0.000 description 2
- 231100000835 liver failure Toxicity 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 229960000423 loxapine Drugs 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229960001962 mefloquine Drugs 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229960004640 memantine Drugs 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960001252 methamphetamine Drugs 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- DOZYTHNHLLSNIK-JOKMOOFLSA-M mycophenolate sodium Chemical compound [Na+].OC1=C(C\C=C(/C)CCC([O-])=O)C(OC)=C(C)C2=C1C(=O)OC2 DOZYTHNHLLSNIK-JOKMOOFLSA-M 0.000 description 2
- OKFDRAHPFKMAJH-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)-8-(methanesulfonamido)dibenzofuran-1-carboxamide Chemical compound C=12C3=CC(NS(=O)(=O)C)=CC=C3OC2=C(OC(F)F)C=CC=1C(=O)NC1=C(Cl)C=NC=C1Cl OKFDRAHPFKMAJH-UHFFFAOYSA-N 0.000 description 2
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 230000002314 neuroinflammatory effect Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 229940032018 neurotrophin 3 Drugs 0.000 description 2
- 229960005366 nilvadipine Drugs 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- QVYRGXJJSLMXQH-UHFFFAOYSA-N orphenadrine Chemical compound C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 QVYRGXJJSLMXQH-UHFFFAOYSA-N 0.000 description 2
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- 229960005434 oxybutynin Drugs 0.000 description 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 208000022821 personality disease Diseases 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 2
- 229960002508 pindolol Drugs 0.000 description 2
- JZQKKSLKJUAGIC-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-UHFFFAOYSA-N 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 238000012877 positron emission topography Methods 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 239000011698 potassium fluoride Substances 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- VJZLQIPZNBPASX-OJJGEMKLSA-L prednisolone sodium phosphate Chemical compound [Na+].[Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 VJZLQIPZNBPASX-OJJGEMKLSA-L 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 2
- MGNVWUDMMXZUDI-UHFFFAOYSA-N propane-1,3-disulfonic acid Chemical compound OS(=O)(=O)CCCS(O)(=O)=O MGNVWUDMMXZUDI-UHFFFAOYSA-N 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 2
- 229960003770 reboxetine Drugs 0.000 description 2
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 description 2
- 229950002652 safinamide Drugs 0.000 description 2
- NEMGRZFTLSKBAP-LBPRGKRZSA-N safinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 NEMGRZFTLSKBAP-LBPRGKRZSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000000698 schizophrenic effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 229960003946 selegiline Drugs 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- QHJLLDJTVQAFAN-UHFFFAOYSA-M sodium meclofenamate monohydrate Chemical compound O.[Na+].CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C([O-])=O)=C1Cl QHJLLDJTVQAFAN-UHFFFAOYSA-M 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 208000012217 specific developmental disease Diseases 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000005415 substituted alkoxy group Chemical group 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 229960001685 tacrine Drugs 0.000 description 2
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 229960002784 thioridazine Drugs 0.000 description 2
- QAXBVGVYDCAVLV-UHFFFAOYSA-N tiletamine Chemical compound C=1C=CSC=1C1(NCC)CCCCC1=O QAXBVGVYDCAVLV-UHFFFAOYSA-N 0.000 description 2
- 229960005013 tiotixene Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 2
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 2
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 2
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000001228 trophic effect Effects 0.000 description 2
- MDYOLVRUBBJPFM-UHFFFAOYSA-N tropolone Chemical compound OC1=CC=CC=CC1=O MDYOLVRUBBJPFM-UHFFFAOYSA-N 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 229960000438 udenafil Drugs 0.000 description 2
- IYFNEFQTYQPVOC-UHFFFAOYSA-N udenafil Chemical compound C1=C(C=2NC=3C(CCC)=NN(C)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)NCCC1CCCN1C IYFNEFQTYQPVOC-UHFFFAOYSA-N 0.000 description 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 2
- 229960002381 vardenafil Drugs 0.000 description 2
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 2
- 229960004751 varenicline Drugs 0.000 description 2
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 230000003936 working memory Effects 0.000 description 2
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 2
- 229960002911 zonisamide Drugs 0.000 description 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- MMAYTCMMKJYIAM-RUGRQLENSA-N (-)-voacangine Chemical compound C([C@H]1C[C@@H]([C@H]2[C@]3(C1)C(=O)OC)CC)N2CCC1=C3NC2=CC=C(OC)C=C12 MMAYTCMMKJYIAM-RUGRQLENSA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- KTGRHKOEFSJQNS-BDQAORGHSA-N (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;oxalic acid Chemical compound OC(=O)C(O)=O.C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 KTGRHKOEFSJQNS-BDQAORGHSA-N 0.000 description 1
- TWUSDDMONZULSC-QMTHXVAHSA-N (1s,2r)-2-(tert-butylamino)-1-(2,5-dimethoxyphenyl)propan-1-ol Chemical compound COC1=CC=C(OC)C([C@H](O)[C@@H](C)NC(C)(C)C)=C1 TWUSDDMONZULSC-QMTHXVAHSA-N 0.000 description 1
- ZERWDZDNDJBYKA-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)ON1C(=O)CCC1=O ZERWDZDNDJBYKA-UHFFFAOYSA-N 0.000 description 1
- GMBQZIIUCVWOCD-UQHLGXRBSA-N (25R)-5beta-spirostan-3beta-ol Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 GMBQZIIUCVWOCD-UQHLGXRBSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- TWHNMSJGYKMTRB-KXYUELECSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;2-[(1r)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 TWHNMSJGYKMTRB-KXYUELECSA-N 0.000 description 1
- XTBQNQMNFXNGLR-MKSBGGEFSA-N (2s)-1-(2-ethylphenoxy)-3-[[(1s)-1,2,3,4-tetrahydronaphthalen-1-yl]amino]propan-2-ol;oxalic acid Chemical compound OC(=O)C(O)=O.CCC1=CC=CC=C1OC[C@@H](O)CN[C@@H]1C2=CC=CC=C2CCC1 XTBQNQMNFXNGLR-MKSBGGEFSA-N 0.000 description 1
- BHVJEDVPEXXDDP-LPCSYZHESA-N (2s)-1-(4-amino-2,3,5-trimethylphenoxy)-3-[4-[4-[(4-fluorophenyl)methyl]phenyl]piperazin-1-yl]propan-2-ol;methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CC1=C(N)C(C)=CC(OC[C@@H](O)CN2CCN(CC2)C=2C=CC(CC=3C=CC(F)=CC=3)=CC=2)=C1C BHVJEDVPEXXDDP-LPCSYZHESA-N 0.000 description 1
- VHKVKWTWHZUFIA-DGOKBZBKSA-N (2s)-1-phenylpropan-2-amine;(2s,3s,4s,5r)-2,3,4,5-tetrahydroxyhexanedioic acid Chemical compound C[C@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O VHKVKWTWHZUFIA-DGOKBZBKSA-N 0.000 description 1
- CETWSOHVEGTIBR-FORAGAHYSA-N (2s)-2,6-diamino-n-[(2s)-1-phenylpropan-2-yl]hexanamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.NCCCC[C@H](N)C(=O)N[C@@H](C)CC1=CC=CC=C1 CETWSOHVEGTIBR-FORAGAHYSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- NRNSHPCDKHOUOE-SNVBAGLBSA-N (2s)-2-amino-2-[(3,4-dihydroxyphenyl)methyl]-3-fluoropropanoic acid Chemical compound FC[C@@](N)(C(O)=O)CC1=CC=C(O)C(O)=C1 NRNSHPCDKHOUOE-SNVBAGLBSA-N 0.000 description 1
- PHOZOHFUXHPOCK-QMMMGPOBSA-N (2s)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decan-3-one Chemical compound N1C(=O)[C@H](CC)SC11CCN(C)CC1 PHOZOHFUXHPOCK-QMMMGPOBSA-N 0.000 description 1
- OOBHFESNSZDWIU-GXSJLCMTSA-N (2s,3s)-3-methyl-2-phenylmorpholine Chemical compound C[C@@H]1NCCO[C@H]1C1=CC=CC=C1 OOBHFESNSZDWIU-GXSJLCMTSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- SGEIEGAXKLMUIZ-ZPTIMJQQSA-N (3e)-n-[(2r)-2-hydroxy-3-piperidin-1-ylpropoxy]-1-oxidopyridin-1-ium-3-carboximidoyl chloride Chemical compound C([C@H](O)CN1CCCCC1)O\N=C(\Cl)C1=CC=C[N+]([O-])=C1 SGEIEGAXKLMUIZ-ZPTIMJQQSA-N 0.000 description 1
- OCKIPDMKGPYYJS-ZDUSSCGKSA-N (3r)-spiro[1-azabicyclo[2.2.2]octane-3,2'-3h-furo[2,3-b]pyridine] Chemical compound C1N(CC2)CCC2[C@]21OC1=NC=CC=C1C2 OCKIPDMKGPYYJS-ZDUSSCGKSA-N 0.000 description 1
- ACTONBBIVMTUAJ-DOLQZWNJSA-N (3r,4as,6r,8as)-6-(2h-tetrazol-5-ylmethyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid Chemical compound C([C@H]1C[C@H]2C[C@@H](NC[C@H]2CC1)C(=O)O)C=1N=NNN=1 ACTONBBIVMTUAJ-DOLQZWNJSA-N 0.000 description 1
- ORJNLCKHRRUOMU-OGPPPPIKSA-N (3r,4s)-3-[(4-methoxyphenoxy)methyl]-1-methyl-4-phenylpiperidine;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 ORJNLCKHRRUOMU-OGPPPPIKSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 1
- DECWLXUOZUMPBF-UHFFFAOYSA-N (4-cyano-3-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(C#N)C(F)=C1 DECWLXUOZUMPBF-UHFFFAOYSA-N 0.000 description 1
- PDVFSPNIEOYOQL-UHFFFAOYSA-N (4-methylphenyl)sulfonyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OS(=O)(=O)C1=CC=C(C)C=C1 PDVFSPNIEOYOQL-UHFFFAOYSA-N 0.000 description 1
- LBJYPLZODCWHKE-GOSISDBHSA-N (4r)-4-cyclopropyl-8-fluoro-5-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-1,4-dihydropyrazolo[4,3-c]quinoline Chemical compound C1([C@H]2N(C3=CC=C(C=C3C=3NN=CC=32)F)S(=O)(=O)C=2C=NC(=CC=2)C(F)(F)F)CC1 LBJYPLZODCWHKE-GOSISDBHSA-N 0.000 description 1
- DQNMZSIJHFEYTM-LEWJYISDSA-N (4s,5r)-3-[3-(azepan-1-yl)propyl]-4-(2-methylpropyl)-5-phenyl-1,3-oxazolidin-2-one Chemical compound O([C@@H]([C@@H]1CC(C)C)C=2C=CC=CC=2)C(=O)N1CCCN1CCCCCC1 DQNMZSIJHFEYTM-LEWJYISDSA-N 0.000 description 1
- GOTMKOSCLKVOGG-OAHLLOKOSA-N (5R)-8-chloro-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol Chemical compound C1([C@@H]2C3=CC(O)=C(Cl)C=C3CCN(C2)C)=CC=CC=C1 GOTMKOSCLKVOGG-OAHLLOKOSA-N 0.000 description 1
- QWSUJKWKMSXSRK-VIFPVBQESA-N (6S)-3-(4-chloro-2-methylphenyl)-6-fluoro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxylic acid Chemical compound ClC1=CC(=C(C=C1)C=1C(=NN2C=1OC[C@H](C2)F)C(=O)O)C QWSUJKWKMSXSRK-VIFPVBQESA-N 0.000 description 1
- DMJWENQHWZZWDF-PKOBYXMFSA-N (6aS,13bR)-11-chloro-7-methyl-5,6,6a,8,9,13b-hexahydronaphtho[1,2-a][3]benzazepin-12-ol Chemical compound CN1CCC2=CC(Cl)=C(O)C=C2[C@H]2C3=CC=CC=C3CC[C@H]12 DMJWENQHWZZWDF-PKOBYXMFSA-N 0.000 description 1
- BGOQGUHWXBGXJW-YOEHRIQHSA-N (6as,12br)-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine-10,11-diol Chemical compound N1CC2=CC=CC=C2[C@@H]2[C@@H]1CCC1=C2C=C(O)C(O)=C1 BGOQGUHWXBGXJW-YOEHRIQHSA-N 0.000 description 1
- XAUYRRGKFRAOHS-YDALLXLXSA-N (7s)-7-(dipropylamino)-4-fluoro-5,6,7,8-tetrahydronaphthalen-1-ol;hydrobromide Chemical compound Br.C1=CC(O)=C2C[C@@H](N(CCC)CCC)CCC2=C1F XAUYRRGKFRAOHS-YDALLXLXSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- SYTBZMRGLBWNTM-SNVBAGLBSA-N (R)-flurbiprofen Chemical compound FC1=CC([C@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-SNVBAGLBSA-N 0.000 description 1
- PMXMIIMHBWHSKN-LJQANCHMSA-N (R)-paliperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCC[C@@H](O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-LJQANCHMSA-N 0.000 description 1
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 1
- RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 1
- GMDCDXMAFMEDAG-CHHFXETESA-N (S,S)-asenapine maleate Chemical compound OC(=O)\C=C/C(O)=O.O1C2=CC=CC=C2[C@H]2CN(C)C[C@@H]2C2=CC(Cl)=CC=C21 GMDCDXMAFMEDAG-CHHFXETESA-N 0.000 description 1
- BRIPGNJWPCKDQZ-WXXKFALUSA-N (e)-but-2-enedioic acid;1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound OC(=O)\C=C\C(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 BRIPGNJWPCKDQZ-WXXKFALUSA-N 0.000 description 1
- GEOCVSMCLVIOEV-BTJKTKAUSA-N (z)-but-2-enedioic acid;2-methyl-4-phenyl-3,4-dihydro-1h-isoquinolin-8-amine Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC(N)=C2CN(C)CC1C1=CC=CC=C1 GEOCVSMCLVIOEV-BTJKTKAUSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- BEQLOSVHRBTANS-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluoro-8-iodododecane Chemical compound CCCCC(I)CC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F BEQLOSVHRBTANS-UHFFFAOYSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
- XBYRMPXUBGMOJC-UHFFFAOYSA-N 1,2-dihydropyrazol-3-one Chemical compound OC=1C=CNN=1 XBYRMPXUBGMOJC-UHFFFAOYSA-N 0.000 description 1
- XZNGUVQDFJHPLU-UHFFFAOYSA-N 1,3-dibromobutane Chemical compound CC(Br)CCBr XZNGUVQDFJHPLU-UHFFFAOYSA-N 0.000 description 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- DKMFBWQBDIGMHM-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-(4-methyl-1-piperidinyl)-1-butanone Chemical compound C1CC(C)CCN1CCCC(=O)C1=CC=C(F)C=C1 DKMFBWQBDIGMHM-UHFFFAOYSA-N 0.000 description 1
- UVSWWUWQVAQPJR-UHFFFAOYSA-N 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine Chemical compound C1=C(OC)C(OC)=CC=C1CCN1CCN(CCCC=2C=CC=CC=2)CC1 UVSWWUWQVAQPJR-UHFFFAOYSA-N 0.000 description 1
- WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 1
- WIHMBLDNRMIGDW-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;hydron;bromide Chemical compound [Br-].O1CC2=CC(C#N)=CC=C2C1(CCC[NH+](C)C)C1=CC=C(F)C=C1 WIHMBLDNRMIGDW-UHFFFAOYSA-N 0.000 description 1
- YFRBKEVUUCQYOW-UHFFFAOYSA-N 1-[6-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)oxy]pyridin-3-yl]pyrrolidin-2-one Chemical compound O=C1CCCN1C(C=N1)=CC=C1OC1=CC=C(CCN(CC2)C3CCC3)C2=C1 YFRBKEVUUCQYOW-UHFFFAOYSA-N 0.000 description 1
- UDZWHXWBCXFBSF-UHFFFAOYSA-N 1-amino-1-cyclohexylethanesulfonic acid Chemical compound OS(=O)(=O)C(N)(C)C1CCCCC1 UDZWHXWBCXFBSF-UHFFFAOYSA-N 0.000 description 1
- NYNOBRTYKCVRJN-UHFFFAOYSA-N 1-benzyl-5-bromopyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(Br)=CN1CC1=CC=CC=C1 NYNOBRTYKCVRJN-UHFFFAOYSA-N 0.000 description 1
- QVXGDUWCYGGRHC-UHFFFAOYSA-N 1-bromo-4-chloro-2,5-difluorobenzene Chemical compound FC1=CC(Br)=C(F)C=C1Cl QVXGDUWCYGGRHC-UHFFFAOYSA-N 0.000 description 1
- KOFZTCSTGIWCQG-UHFFFAOYSA-N 1-bromotetradecane Chemical compound CCCCCCCCCCCCCCBr KOFZTCSTGIWCQG-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- YAYNEUUHHLGGAH-UHFFFAOYSA-N 1-chlorododecane Chemical compound CCCCCCCCCCCCCl YAYNEUUHHLGGAH-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical compound CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- SKIDNYUZJPMKFC-UHFFFAOYSA-N 1-iododecane Chemical compound CCCCCCCCCCI SKIDNYUZJPMKFC-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 1
- KERWHSMECDFMFY-UHFFFAOYSA-N 2-(4-chloro-2,3-difluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(Cl)C(F)=C1F KERWHSMECDFMFY-UHFFFAOYSA-N 0.000 description 1
- OJERJYBDUGRDKV-UHFFFAOYSA-N 2-(4-chloro-2,5-difluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC(F)=C(Cl)C=C1F OJERJYBDUGRDKV-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical class NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- LFWHFZJPXXOYNR-RQZCQDPDSA-N 2-[(3e)-6-fluoro-2-methyl-3-[(4-methylsulfanylphenyl)methylidene]inden-1-yl]acetic acid Chemical compound C1=CC(SC)=CC=C1\C=C/1C2=CC=C(F)C=C2C(CC(O)=O)=C\1C LFWHFZJPXXOYNR-RQZCQDPDSA-N 0.000 description 1
- VRHJBWUIWQOFLF-WLHGVMLRSA-N 2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 VRHJBWUIWQOFLF-WLHGVMLRSA-N 0.000 description 1
- FTGBVHPWUIHWRH-UHFFFAOYSA-N 2-[2-[2-[2-[carboxymethyl-[2-(2-octoxyethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(2-octoxyethoxy)-2-oxoethyl]anilino]acetic acid Chemical compound CCCCCCCCOCCOC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(=O)OCCOCCCCCCCC FTGBVHPWUIHWRH-UHFFFAOYSA-N 0.000 description 1
- WBVDZJSGCDVVRO-UHFFFAOYSA-N 2-[2-hydroxy-3-(5-methyl-2-sulfophenyl)propyl]-4-methylbenzenesulfonic acid Chemical compound CC(C=C1)=CC(CC(CC(C=C(C)C=C2)=C2S(O)(=O)=O)O)=C1S(O)(=O)=O WBVDZJSGCDVVRO-UHFFFAOYSA-N 0.000 description 1
- UIKWDDSLMBHIFT-WKIKZPBSSA-N 2-[4-[(3z)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethyl decanoate Chemical compound C1CN(CCOC(=O)CCCCCCCCC)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 UIKWDDSLMBHIFT-WKIKZPBSSA-N 0.000 description 1
- UEBBYLJZCHTLEG-UTKZUKDTSA-N 2-[[(1r,2s)-6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl]methyl-methylamino]acetic acid Chemical compound C1([C@@H]2C3=CC=C(C=C3CC[C@@H]2CN(C)CC(O)=O)OC)=CC=CC=C1 UEBBYLJZCHTLEG-UTKZUKDTSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- YSGASDXSLKIKOD-UHFFFAOYSA-N 2-amino-N-(1,2-diphenylpropan-2-yl)acetamide Chemical compound C=1C=CC=CC=1C(C)(NC(=O)CN)CC1=CC=CC=C1 YSGASDXSLKIKOD-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- OFCHKLACMXYUHP-UHFFFAOYSA-N 2-fluoro-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile Chemical compound CC1=CC(C#N)=C(F)C=C1B1OC(C)(C)C(C)(C)O1 OFCHKLACMXYUHP-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- NWIQTMVDEWDMAM-UHFFFAOYSA-N 2-fluoropropane-1,3-diol Chemical compound OCC(F)CO NWIQTMVDEWDMAM-UHFFFAOYSA-N 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- KGWNRZLPXLBMPS-UHFFFAOYSA-N 2h-1,3-oxazine Chemical group C1OC=CC=N1 KGWNRZLPXLBMPS-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- JOSXKPZXMVHRKU-UHFFFAOYSA-N 3,5-bis(4-nitrophenoxy)benzoic acid Chemical compound C=1C(OC=2C=CC(=CC=2)[N+]([O-])=O)=CC(C(=O)O)=CC=1OC1=CC=C([N+]([O-])=O)C=C1 JOSXKPZXMVHRKU-UHFFFAOYSA-N 0.000 description 1
- HYHNPUGUPISSQO-FYWRMAATSA-N 3-(2-chlorophenyl)-2-[(e)-2-[6-(diethylaminomethyl)pyridin-2-yl]ethenyl]-6-fluoroquinazolin-4-one Chemical compound CCN(CC)CC1=CC=CC(\C=C\C=2N(C(=O)C3=CC(F)=CC=C3N=2)C=2C(=CC=CC=2)Cl)=N1 HYHNPUGUPISSQO-FYWRMAATSA-N 0.000 description 1
- MHNSPTUQQIYJOT-UHFFFAOYSA-N 3-(6h-benzo[c][1]benzoxepin-11-ylidene)propyl-dimethylazanium;chloride Chemical compound Cl.C1OC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 MHNSPTUQQIYJOT-UHFFFAOYSA-N 0.000 description 1
- KSAUCBGUWGWPDL-UHFFFAOYSA-N 3-(benzenesulfonyl)-5,7-dimethyl-2-methylsulfanylpyrazolo[1,5-a]pyrimidine Chemical compound CSC1=NN2C(C)=CC(C)=NC2=C1S(=O)(=O)C1=CC=CC=C1 KSAUCBGUWGWPDL-UHFFFAOYSA-N 0.000 description 1
- OFKWWALNMPEOSZ-UHFFFAOYSA-N 3-(hydrazinylmethyl)phenol Chemical compound NNCC1=CC=CC(O)=C1 OFKWWALNMPEOSZ-UHFFFAOYSA-N 0.000 description 1
- KJNNWYBAOPXVJY-UHFFFAOYSA-N 3-[4-[2-butyl-1-[4-(4-chlorophenoxy)phenyl]imidazol-4-yl]phenoxy]-n,n-diethylpropan-1-amine Chemical compound CCCCC1=NC(C=2C=CC(OCCCN(CC)CC)=CC=2)=CN1C(C=C1)=CC=C1OC1=CC=C(Cl)C=C1 KJNNWYBAOPXVJY-UHFFFAOYSA-N 0.000 description 1
- JYLNVJYYQQXNEK-UHFFFAOYSA-N 3-amino-2-(4-chlorophenyl)-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(CN)C1=CC=C(Cl)C=C1 JYLNVJYYQQXNEK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- BIAVGWDGIJKWRM-FQEVSTJZSA-N 3-hydroxy-2-phenyl-n-[(1s)-1-phenylpropyl]quinoline-4-carboxamide Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(=O)C(C1=CC=CC=C1N=1)=C(O)C=1C1=CC=CC=C1 BIAVGWDGIJKWRM-FQEVSTJZSA-N 0.000 description 1
- LBSRZVRITCRLIU-UHFFFAOYSA-N 3-o-ethyl 5-o-(2-piperidin-1-ylethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCCCC2)C1C1=CC=CC([N+]([O-])=O)=C1 LBSRZVRITCRLIU-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- UTUUPXBCDMQYRR-HSZRJFAPSA-N 4-[(2r)-2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine Chemical compound COC1=CC=C([C@H](CC=2C=CN=CC=2)C=2C=CC=CC=2)C=C1OC1CCCC1 UTUUPXBCDMQYRR-HSZRJFAPSA-N 0.000 description 1
- PDMUULPVBYQBBK-UHFFFAOYSA-N 4-[(3-butoxy-4-methoxyphenyl)methyl]-2-imidazolidinone Chemical compound C1=C(OC)C(OCCCC)=CC(CC2NC(=O)NC2)=C1 PDMUULPVBYQBBK-UHFFFAOYSA-N 0.000 description 1
- CXFZFEJJLNLOTA-UHFFFAOYSA-N 4-[(3-chlorophenyl)carbamoyloxy]but-2-ynyl-trimethylazanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC#CCOC(=O)NC1=CC=CC(Cl)=C1 CXFZFEJJLNLOTA-UHFFFAOYSA-N 0.000 description 1
- IPHACPSYWWYGQN-UHFFFAOYSA-N 4-[(6-methoxy-3,8-dimethyl-2h-pyrazolo[3,4-b]quinolin-4-yl)methyl]-1,4-oxazepane Chemical compound C=12C=C(OC)C=C(C)C2=NC2=NNC(C)=C2C=1CN1CCCOCC1 IPHACPSYWWYGQN-UHFFFAOYSA-N 0.000 description 1
- AVBKISZUVMWQIA-UHFFFAOYSA-N 4-bromo-2-fluoro-5-methylbenzonitrile Chemical compound CC1=CC(C#N)=C(F)C=C1Br AVBKISZUVMWQIA-UHFFFAOYSA-N 0.000 description 1
- NRPQELCNMADTOZ-OAQYLSRUSA-N 4-cyano-n-[(2r)-2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-n-pyridin-2-ylbenzamide Chemical compound C([C@@H](C)N1CCN(CC1)C=1C=2OCCOC=2C=CC=1)N(C=1N=CC=CC=1)C(=O)C1=CC=C(C#N)C=C1 NRPQELCNMADTOZ-OAQYLSRUSA-N 0.000 description 1
- VJXRKZJMGVSXPX-UHFFFAOYSA-N 4-ethylpyridine Chemical compound CCC1=CC=NC=C1 VJXRKZJMGVSXPX-UHFFFAOYSA-N 0.000 description 1
- SGOOQMRIPALTEL-UHFFFAOYSA-N 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- KGTKBEOZGJLPNC-UHFFFAOYSA-N 4-methyl-2-[3-(5-methyl-2-sulfophenyl)-2-oxopropyl]benzenesulfonic acid Chemical compound CC(C=C1)=CC(CC(CC(C=C(C)C=C2)=C2S(O)(=O)=O)=O)=C1S(O)(=O)=O KGTKBEOZGJLPNC-UHFFFAOYSA-N 0.000 description 1
- GRRBXRZINPHFGD-UHFFFAOYSA-N 4h-quinolin-3-one Chemical compound C1=CC=C2N=CC(=O)CC2=C1 GRRBXRZINPHFGD-UHFFFAOYSA-N 0.000 description 1
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
- QNWOSJAGFSUDFE-UHFFFAOYSA-N 5-(aminooxymethyl)-2-bromophenol Chemical compound NOCC1=CC=C(Br)C(O)=C1 QNWOSJAGFSUDFE-UHFFFAOYSA-N 0.000 description 1
- MXUNKHLAEDCYJL-UHFFFAOYSA-N 5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one Chemical compound CC1=CC=CC(N2C(OC(CO)C2)=O)=C1 MXUNKHLAEDCYJL-UHFFFAOYSA-N 0.000 description 1
- DGWKVXVCPCPOAK-UHFFFAOYSA-N 5-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)oxy]-n-methylpyrazine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CN=C1OC1=CC=C(CCN(CC2)C3CCC3)C2=C1 DGWKVXVCPCPOAK-UHFFFAOYSA-N 0.000 description 1
- JCPWIGCGJUGLJQ-OGFXRTJISA-N 5-[[(2r)-azetidin-2-yl]methoxy]-2-chloropyridine;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C1=NC(Cl)=CC=C1OC[C@@H]1NCC1 JCPWIGCGJUGLJQ-OGFXRTJISA-N 0.000 description 1
- YIEAVVIJPFEHCX-UHFFFAOYSA-N 5-ethyl-2-[5-[4-(2-hydroxyethyl)piperazin-1-yl]sulfonyl-2-propoxyphenyl]-7-propyl-4a,7a-dihydro-3H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound CCCOC1=CC=C(C=C1C1=NC2C(N(CC)C=C2CCC)C(=O)N1)S(=O)(=O)N1CCN(CCO)CC1 YIEAVVIJPFEHCX-UHFFFAOYSA-N 0.000 description 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
- FCBQJNCAKZSIAH-UHFFFAOYSA-N 6-[2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]ethylsulfinyl]-3h-1,3-benzoxazol-2-one Chemical compound C1=CC(F)=CC=C1CC1CCN(CCS(=O)C=2C=C3OC(=O)NC3=CC=2)CC1 FCBQJNCAKZSIAH-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- MEUGUMOVYNSGEW-UHFFFAOYSA-N 7-Hydroxyamoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC(O)=CC=C2N=C1N1CCNCC1 MEUGUMOVYNSGEW-UHFFFAOYSA-N 0.000 description 1
- XFTVOHWWEQGXLS-UHFFFAOYSA-N 8-bromo-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol Chemical compound C1N(C)CCC2=CC(Br)=C(O)C=C2C1C1=CC=CC=C1 XFTVOHWWEQGXLS-UHFFFAOYSA-N 0.000 description 1
- MKJIEFSOBYUXJB-UHFFFAOYSA-N 9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2CC(CC(C)C)C(=O)CC2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-UHFFFAOYSA-N 0.000 description 1
- HJWHHQIVUHOBQN-UHFFFAOYSA-N 9-chloro-5-phenyl-3-prop-2-enyl-1,2,4,5-tetrahydro-3-benzazepine-7,8-diol Chemical compound C1N(CC=C)CCC=2C(Cl)=C(O)C(O)=CC=2C1C1=CC=CC=C1 HJWHHQIVUHOBQN-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010049153 Allergic sinusitis Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000062938 Anapos Species 0.000 description 1
- 108010001779 Ancrod Proteins 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- XEAOPVUAMONVLA-QGZVFWFLSA-N Avagacestat Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)N([C@H](CCC(F)(F)F)C(=O)N)CC(C(=C1)F)=CC=C1C=1N=CON=1 XEAOPVUAMONVLA-QGZVFWFLSA-N 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- XJIUYRIYHOLNLE-UHFFFAOYSA-N BN(C(CC1)=O)C1=O Chemical compound BN(C(CC1)=O)C1=O XJIUYRIYHOLNLE-UHFFFAOYSA-N 0.000 description 1
- VPYXOTRNCRBVBT-UHFFFAOYSA-N Bc1c2OC(C)CC[n]2nc1C(OCC)=O Chemical compound Bc1c2OC(C)CC[n]2nc1C(OCC)=O VPYXOTRNCRBVBT-UHFFFAOYSA-N 0.000 description 1
- BLRCTZLOSJQHFY-UHFFFAOYSA-N Bc1c2OCCC(C)[n]2nc1C(OCC)=O Chemical compound Bc1c2OCCC(C)[n]2nc1C(OCC)=O BLRCTZLOSJQHFY-UHFFFAOYSA-N 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 206010060999 Benign neoplasm Diseases 0.000 description 1
- 102100021257 Beta-secretase 1 Human genes 0.000 description 1
- XVGOZDAJGBALKS-UHFFFAOYSA-N Blonanserin Chemical compound C1CN(CC)CCN1C1=CC(C=2C=CC(F)=CC=2)=C(CCCCCC2)C2=N1 XVGOZDAJGBALKS-UHFFFAOYSA-N 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- HWIXWOYUNOOYNZ-UHFFFAOYSA-N BrC=1C(=NN2C=1OCCC2C)C(=O)OCC Chemical compound BrC=1C(=NN2C=1OCCC2C)C(=O)OCC HWIXWOYUNOOYNZ-UHFFFAOYSA-N 0.000 description 1
- IOSAXDLGYYUPGT-YFKPBYRVSA-N BrC=1C(=NN2C=1OC[C@H](C2)F)C(=O)NC1CC1 Chemical compound BrC=1C(=NN2C=1OC[C@H](C2)F)C(=O)NC1CC1 IOSAXDLGYYUPGT-YFKPBYRVSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- CRWXUEWMLPODHY-UHFFFAOYSA-N C#CCCC.CCC Chemical compound C#CCCC.CCC CRWXUEWMLPODHY-UHFFFAOYSA-N 0.000 description 1
- RXEJADJURMFUCD-CYBMUJFWSA-N C1(=CC=CC=C1)S(=O)(=O)N[C@@H](C(CC)CC)CO Chemical compound C1(=CC=CC=C1)S(=O)(=O)N[C@@H](C(CC)CC)CO RXEJADJURMFUCD-CYBMUJFWSA-N 0.000 description 1
- VBMYGJCOPNXMKF-QMMMGPOBSA-N C1CC1N2CC(=C3N2C[C@@H](CO3)F)C4=CC(=C(C=C4F)Cl)F Chemical compound C1CC1N2CC(=C3N2C[C@@H](CO3)F)C4=CC(=C(C=C4F)Cl)F VBMYGJCOPNXMKF-QMMMGPOBSA-N 0.000 description 1
- 108010081642 CA 074 methyl ester Proteins 0.000 description 1
- SYELXSFXIYSHTO-UHFFFAOYSA-N CC(CCOc1c2)[n]1nc2C(OC=C)=O Chemical compound CC(CCOc1c2)[n]1nc2C(OC=C)=O SYELXSFXIYSHTO-UHFFFAOYSA-N 0.000 description 1
- AOLQTUHQPNITNH-UHFFFAOYSA-N CCOC(c1n[n](C(C)CCO2)c2c1-c1ccc(C)cc1)=O Chemical compound CCOC(c1n[n](C(C)CCO2)c2c1-c1ccc(C)cc1)=O AOLQTUHQPNITNH-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 102100028892 Cardiotrophin-1 Human genes 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 0 Cc(cc(cc1)Cl)c1C1=C2OCCCN2NC1*(N1CCC1)=O Chemical compound Cc(cc(cc1)Cl)c1C1=C2OCCCN2NC1*(N1CCC1)=O 0.000 description 1
- LCDYAXIRPINPDS-UHFFFAOYSA-N Cc(cc(cc1)Cl)c1S(O)O Chemical compound Cc(cc(cc1)Cl)c1S(O)O LCDYAXIRPINPDS-UHFFFAOYSA-N 0.000 description 1
- FHEWIPLOQBOBQN-UHFFFAOYSA-N Cc(cc1)ccc1-c1c2OCC=C(C)[n]2nc1C(O)=O Chemical compound Cc(cc1)ccc1-c1c2OCC=C(C)[n]2nc1C(O)=O FHEWIPLOQBOBQN-UHFFFAOYSA-N 0.000 description 1
- 206010064012 Central pain syndrome Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 description 1
- 239000004381 Choline salt Substances 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 208000022497 Cocaine-Related disease Diseases 0.000 description 1
- REPUIDONRHUURG-HQIVDAARSA-N Coelovirin C Natural products O=C(O)[C@H](O)[C@](O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)([C@@H](CC)C)C(=O)OCc1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1 REPUIDONRHUURG-HQIVDAARSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- DSCFFEYYQKSRSV-KLJZZCKASA-N D-pinitol Chemical compound CO[C@@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]1O DSCFFEYYQKSRSV-KLJZZCKASA-N 0.000 description 1
- 229940081615 DOPA decarboxylase inhibitor Drugs 0.000 description 1
- HCMCKZWEUHDBNH-IGPVODHVSA-N Dactylorhin B Natural products O=C(OCc1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1)[C@@H](O)[C@](O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)([C@H](CC)C)C(=O)OCc1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1 HCMCKZWEUHDBNH-IGPVODHVSA-N 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 108010057987 Desmodus rotundus salivary plasminogen activator alpha 1 Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 102100022273 Disrupted in schizophrenia 1 protein Human genes 0.000 description 1
- 101710118116 Disrupted in schizophrenia 1 protein Proteins 0.000 description 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 1
- 229940121891 Dopamine receptor antagonist Drugs 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 206010013754 Drug withdrawal syndrome Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- NLPRAJRHRHZCQQ-UHFFFAOYSA-N Epibatidine Natural products C1=NC(Cl)=CC=C1C1C(N2)CCC2C1 NLPRAJRHRHZCQQ-UHFFFAOYSA-N 0.000 description 1
- 206010073681 Epidural haemorrhage Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010015605 Excessive masturbation Diseases 0.000 description 1
- 208000027776 Extrapyramidal disease Diseases 0.000 description 1
- 208000026097 Factitious disease Diseases 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- LFMYNZPAVPMEGP-PIDGMYBPSA-N Fluvoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 LFMYNZPAVPMEGP-PIDGMYBPSA-N 0.000 description 1
- 208000010235 Food Addiction Diseases 0.000 description 1
- XWLUWCNOOVRFPX-UHFFFAOYSA-N Fosphenytoin Chemical compound O=C1N(COP(O)(=O)O)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 XWLUWCNOOVRFPX-UHFFFAOYSA-N 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000001613 Gambling Diseases 0.000 description 1
- 102100030671 Gastrin-releasing peptide receptor Human genes 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- BXNJHAXVSOCGBA-UHFFFAOYSA-N Harmine Chemical compound N1=CC=C2C3=CC=C(OC)C=C3NC2=C1C BXNJHAXVSOCGBA-UHFFFAOYSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 1
- 101001010479 Homo sapiens Gastrin-releasing peptide receptor Proteins 0.000 description 1
- 101100296709 Homo sapiens PDE4B gene Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010021030 Hypomania Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000030990 Impulse-control disease Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100021496 Insulin-degrading enzyme Human genes 0.000 description 1
- 108090000828 Insulysin Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000045959 Interleukin-1 Receptor-Like 1 Human genes 0.000 description 1
- 108700003107 Interleukin-1 Receptor-Like 1 Proteins 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 239000001358 L(+)-tartaric acid Substances 0.000 description 1
- 235000011002 L(+)-tartaric acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 1
- WXFIGDLSSYIKKV-RCOVLWMOSA-N L-Metaraminol Chemical compound C[C@H](N)[C@H](O)C1=CC=CC(O)=C1 WXFIGDLSSYIKKV-RCOVLWMOSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- DAQAKHDKYAWHCG-UHFFFAOYSA-N Lactacystin Natural products CC(=O)NC(C(O)=O)CSC(=O)C1(C(O)C(C)C)NC(=O)C(C)C1O DAQAKHDKYAWHCG-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 108010016230 MBP-8298 Proteins 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- JUOSGGQXEBBCJB-UHFFFAOYSA-N Metanicotine Natural products CNCCC=CC1=CC=CN=C1 JUOSGGQXEBBCJB-UHFFFAOYSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- RLJFTICUTYVZDG-UHFFFAOYSA-N Methiothepine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2CC1N1CCN(C)CC1 RLJFTICUTYVZDG-UHFFFAOYSA-N 0.000 description 1
- WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 description 1
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- BATFHSIVMJJJAF-UHFFFAOYSA-N Morindone Chemical compound OC1=CC=C2C(=O)C3=C(O)C(C)=CC=C3C(=O)C2=C1O BATFHSIVMJJJAF-UHFFFAOYSA-N 0.000 description 1
- 208000015903 Munchausen Syndrome Diseases 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- YLXDSYKOBKBWJQ-LBPRGKRZSA-N N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide Chemical compound C1=C2OCCC2=C2[C@H](CCNC(=O)CC)CCC2=C1 YLXDSYKOBKBWJQ-LBPRGKRZSA-N 0.000 description 1
- JNNOSTQEZICQQP-UHFFFAOYSA-N N-desmethylclozapine Chemical compound N=1C2=CC(Cl)=CC=C2NC2=CC=CC=C2C=1N1CCNCC1 JNNOSTQEZICQQP-UHFFFAOYSA-N 0.000 description 1
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 1
- SJDOMIRMMUGQQK-UHFFFAOYSA-N NAN 190 Chemical compound COC1=CC=CC=C1N1CCN(CCCCN2C(C3=CC=CC=C3C2=O)=O)CC1 SJDOMIRMMUGQQK-UHFFFAOYSA-N 0.000 description 1
- OJNSNSZTGUACNI-IBFUIWIBSA-N N[C@H](CC(O)=O)C(O)=O.CC(N)CC1=CC=CC=C1.CC(N)CC1=CC=CC=C1 Chemical compound N[C@H](CC(O)=O)C(O)=O.CC(N)CC1=CC=CC=C1.CC(N)CC1=CC=CC=C1 OJNSNSZTGUACNI-IBFUIWIBSA-N 0.000 description 1
- 229910019093 NaOCl Inorganic materials 0.000 description 1
- 208000018526 Narcotic-Related disease Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- UPMRZALMHVUCIN-UHFFFAOYSA-N Nitecapone Chemical compound CC(=O)C(C(C)=O)=CC1=CC(O)=C(O)C([N+]([O-])=O)=C1 UPMRZALMHVUCIN-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 description 1
- DITOENWBJBNZSL-UHFFFAOYSA-N O-methyl-hippeastrine Natural products C1=C2C3C4N(C)CCC4=CC(OC)C3OC(=O)C2=CC2=C1OCO2 DITOENWBJBNZSL-UHFFFAOYSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 208000026251 Opioid-Related disease Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- RSDOPYMFZBJHRL-UHFFFAOYSA-N Oxotremorine Chemical compound O=C1CCCN1CC#CCN1CCCC1 RSDOPYMFZBJHRL-UHFFFAOYSA-N 0.000 description 1
- 102000039036 PDE4 family Human genes 0.000 description 1
- 108091065684 PDE4 family Proteins 0.000 description 1
- 101150056090 PDE4B gene Proteins 0.000 description 1
- 229940076380 PDE9 inhibitor Drugs 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 208000022779 Passive-Aggressive Personality disease Diseases 0.000 description 1
- 206010034158 Pathological gambling Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- 208000012202 Pervasive developmental disease Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 229940122233 Phosphodiesterase 8B inhibitor Drugs 0.000 description 1
- 229940121836 Phosphodiesterase 1 inhibitor Drugs 0.000 description 1
- 229940122353 Phosphodiesterase 11 inhibitor Drugs 0.000 description 1
- 229940121828 Phosphodiesterase 2 inhibitor Drugs 0.000 description 1
- 229940123263 Phosphodiesterase 3 inhibitor Drugs 0.000 description 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 1
- 229940123304 Phosphodiesterase 7 inhibitor Drugs 0.000 description 1
- 108050008598 Phosphoesterases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 208000024571 Pick disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- RBQOQRRFDPXAGN-UHFFFAOYSA-N Propentofylline Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC RBQOQRRFDPXAGN-UHFFFAOYSA-N 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039094 Rhinitis perennial Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 208000008039 Secondary Parkinson Disease Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- 206010042364 Subdural haemorrhage Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 206010042928 Syringomyelia Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- JOAHPSVPXZTVEP-YXJHDRRASA-N Terguride Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NC(=O)N(CC)CC)=C3C2=CNC3=C1 JOAHPSVPXZTVEP-YXJHDRRASA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- DHCOPPHTVOXDKU-UHFFFAOYSA-N Tofimilast Chemical compound C1CN2C(C=3SC=CC=3)=NN=C2C2=C1C(CC)=NN2C1CCCC1 DHCOPPHTVOXDKU-UHFFFAOYSA-N 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 206010044074 Torticollis Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000009443 Vascular Malformations Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- VOXIUXZAOFEFBL-UHFFFAOYSA-N Voacangin Natural products CCC1CC2CN3CC1C(C2)(OC(=O)C)c4[nH]c5ccc(OC)cc5c4C3 VOXIUXZAOFEFBL-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000013142 Writer cramp Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- WVHBEIJGAINUBW-UHFFFAOYSA-N Xaliproden hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WVHBEIJGAINUBW-UHFFFAOYSA-N 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- IHHXIUAEPKVVII-ZSCHJXSPSA-N [(1s)-5-amino-1-carboxypentyl]azanium;2-[4-(2-methylpropyl)phenyl]propanoate Chemical compound OC(=O)[C@@H](N)CCCC[NH3+].CC(C)CC1=CC=C(C(C)C([O-])=O)C=C1 IHHXIUAEPKVVII-ZSCHJXSPSA-N 0.000 description 1
- JGAGHIIOCADQOV-CTNGQTDRSA-N [(3ar,8bs)-3,4,8b-trimethyl-2,3a-dihydro-1h-pyrrolo[2,3-b]indol-7-yl] n-(2-methylphenyl)carbamate Chemical compound CN([C@@H]1[C@@](C2=C3)(C)CCN1C)C2=CC=C3OC(=O)NC1=CC=CC=C1C JGAGHIIOCADQOV-CTNGQTDRSA-N 0.000 description 1
- PBHFNBQPZCRWQP-QUCCMNQESA-N [(3ar,8bs)-3,4,8b-trimethyl-2,3a-dihydro-1h-pyrrolo[2,3-b]indol-7-yl] n-phenylcarbamate Chemical compound CN([C@@H]1[C@@](C2=C3)(C)CCN1C)C2=CC=C3OC(=O)NC1=CC=CC=C1 PBHFNBQPZCRWQP-QUCCMNQESA-N 0.000 description 1
- YYBNDIVPHIWTPK-KYJQVDHRSA-N [(3as,8bs)-3,4,8b-trimethyl-1,2,3,3a-tetrahydropyrrolo[2,3-b]indol-3-ium-7-yl] n-methylcarbamate;sulfate Chemical compound [O-]S([O-])(=O)=O.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CC[NH+]2C.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CC[NH+]2C YYBNDIVPHIWTPK-KYJQVDHRSA-N 0.000 description 1
- ZOBDWFRKFSPCRB-UNMCSNQZSA-N [(4as,9as)-2,4a,9-trimethyl-4,9a-dihydro-3h-oxazino[6,5-b]indol-6-yl] n-(2-ethylphenyl)carbamate Chemical compound CCC1=CC=CC=C1NC(=O)OC1=CC=C(N(C)[C@@H]2[C@@]3(C)CCN(C)O2)C3=C1 ZOBDWFRKFSPCRB-UNMCSNQZSA-N 0.000 description 1
- FCGXYEQRXFTVRW-UHFFFAOYSA-N [2,2-difluoro-3-(4-methylphenyl)sulfonyloxypropyl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCC(F)(F)COS(=O)(=O)C1=CC=C(C)C=C1 FCGXYEQRXFTVRW-UHFFFAOYSA-N 0.000 description 1
- FKWIITNJZCDZQR-UHFFFAOYSA-N [2-fluoro-3-(4-methylphenyl)sulfonyloxypropyl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCC(F)COS(=O)(=O)C1=CC=C(C)C=C1 FKWIITNJZCDZQR-UHFFFAOYSA-N 0.000 description 1
- HXRNADMHJBXZGO-UHFFFAOYSA-N [5-chloro-2-(4-methoxyphenyl)-1-benzofuran-3-yl]-[4-[3-(diethylamino)propoxy]phenyl]methanone Chemical compound C1=CC(OCCCN(CC)CC)=CC=C1C(=O)C1=C(C=2C=CC(OC)=CC=2)OC2=CC=C(Cl)C=C12 HXRNADMHJBXZGO-UHFFFAOYSA-N 0.000 description 1
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- KRHYYFGTRYWZRS-BJUDXGSMSA-N ac1l2y5h Chemical compound [18FH] KRHYYFGTRYWZRS-BJUDXGSMSA-N 0.000 description 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 description 1
- 229960004047 acamprosate Drugs 0.000 description 1
- BUVGWDNTAWHSKI-UHFFFAOYSA-L acamprosate calcium Chemical compound [Ca+2].CC(=O)NCCCS([O-])(=O)=O.CC(=O)NCCCS([O-])(=O)=O BUVGWDNTAWHSKI-UHFFFAOYSA-L 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960002122 acebutolol Drugs 0.000 description 1
- KTUFKADDDORSSI-UHFFFAOYSA-N acebutolol hydrochloride Chemical compound Cl.CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 KTUFKADDDORSSI-UHFFFAOYSA-N 0.000 description 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000026345 acute stress disease Diseases 0.000 description 1
- 229940092980 adalat Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229940047812 adderall Drugs 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- CGNMLOKEMNBUAI-UHFFFAOYSA-N adrafinil Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)NO)C1=CC=CC=C1 CGNMLOKEMNBUAI-UHFFFAOYSA-N 0.000 description 1
- 229960002820 adrafinil Drugs 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940013181 advil Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229940060515 aleve Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- DXUUXWKFVDVHIK-UHFFFAOYSA-N ambenonium chloride Chemical compound [Cl-].[Cl-].C=1C=CC=C(Cl)C=1C[N+](CC)(CC)CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl DXUUXWKFVDVHIK-UHFFFAOYSA-N 0.000 description 1
- 229960000959 amineptine Drugs 0.000 description 1
- ONNOFKFOZAJDHT-UHFFFAOYSA-N amineptine Chemical compound C1CC2=CC=CC=C2C(NCCCCCCC(=O)O)C2=CC=CC=C21 ONNOFKFOZAJDHT-UHFFFAOYSA-N 0.000 description 1
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- 229940052327 amphetamine aspartate Drugs 0.000 description 1
- PYHRZPFZZDCOPH-UHFFFAOYSA-N amphetamine sulfate Chemical compound OS(O)(=O)=O.CC(N)CC1=CC=CC=C1.CC(N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-UHFFFAOYSA-N 0.000 description 1
- 229940008238 amphetamine sulfate Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
- 229960001694 anagrelide Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940072359 anaprox Drugs 0.000 description 1
- 229960004233 ancrod Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229960000793 aniracetam Drugs 0.000 description 1
- ZXNRTKGTQJPIJK-UHFFFAOYSA-N aniracetam Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(=O)CCC1 ZXNRTKGTQJPIJK-UHFFFAOYSA-N 0.000 description 1
- 229940089918 ansaid Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 229940070343 apokyn Drugs 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000005735 apoptotic response Effects 0.000 description 1
- BFNCJMURTMZBTE-UHFFFAOYSA-N aptiganel Chemical compound CCC1=CC=CC(N(C)C(N)=NC=2C3=CC=CC=C3C=CC=2)=C1 BFNCJMURTMZBTE-UHFFFAOYSA-N 0.000 description 1
- 229950001180 aptiganel Drugs 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229950011582 arimoclomol Drugs 0.000 description 1
- 229960004823 armodafinil Drugs 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 229950005776 arundic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229960005245 asenapine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 229960000307 avanafil Drugs 0.000 description 1
- WEAJZXNPAWBCOA-INIZCTEOSA-N avanafil Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(N2[C@@H](CCC2)CO)=NC=C1C(=O)NCC1=NC=CC=N1 WEAJZXNPAWBCOA-INIZCTEOSA-N 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 229940031774 azilect Drugs 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 229950001863 bapineuzumab Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 208000018300 basal ganglia disease Diseases 0.000 description 1
- MYTWFJKBZGMYCS-NQIIRXRSSA-N bay 60-7550 Chemical compound C1=C(OC)C(OC)=CC=C1CC(NN12)=NC(=O)C1=C(C)N=C2[C@H]([C@@H](C)O)CCCC1=CC=CC=C1 MYTWFJKBZGMYCS-NQIIRXRSSA-N 0.000 description 1
- IALVDLPLCLFBCF-CHWSQXEVSA-N befloxatone Chemical compound O=C1O[C@@H](COC)CN1C1=CC=C(OCC[C@@H](O)C(F)(F)F)C=C1 IALVDLPLCLFBCF-CHWSQXEVSA-N 0.000 description 1
- 229950000017 befloxatone Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229940088007 benadryl Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
- 229960000911 benserazide Drugs 0.000 description 1
- 229940090012 bentyl Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 1
- 229960002837 benzphetamine Drugs 0.000 description 1
- 229940024774 benztropine mesylate Drugs 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000002439 beta secretase inhibitor Substances 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229940021459 betaseron Drugs 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 239000003225 biodiesel Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- KGCBATGZRGGGQG-KQHOVRMTSA-N bis[[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]methyl] (2R,3S)-3-hydroxy-2-(2-methylpropyl)-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybutanedioate Chemical compound O([C@](CC(C)C)([C@H](O)C(=O)OCC=1C=CC(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=1)C(=O)OCC=1C=CC(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KGCBATGZRGGGQG-KQHOVRMTSA-N 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- OXKRFEWMSWPKKV-RXVVDRJESA-N bradanicline Chemical compound C([C@@H]1N2CCC(CC2)[C@@H]1NC(=O)C=1OC2=CC=CC=C2C=1)C1=CC=CN=C1 OXKRFEWMSWPKKV-RXVVDRJESA-N 0.000 description 1
- 229940097683 brevibloc Drugs 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229940088033 calan Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229940058898 campral Drugs 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- QTAOMKOIBXZKND-PPHPATTJSA-N carbidopa Chemical compound O.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 QTAOMKOIBXZKND-PPHPATTJSA-N 0.000 description 1
- 229960004205 carbidopa Drugs 0.000 description 1
- 229950005499 carbon tetrachloride Drugs 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229940097611 cardene Drugs 0.000 description 1
- 108010041776 cardiotrophin 1 Proteins 0.000 description 1
- 229940088029 cardizem Drugs 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229940063628 catapres Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229940047493 celexa Drugs 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 229940029783 cerebyx Drugs 0.000 description 1
- 201000002866 cervical dystonia Diseases 0.000 description 1
- WUTYZMFRCNBCHQ-PSASIEDQSA-N cevimeline Chemical compound C1S[C@H](C)O[C@]21C(CC1)CCN1C2 WUTYZMFRCNBCHQ-PSASIEDQSA-N 0.000 description 1
- 229960001314 cevimeline Drugs 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- FFPXPXOAFQCNBS-MRVPVSSYSA-N chembl1513993 Chemical compound N1=CC=2C(=O)NC(C[C@@H](C)C(F)(F)F)=NC=2N1C1=CC=CC=C1Cl FFPXPXOAFQCNBS-MRVPVSSYSA-N 0.000 description 1
- RCTCWZRPYFBGLQ-KVBIMOIYSA-N chembl2105639 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 RCTCWZRPYFBGLQ-KVBIMOIYSA-N 0.000 description 1
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JOYKCMAPFCSKNO-UHFFFAOYSA-N chloro benzenesulfonate Chemical compound ClOS(=O)(=O)C1=CC=CC=C1 JOYKCMAPFCSKNO-UHFFFAOYSA-N 0.000 description 1
- NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 235000019417 choline salt Nutrition 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 229960001284 citicoline Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229960005228 clioquinol Drugs 0.000 description 1
- 229960004414 clomethiazole Drugs 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 201000006145 cocaine dependence Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940097480 cogentin Drugs 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 108010002212 colostrinine Proteins 0.000 description 1
- 229940003372 compro Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940038717 copaxone Drugs 0.000 description 1
- 229940097488 corgard Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- JCWIWBWXCVGEAN-UHFFFAOYSA-L cyclopentyl(diphenyl)phosphane;dichloropalladium;iron Chemical compound [Fe].Cl[Pd]Cl.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1 JCWIWBWXCVGEAN-UHFFFAOYSA-L 0.000 description 1
- 229940029644 cymbalta Drugs 0.000 description 1
- 229940022769 d- lactic acid Drugs 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- WBSSVHBTDKPYQF-UHFFFAOYSA-N dactylorhin D Natural products C=1C=C(OC2C(C(O)C(O)C(CO)O2)O)C=CC=1COC(=O)C(CC(C)C)(C(O)C(O)=O)OC1OC(CO)C(O)C(O)C1O WBSSVHBTDKPYQF-UHFFFAOYSA-N 0.000 description 1
- 229940006829 daliresp Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229940098357 daytrana Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 229940075922 depacon Drugs 0.000 description 1
- 229940075925 depakote Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000007357 depressive behavior Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 229950001282 desmoteplase Drugs 0.000 description 1
- 229940099340 desoxyn Drugs 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 229960001623 desvenlafaxine Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940076405 detrol Drugs 0.000 description 1
- 239000011903 deuterated solvents Substances 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- SSQJFGMEZBFMNV-PMACEKPBSA-N dexanabinol Chemical compound C1C(CO)=CC[C@@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@H]21 SSQJFGMEZBFMNV-PMACEKPBSA-N 0.000 description 1
- 229940099242 dexedrine Drugs 0.000 description 1
- 229960001042 dexmethylphenidate Drugs 0.000 description 1
- DUGOZIWVEXMGBE-CHWSQXEVSA-N dexmethylphenidate Chemical compound C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-CHWSQXEVSA-N 0.000 description 1
- 229940052370 dextroamphetamine saccharate Drugs 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- LMEDOLJKVASKTP-UHFFFAOYSA-N dibutyl sulfate Chemical compound CCCCOS(=O)(=O)OCCCC LMEDOLJKVASKTP-UHFFFAOYSA-N 0.000 description 1
- KXZOIWWTXOCYKR-UHFFFAOYSA-M diclofenac potassium Chemical compound [K+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KXZOIWWTXOCYKR-UHFFFAOYSA-M 0.000 description 1
- 229960004515 diclofenac potassium Drugs 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 1
- GUBNMFJOJGDCEL-UHFFFAOYSA-N dicyclomine hydrochloride Chemical compound [Cl-].C1CCCCC1C1(C(=O)OCC[NH+](CC)CC)CCCCC1 GUBNMFJOJGDCEL-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 1
- 229940008406 diethyl sulfate Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 150000005332 diethylamines Chemical class 0.000 description 1
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 1
- PBUNVLRHZGSROC-VTIMJTGVSA-N dihydro-alpha-ergocryptine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1 PBUNVLRHZGSROC-VTIMJTGVSA-N 0.000 description 1
- 229960002032 dihydroergocryptine Drugs 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZVXHZSXYHFBIEW-UHFFFAOYSA-N dimethyl 2-fluoropropanedioate Chemical compound COC(=O)C(F)C(=O)OC ZVXHZSXYHFBIEW-UHFFFAOYSA-N 0.000 description 1
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 description 1
- 229960004419 dimethyl fumarate Drugs 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical compound CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- XLZOVRYBVCMCGL-BPNVQINPSA-L disodium;4-[(z)-[tert-butyl(oxido)azaniumylidene]methyl]benzene-1,3-disulfonate Chemical compound [Na+].[Na+].CC(C)(C)[N+](\[O-])=C\C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O XLZOVRYBVCMCGL-BPNVQINPSA-L 0.000 description 1
- SACNIGZYDTUHKB-UHFFFAOYSA-N ditert-butyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C(C)(C)C)C(C)(C)C SACNIGZYDTUHKB-UHFFFAOYSA-N 0.000 description 1
- 229940099170 ditropan Drugs 0.000 description 1
- 229950004794 dizocilpine Drugs 0.000 description 1
- 229940048879 dl tartaric acid Drugs 0.000 description 1
- 229940110377 dl- arginine Drugs 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940072340 dolophine Drugs 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 229960003135 donepezil hydrochloride Drugs 0.000 description 1
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 229950009714 ecopipam Drugs 0.000 description 1
- 229960003748 edrophonium Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229940098766 effexor Drugs 0.000 description 1
- 229940011681 elavil Drugs 0.000 description 1
- 229940084238 eldepryl Drugs 0.000 description 1
- 229940071670 emsam Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 230000008497 endothelial barrier function Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940072357 enlon Drugs 0.000 description 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
- 229960003337 entacapone Drugs 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- NLPRAJRHRHZCQQ-IVZWLZJFSA-N epibatidine Chemical compound C1=NC(Cl)=CC=C1[C@@H]1[C@H](N2)CC[C@H]2C1 NLPRAJRHRHZCQQ-IVZWLZJFSA-N 0.000 description 1
- 229960003367 ersofermin Drugs 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- 229960003745 esmolol Drugs 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical compound N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 description 1
- QOGSRABDPHBSNV-NSHDSACASA-N ethyl (6S)-3-(4-chloro-2-methylphenyl)-6-fluoro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxylate Chemical compound ClC1=CC(=C(C=C1)C=1C(=NN2C=1OC[C@H](C2)F)C(=O)OCC)C QOGSRABDPHBSNV-NSHDSACASA-N 0.000 description 1
- OEGQDEQMIBCRQA-UHFFFAOYSA-N ethyl 3-(4-chloro-2,3-difluorophenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxylate Chemical compound ClC1=C(C(=C(C=C1)C=1C(=NN2C=1OCCC2)C(=O)OCC)F)F OEGQDEQMIBCRQA-UHFFFAOYSA-N 0.000 description 1
- LIVBXUFCKSHUTN-UHFFFAOYSA-N ethyl 3-(4-chlorophenyl)-5-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxylate Chemical compound ClC1=CC=C(C=C1)C=1C(=NN2C=1OC(CC2)C)C(=O)OCC LIVBXUFCKSHUTN-UHFFFAOYSA-N 0.000 description 1
- NWEGXSNJVQIJET-UHFFFAOYSA-N ethyl 3-(4-chlorophenyl)-7-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxylate Chemical compound ClC1=CC=C(C=C1)C=1C(=NN2C=1OCCC2C)C(=O)OCC NWEGXSNJVQIJET-UHFFFAOYSA-N 0.000 description 1
- AMMZENYQMTVOQP-UHFFFAOYSA-N ethyl 3-(4-cyano-3-fluorophenyl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxylate Chemical compound CCOC(=O)c1nn2CCCOc2c1-c1ccc(C#N)c(F)c1 AMMZENYQMTVOQP-UHFFFAOYSA-N 0.000 description 1
- LEDMDQUWGTXLKY-UHFFFAOYSA-N ethyl 3-bromo-5-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxylate Chemical compound BrC=1C(=NN2C=1OC(CC2)C)C(=O)OCC LEDMDQUWGTXLKY-UHFFFAOYSA-N 0.000 description 1
- PYKKGBVPQBHKQH-UHFFFAOYSA-N ethyl 3-bromo-6,6-difluoro-5,7-dihydropyrazolo[5,1-b][1,3]oxazine-2-carboxylate Chemical compound CCOC(=O)c1nn2CC(F)(F)COc2c1Br PYKKGBVPQBHKQH-UHFFFAOYSA-N 0.000 description 1
- LWJQNZGEBBWCFP-UHFFFAOYSA-N ethyl 3-bromo-6-fluoro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxylate Chemical compound BrC=1C(=NN2C=1OCC(C2)F)C(=O)OCC LWJQNZGEBBWCFP-UHFFFAOYSA-N 0.000 description 1
- FGCPAXRNQIOISG-UHFFFAOYSA-N ethyl 5-oxo-1,2-dihydropyrazole-3-carboxylate Chemical compound CCOC(=O)C=1C=C(O)NN=1 FGCPAXRNQIOISG-UHFFFAOYSA-N 0.000 description 1
- CHMLPWXOSRALQJ-UHFFFAOYSA-N ethyl 6,6-difluoro-5,7-dihydropyrazolo[5,1-b][1,3]oxazine-2-carboxylate Chemical compound FC1(CN2C(OC1)=CC(=N2)C(=O)OCC)F CHMLPWXOSRALQJ-UHFFFAOYSA-N 0.000 description 1
- MFJQBPOGFVVDAN-UHFFFAOYSA-N ethyl 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxylate Chemical compound O1CCCN2N=C(C(=O)OCC)C=C21 MFJQBPOGFVVDAN-UHFFFAOYSA-N 0.000 description 1
- SNSXVLPZBPAQGM-UHFFFAOYSA-N ethyl 6-fluoro-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxylate Chemical compound FC1CN2C(OC1)=CC(=N2)C(=O)OCC SNSXVLPZBPAQGM-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 229940108366 exelon Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 231100000040 eye damage Toxicity 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-UHFFFAOYSA-N felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 description 1
- OJSFTALXCYKKFQ-YLJYHZDGSA-N femoxetine Chemical compound C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 OJSFTALXCYKKFQ-YLJYHZDGSA-N 0.000 description 1
- 229950003930 femoxetine Drugs 0.000 description 1
- NMCHYWGKBADVMK-UHFFFAOYSA-N fenetylline Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCNC(C)CC1=CC=CC=C1 NMCHYWGKBADVMK-UHFFFAOYSA-N 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 229960002724 fenoldopam Drugs 0.000 description 1
- TVURRHSHRRELCG-UHFFFAOYSA-N fenoldopam Chemical compound C1=CC(O)=CC=C1C1C2=CC(O)=C(O)C(Cl)=C2CCNC1 TVURRHSHRRELCG-UHFFFAOYSA-N 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960002419 flupentixol Drugs 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 229960001374 fluphenazine decanoate Drugs 0.000 description 1
- VIQCGTZFEYDQMR-UHFFFAOYSA-N fluphenazine decanoate Chemical compound C1CN(CCOC(=O)CCCCCCCCC)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 VIQCGTZFEYDQMR-UHFFFAOYSA-N 0.000 description 1
- 229960001258 fluphenazine hydrochloride Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 201000002904 focal dystonia Diseases 0.000 description 1
- 201000002865 focal hand dystonia Diseases 0.000 description 1
- 229940053650 focalin Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- ZZBSPTCNZDTZBR-QGXZNONUSA-N formobactin Chemical compound N([C@@H](CCCCN(O)C=O)C(=O)OC(CCCCCCCCC)C(C)(C)C(=O)NC1C(N(O)CCCC1)=O)C(=O)C(=C(O1)C)N=C1C1=CC=CC=C1O ZZBSPTCNZDTZBR-QGXZNONUSA-N 0.000 description 1
- HEDXEAAVEOJUCR-UHFFFAOYSA-N furtrethonium Chemical compound C[N+](C)(C)CC1=CC=CO1 HEDXEAAVEOJUCR-UHFFFAOYSA-N 0.000 description 1
- 229950008234 furtrethonium Drugs 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 229960002024 galantamine hydrobromide Drugs 0.000 description 1
- 229950000264 ganstigmine Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 229940003380 geodon Drugs 0.000 description 1
- 229960003776 glatiramer acetate Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 229940015042 glycopyrrolate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960002048 guanfacine Drugs 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 239000000380 hallucinogen Substances 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- NIBOMXUDFLRHRV-UHFFFAOYSA-N hydron;8-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-8-azaspiro[4.5]decane-7,9-dione;dichloride Chemical compound Cl.Cl.COC1=CC=CC=C1N1CCN(CCN2C(CC3(CCCC3)CC2=O)=O)CC1 NIBOMXUDFLRHRV-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229930005342 hyoscyamine Natural products 0.000 description 1
- 229960003210 hyoscyamine Drugs 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- HSIBGVUMFOSJPD-CFDPKNGZSA-N ibogaine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(OC)C=C12 HSIBGVUMFOSJPD-CFDPKNGZSA-N 0.000 description 1
- OLOCMRXSJQJJPL-UHFFFAOYSA-N ibogaine Natural products CCC1CC2CC3C1N(C2)C=Cc4c3[nH]c5ccc(OC)cc45 OLOCMRXSJQJJPL-UHFFFAOYSA-N 0.000 description 1
- AREITJMUSRHSBK-UHFFFAOYSA-N ibogamine Natural products CCC1CC2C3CC1CN2CCc4c3[nH]c5ccccc45 AREITJMUSRHSBK-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229960004135 idebenone Drugs 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 229960003162 iloperidone Drugs 0.000 description 1
- 125000004282 imidazolidin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])N([H])C1([H])* 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960002102 imipramine hydrochloride Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000005032 impulse control Effects 0.000 description 1
- 229940073062 imuran Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229950008308 indantadol Drugs 0.000 description 1
- 229940095990 inderal Drugs 0.000 description 1
- 230000000053 inderal effect Effects 0.000 description 1
- 125000003406 indolizinyl group Chemical class C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229960004461 interferon beta-1a Drugs 0.000 description 1
- 229960003161 interferon beta-1b Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 208000015046 intermittent explosive disease Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229950010499 ipenoxazone Drugs 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- RPCVIAXDAUMJJP-PZBABLGHSA-N ispronicline Chemical compound CN[C@@H](C)C\C=C\C1=CN=CC(OC(C)C)=C1 RPCVIAXDAUMJJP-PZBABLGHSA-N 0.000 description 1
- 229950001646 ispronicline Drugs 0.000 description 1
- PTKHFRNHJULJKT-UHFFFAOYSA-N jnj-5207852 Chemical compound C1CCCCN1CCCOC(C=C1)=CC=C1CN1CCCCC1 PTKHFRNHJULJKT-UHFFFAOYSA-N 0.000 description 1
- 229940102367 kemstro Drugs 0.000 description 1
- 229940039412 ketalar Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 1
- DAQAKHDKYAWHCG-RWTHQLGUSA-N lactacystin Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)[C@]1([C@@H](O)C(C)C)NC(=O)[C@H](C)[C@@H]1O DAQAKHDKYAWHCG-RWTHQLGUSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- 229960004577 laquinimod Drugs 0.000 description 1
- JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 description 1
- 229940036674 latuda Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229950007396 lecozotan Drugs 0.000 description 1
- 229940063725 leukeran Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 1
- 229960004002 levetiracetam Drugs 0.000 description 1
- 229940097443 levitra Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229960003406 levorphanol Drugs 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 229940054157 lexapro Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940063721 lioresal Drugs 0.000 description 1
- 229940002661 lipitor Drugs 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229960002813 lofepramine Drugs 0.000 description 1
- SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 description 1
- 229960005209 lofexidine Drugs 0.000 description 1
- KSMAGQUYOIHWFS-UHFFFAOYSA-N lofexidine Chemical compound N=1CCNC=1C(C)OC1=C(Cl)C=CC=C1Cl KSMAGQUYOIHWFS-UHFFFAOYSA-N 0.000 description 1
- 229940089504 lopressor Drugs 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 229940089527 loxitane Drugs 0.000 description 1
- 229960001432 lurasidone Drugs 0.000 description 1
- 229940009622 luvox Drugs 0.000 description 1
- STIRHCNEGQQBOY-QEYWKRMJSA-N ly-235,959 Chemical compound C1[C@@H](CP(O)(O)=O)CC[C@H]2CN[C@H](C(=O)O)C[C@H]21 STIRHCNEGQQBOY-QEYWKRMJSA-N 0.000 description 1
- MRSJBSHLMOBYSH-UHFFFAOYSA-N m-Nisoldipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 MRSJBSHLMOBYSH-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- CRGZYKWWYNQGEC-UHFFFAOYSA-N magnesium;methanolate Chemical compound [Mg+2].[O-]C.[O-]C CRGZYKWWYNQGEC-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- UGVOBAHBYOONQU-UHFFFAOYSA-I manganese(3+) (20Z)-5,10,15-tris(1-ethylpyridin-1-ium-2-yl)-20-(1-ethylpyridin-2-ylidene)porphyrin-22-ide pentachloride Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Mn+3].CC[N+]1=CC=CC=C1C(C1=CC=C([N-]1)C(C=1[N+](=CC=CC=1)CC)=C1C=CC(=N1)C(C=1[N+](=CC=CC=1)CC)=C1C=CC([N-]1)=C1C=2[N+](=CC=CC=2)CC)=C2N=C1C=C2 UGVOBAHBYOONQU-UHFFFAOYSA-I 0.000 description 1
- 229940110127 marplan Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229940064748 medrol Drugs 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229960001861 melperone Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007074 memory dysfunction Effects 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- DAHIQPJTGIHDGO-IAGOWNOFSA-N mesembrine Chemical compound C1=C(OC)C(OC)=CC=C1[C@]1(CCC(=O)C2)[C@@H]2N(C)CC1 DAHIQPJTGIHDGO-IAGOWNOFSA-N 0.000 description 1
- DAHIQPJTGIHDGO-UHFFFAOYSA-N mesembrine Natural products C1=C(OC)C(OC)=CC=C1C1(CCC(=O)C2)C2N(C)CC1 DAHIQPJTGIHDGO-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000003514 metabotropic receptor agonist Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960005192 methoxamine Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- XGWSRLSPWIEMLQ-YTFOTSKYSA-N methyl n-({(2s,3s)-3-[(propylamino)carbonyl]oxiran-2-yl}carbonyl)-l-isoleucyl-l-prolinate Chemical compound CCCNC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@H](C(=O)OC)CCC1 XGWSRLSPWIEMLQ-YTFOTSKYSA-N 0.000 description 1
- IYETZZCWLLUHIJ-UHFFFAOYSA-N methyl-(1-phenylpropan-2-yl)-prop-2-ynylazanium;chloride Chemical compound Cl.C#CCN(C)C(C)CC1=CC=CC=C1 IYETZZCWLLUHIJ-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 229960001033 methylphenidate hydrochloride Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 description 1
- 229960001383 methylscopolamine Drugs 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 229960000939 metoprolol succinate Drugs 0.000 description 1
- 229960001300 metoprolol tartrate Drugs 0.000 description 1
- 229960001952 metrifonate Drugs 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 229950005726 mibampator Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 108010068982 microplasmin Proteins 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 229960000600 milnacipran Drugs 0.000 description 1
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 1
- 229960003574 milrinone Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940088319 miostat Drugs 0.000 description 1
- 229940101972 mirapex Drugs 0.000 description 1
- 229950002245 mirodenafil Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940028394 moban Drugs 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- 229960001165 modafinil Drugs 0.000 description 1
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N momelotinib Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 description 1
- 229950008814 momelotinib Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 229940072709 motrin Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000002901 multifocal dystonia Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 229940083410 myfortic Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229940090010 mysoline Drugs 0.000 description 1
- 229940103801 mytelase Drugs 0.000 description 1
- FMYPJTRYAPFMCM-UHFFFAOYSA-N n,n-dimethyl-4-phosphanylaniline Chemical compound CN(C)C1=CC=C(P)C=C1 FMYPJTRYAPFMCM-UHFFFAOYSA-N 0.000 description 1
- WYUGOKOOOAHPMP-UHFFFAOYSA-N n-(1,2,4,9-tetrahydrocarbazol-3-ylidene)hydroxylamine Chemical compound N1C2=CC=CC=C2C2=C1CCC(=NO)C2 WYUGOKOOOAHPMP-UHFFFAOYSA-N 0.000 description 1
- ATKZKAYWARYLBW-UHFFFAOYSA-N n-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide Chemical compound COC1=CC=C(S(=O)(=O)NC=2C(=C(Cl)C=C(Cl)C=2)OC)C=C1N1CCNCC1 ATKZKAYWARYLBW-UHFFFAOYSA-N 0.000 description 1
- ULRDYYKSPCRXAJ-KRWDZBQOSA-N n-[(2r)-2-[4-[4-[2-(methanesulfonamido)ethyl]phenyl]phenyl]propyl]propane-2-sulfonamide Chemical compound C1=CC([C@@H](C)CNS(=O)(=O)C(C)C)=CC=C1C1=CC=C(CCNS(C)(=O)=O)C=C1 ULRDYYKSPCRXAJ-KRWDZBQOSA-N 0.000 description 1
- HNWIZDPHFDXSOR-BSSYVKIHSA-N n-[(2s)-2-amino-3-[[(2s)-1-[[(2s)-3-cyclohexyl-1-[[(2s,3r)-3-hydroxy-4-oxo-1-phenyl-4-[3-(2h-tetrazol-5-yl)anilino]butan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-oxopropyl]-5-fluoro-2,4-dioxo-1h-pyrimidine-6-carboxamide Chemical compound C([C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)[C@@H](O)C(=O)NC=1C=C(C=CC=1)C1=NNN=N1)NC(=O)C=1NC(=O)NC(=O)C=1F HNWIZDPHFDXSOR-BSSYVKIHSA-N 0.000 description 1
- QXQSUBKWSHMXDP-INIZCTEOSA-N n-[(2s)-5-(6-fluoropyridin-3-yl)-2,3-dihydro-1h-inden-2-yl]propane-2-sulfonamide Chemical compound C([C@@H](CC1=C2)NS(=O)(=O)C(C)C)C1=CC=C2C1=CC=C(F)N=C1 QXQSUBKWSHMXDP-INIZCTEOSA-N 0.000 description 1
- SSRDSYXGYPJKRR-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-7-chloro-1-benzothiophene-2-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=CC(C=CC=C2Cl)=C2S1 SSRDSYXGYPJKRR-ZDUSSCGKSA-N 0.000 description 1
- CMRLNEYJEPELSM-BTQNPOSSSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1h-indazole-3-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C(N[C@H]3C4CCN(CC4)C3)=O)=NNC2=C1 CMRLNEYJEPELSM-BTQNPOSSSA-N 0.000 description 1
- RIJLVEAXPNLDTC-UHFFFAOYSA-N n-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(=NN12)N=C1C=CC=C2C(C=C1)=CC=C1CN1CCS(=O)(=O)CC1 RIJLVEAXPNLDTC-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- CVFSMSTXULJISA-UHFFFAOYSA-N n-ethyl-2-phenylbicyclo[2.2.1]heptan-3-amine;hydrochloride Chemical compound Cl.CCNC1C(C2)CCC2C1C1=CC=CC=C1 CVFSMSTXULJISA-UHFFFAOYSA-N 0.000 description 1
- SXMBKHYDZOCBMT-UHFFFAOYSA-N n-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]cyclobutane-1-carboxamide Chemical compound C1C(C(=O)NCC)CC1(F)C(C=C1F)=CC=C1CN1CCCC1 SXMBKHYDZOCBMT-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- 229940089466 nalfon Drugs 0.000 description 1
- 229940033872 namenda Drugs 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229960003940 naproxen sodium Drugs 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 238000009099 neoadjuvant therapy Methods 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- OGZQTTHDGQBLBT-UHFFFAOYSA-N neramexane Chemical compound CC1(C)CC(C)(C)CC(C)(N)C1 OGZQTTHDGQBLBT-UHFFFAOYSA-N 0.000 description 1
- 229950004543 neramexane Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229940020452 neupro Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000003962 neuroinflammatory response Effects 0.000 description 1
- 208000037860 neuroleptic-induced Akathisia Diseases 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- 229960003642 nicergoline Drugs 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 229950008980 nitecapone Drugs 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- DLWSRGHNJVLJAH-UHFFFAOYSA-N nitroflurbiprofen Chemical compound FC1=CC(C(C(=O)OCCCCO[N+]([O-])=O)C)=CC=C1C1=CC=CC=C1 DLWSRGHNJVLJAH-UHFFFAOYSA-N 0.000 description 1
- 229960001073 nomifensine Drugs 0.000 description 1
- 229960002498 nomifensine maleate Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940079063 norflex Drugs 0.000 description 1
- 229940087480 norpramin Drugs 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 229940036132 norvasc Drugs 0.000 description 1
- 229940117152 nuvigil Drugs 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229950000175 oglemilast Drugs 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- JPAWFIIYTJQOKW-UHFFFAOYSA-N olprinone Chemical compound N1C(=O)C(C#N)=CC(C2=CN3C=CN=C3C=C2)=C1C JPAWFIIYTJQOKW-UHFFFAOYSA-N 0.000 description 1
- 229950005421 olprinone Drugs 0.000 description 1
- 229940003740 omnipred Drugs 0.000 description 1
- 201000005040 opiate dependence Diseases 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 229940109739 orap Drugs 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 229960003941 orphenadrine Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229940011530 otezla Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001816 oxcarbazepine Drugs 0.000 description 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 1
- 229960001227 oxiracetam Drugs 0.000 description 1
- IHLAQQPQKRMGSS-UHFFFAOYSA-N oxiracetam Chemical compound NC(=O)CN1CC(O)CC1=O IHLAQQPQKRMGSS-UHFFFAOYSA-N 0.000 description 1
- 229960004570 oxprenolol Drugs 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- 229940055692 pamelor Drugs 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 229940026768 parcopa Drugs 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 229960001779 pargyline Drugs 0.000 description 1
- 229940000596 parlodel Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- YZPOQCQXOSEMAZ-UHFFFAOYSA-N pbt2 Chemical compound ClC1=CC(Cl)=C(O)C2=NC(CN(C)C)=CC=C21 YZPOQCQXOSEMAZ-UHFFFAOYSA-N 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 229960000761 pemoline Drugs 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 208000022719 perennial allergic rhinitis Diseases 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 229940090007 persantine Drugs 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 229960000436 phendimetrazine Drugs 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 229960003209 phenmetrazine Drugs 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229940052794 phenytek Drugs 0.000 description 1
- 229960002790 phenytoin sodium Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 239000002606 phosphodiesterase VII inhibitor Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- HZOTZTANVBDFOF-PBCQUBLHSA-N physostigmine salicylate Chemical compound OC(=O)C1=CC=CC=C1O.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C HZOTZTANVBDFOF-PBCQUBLHSA-N 0.000 description 1
- 229960002516 physostigmine salicylate Drugs 0.000 description 1
- 229960001847 physostigmine sulfate Drugs 0.000 description 1
- URMTUEWUIGOJBW-UHFFFAOYSA-N piclozotan Chemical compound ClC1=COC2=CC=CC=C2C(=O)N1CCCCN(CC=1)CCC=1C1=CC=CC=N1 URMTUEWUIGOJBW-UHFFFAOYSA-N 0.000 description 1
- 229950002181 piclozotan Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 229960003300 pimavanserin Drugs 0.000 description 1
- RGSULKHNAKTFIZ-CEAXSRTFSA-N pimavanserin tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(OCC(C)C)=CC=C1CNC(=O)N(C1CCN(C)CC1)CC1=CC=C(F)C=C1.C1=CC(OCC(C)C)=CC=C1CNC(=O)N(C1CCN(C)CC1)CC1=CC=C(F)C=C1 RGSULKHNAKTFIZ-CEAXSRTFSA-N 0.000 description 1
- 229960002164 pimobendan Drugs 0.000 description 1
- GLBJJMFZWDBELO-UHFFFAOYSA-N pimobendane Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=C(C=3C(CC(=O)NN=3)C)C=C2N1 GLBJJMFZWDBELO-UHFFFAOYSA-N 0.000 description 1
- 229960003634 pimozide Drugs 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004574 piperidin-2-yl group Chemical group N1C(CCCC1)* 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229940072689 plaquenil Drugs 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229950003486 ponezumab Drugs 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- MICLTPPSCUXHJT-UHFFFAOYSA-M potassium;4-[3-(6-oxo-3h-purin-9-yl)propanoylamino]benzoate Chemical compound [K+].C1=CC(C(=O)[O-])=CC=C1NC(=O)CCN1C(NC=NC2=O)=C2N=C1 MICLTPPSCUXHJT-UHFFFAOYSA-M 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- YRVIKLBSVVNSHF-JTQLQIEISA-N pozanicline Chemical compound CC1=NC=CC=C1OC[C@H]1NCCC1 YRVIKLBSVVNSHF-JTQLQIEISA-N 0.000 description 1
- APVQOOKHDZVJEX-QTPLPEIMSA-N pramipexole hydrochloride Chemical compound O.Cl.Cl.C1[C@@H](NCCC)CCC2=C1SC(N)=N2 APVQOOKHDZVJEX-QTPLPEIMSA-N 0.000 description 1
- 229960003389 pramiracetam Drugs 0.000 description 1
- ZULJGOSFKWFVRX-UHFFFAOYSA-N pramiracetam Chemical compound CC(C)N(C(C)C)CCNC(=O)CN1CCCC1=O ZULJGOSFKWFVRX-UHFFFAOYSA-N 0.000 description 1
- 229940063161 pred forte Drugs 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- 229960002943 prednisolone sodium phosphate Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 229940089949 procardia Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- TURAMGVWNUTQKH-UHFFFAOYSA-N propa-1,2-dien-1-one Chemical compound C=C=C=O TURAMGVWNUTQKH-UHFFFAOYSA-N 0.000 description 1
- 229960002934 propentofylline Drugs 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940117394 provigil Drugs 0.000 description 1
- SCHKZZSVELPJKU-UHFFFAOYSA-N prx-03140 Chemical compound O=C1N(C(C)C)C=2SC=CC=2C(O)=C1C(=O)NCCCN1CCCCC1 SCHKZZSVELPJKU-UHFFFAOYSA-N 0.000 description 1
- 230000001003 psychopharmacologic effect Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 229940117820 purinethol Drugs 0.000 description 1
- 229960002290 pyridostigmine Drugs 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 229950001037 quinpirole Drugs 0.000 description 1
- FTSUPYGMFAPCFZ-ZWNOBZJWSA-N quinpirole Chemical compound C([C@H]1CCCN([C@@H]1C1)CCC)C2=C1C=NN2 FTSUPYGMFAPCFZ-ZWNOBZJWSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229960001150 ramelteon Drugs 0.000 description 1
- 229960000245 rasagiline Drugs 0.000 description 1
- 229940051845 razadyne Drugs 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229940038850 rebif Drugs 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940080693 reglan Drugs 0.000 description 1
- 230000014786 regulation of synaptic transmission Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 229950000659 remacemide Drugs 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 229960003312 retigabine Drugs 0.000 description 1
- 229940039245 revatio Drugs 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229960004181 riluzole Drugs 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- 229940099204 ritalin Drugs 0.000 description 1
- JUQLTPCYUFPYKE-UHFFFAOYSA-N ritanserin Chemical compound CC=1N=C2SC=CN2C(=O)C=1CCN(CC1)CCC1=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 JUQLTPCYUFPYKE-UHFFFAOYSA-N 0.000 description 1
- 229950009626 ritanserin Drugs 0.000 description 1
- JUOSGGQXEBBCJB-GORDUTHDSA-N rivanicline Chemical compound CNCC\C=C\C1=CC=CN=C1 JUOSGGQXEBBCJB-GORDUTHDSA-N 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- MQTUXRKNJYPMCG-CYBMUJFWSA-N robalzotan Chemical compound C1CCC1N([C@H]1COC=2C(F)=CC=C(C=2C1)C(=O)N)C1CCC1 MQTUXRKNJYPMCG-CYBMUJFWSA-N 0.000 description 1
- 229940106905 robinul Drugs 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- 229960003522 roquinimex Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229960003179 rotigotine Drugs 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 229940063635 salagen Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940042084 saphris Drugs 0.000 description 1
- HKFMQJUJWSFOLY-OAQYLSRUSA-N sarizotan Chemical compound C1=CC(F)=CC=C1C1=CN=CC(CNC[C@@H]2OC3=CC=CC=C3CC2)=C1 HKFMQJUJWSFOLY-OAQYLSRUSA-N 0.000 description 1
- 229950007903 sarizotan Drugs 0.000 description 1
- OLWRVVHPJFLNPW-UHFFFAOYSA-N sb-277,011-a Chemical compound C1=CC=C2C(C(NC3CCC(CCN4CC5=CC=C(C=C5CC4)C#N)CC3)=O)=CC=NC2=C1 OLWRVVHPJFLNPW-UHFFFAOYSA-N 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- CXYRUNPLKGGUJF-RAFJPFSSSA-M scopolamine methobromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 CXYRUNPLKGGUJF-RAFJPFSSSA-M 0.000 description 1
- 208000017022 seasonal allergic rhinitis Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000009991 second messenger activation Effects 0.000 description 1
- 229940082552 sectral Drugs 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 201000002899 segmental dystonia Diseases 0.000 description 1
- 229960003678 selegiline hydrochloride Drugs 0.000 description 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
- 229940035004 seroquel Drugs 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- BLFQGGGGFNSJKA-XHXSRVRCSA-N sertraline hydrochloride Chemical compound Cl.C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 BLFQGGGGFNSJKA-XHXSRVRCSA-N 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229940001089 sinemet Drugs 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 229940084026 sodium valproate Drugs 0.000 description 1
- UJZUICGIJODKOS-YSMBQZINSA-M sodium;(z)-1,4-diethoxy-1,4-dioxobut-2-en-2-olate Chemical compound [Na+].CCOC(=O)\C=C(/[O-])C(=O)OCC UJZUICGIJODKOS-YSMBQZINSA-M 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- FJPYVLNWWICYDW-UHFFFAOYSA-M sodium;5,5-diphenylimidazolidin-1-ide-2,4-dione Chemical compound [Na+].O=C1[N-]C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 FJPYVLNWWICYDW-UHFFFAOYSA-M 0.000 description 1
- ZLBSUOGMZDXYKE-UHFFFAOYSA-M sodium;7-[(3-chloro-6-methyl-5,5-dioxo-11h-benzo[c][2,1]benzothiazepin-11-yl)amino]heptanoate Chemical compound [Na+].O=S1(=O)N(C)C2=CC=CC=C2C(NCCCCCCC([O-])=O)C2=CC=C(Cl)C=C21 ZLBSUOGMZDXYKE-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229950007874 solanezumab Drugs 0.000 description 1
- 229940087854 solu-medrol Drugs 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 201000001716 specific phobia Diseases 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical group 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 description 1
- 229950011332 talnetant Drugs 0.000 description 1
- 229940000238 tasmar Drugs 0.000 description 1
- 229940090016 tegretol Drugs 0.000 description 1
- 229940065385 tenex Drugs 0.000 description 1
- 229940108485 tenormin Drugs 0.000 description 1
- 229960004558 terguride Drugs 0.000 description 1
- WUBVEMGCQRSBBT-UHFFFAOYSA-N tert-butyl 4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(=O)(=O)C(F)(F)F)=CC1 WUBVEMGCQRSBBT-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229950002896 tetomilast Drugs 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 150000003527 tetrahydropyrans Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 229960005138 tianeptine Drugs 0.000 description 1
- PMJIHLSCWIDGMD-UHFFFAOYSA-N tideglusib Chemical compound O=C1SN(C=2C3=CC=CC=C3C=CC=2)C(=O)N1CC1=CC=CC=C1 PMJIHLSCWIDGMD-UHFFFAOYSA-N 0.000 description 1
- 229960004523 tiletamine Drugs 0.000 description 1
- 229940034744 timoptic Drugs 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 229960000488 tizanidine Drugs 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 229950003899 tofimilast Drugs 0.000 description 1
- 229940041597 tofranil Drugs 0.000 description 1
- 229960004603 tolcapone Drugs 0.000 description 1
- 229960002309 toloxatone Drugs 0.000 description 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 1
- 229960004045 tolterodine Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229940035305 topamax Drugs 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 229940108522 trandate Drugs 0.000 description 1
- 229940035321 transderm scop Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- OHHDIOKRWWOXMT-UHFFFAOYSA-N trazodone hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 OHHDIOKRWWOXMT-UHFFFAOYSA-N 0.000 description 1
- 229940111528 trexall Drugs 0.000 description 1
- NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- NTJBWZHVSJNKAD-UHFFFAOYSA-N triethylazanium;fluoride Chemical compound [F-].CC[NH+](CC)CC NTJBWZHVSJNKAD-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 229960002324 trifluoperazine Drugs 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 229960001032 trihexyphenidyl Drugs 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229940079023 tysabri Drugs 0.000 description 1
- 229940089541 uniphyl Drugs 0.000 description 1
- 229940045137 urecholine Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- NAUWTFJOPJWYOT-UHFFFAOYSA-N vanoxerine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)OCCN1CCN(CCCC=2C=CC=CC=2)CC1 NAUWTFJOPJWYOT-UHFFFAOYSA-N 0.000 description 1
- 108010084171 vanutide cridificar Proteins 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229940055010 verelan Drugs 0.000 description 1
- RNOBTWYQAWEZHH-JGVFFNPUSA-N vi5lr1eu47 Chemical compound C12=CC(C(F)(F)F)=CC=C2[C@]2([H])CNC[C@@]1([H])C2 RNOBTWYQAWEZHH-JGVFFNPUSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940094720 viagra Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940063670 visken Drugs 0.000 description 1
- CKWXDLJHOHJWOX-UHFFFAOYSA-N voacangine hydroxyindolenine Natural products CCC1CC2N3CCC4(O)C(=Nc5ccc(OC)cc45)C2(CC1C3)C(=O)OC CKWXDLJHOHJWOX-UHFFFAOYSA-N 0.000 description 1
- 210000001260 vocal cord Anatomy 0.000 description 1
- 229940063674 voltaren Drugs 0.000 description 1
- 229940013007 vyvanse Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229940009065 wellbutrin Drugs 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229960004664 xaliproden Drugs 0.000 description 1
- WJJYZXPHLSLMGE-UHFFFAOYSA-N xaliproden Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WJJYZXPHLSLMGE-UHFFFAOYSA-N 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
- 229940000119 zanaflex Drugs 0.000 description 1
- 229960002811 ziconotide Drugs 0.000 description 1
- BPKIMPVREBSLAJ-QTBYCLKRSA-N ziconotide Chemical compound C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 BPKIMPVREBSLAJ-QTBYCLKRSA-N 0.000 description 1
- 229960002791 zimeldine Drugs 0.000 description 1
- OYPPVKRFBIWMSX-SXGWCWSVSA-N zimeldine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- 229940020965 zoloft Drugs 0.000 description 1
- 229940083488 zonalon Drugs 0.000 description 1
- 229940061740 zyvox Drugs 0.000 description 1
- XZVHHLNLLVICFA-SNVBAGLBSA-N α-difluoromethyl-dopa Chemical compound FC(F)[C@](C(O)=O)(N)CC1=CC=C(O)C(O)=C1 XZVHHLNLLVICFA-SNVBAGLBSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
R1は、(C3〜C8)シクロアルキル、(4〜10員)ヘテロシクロアルキル、(C6〜C10)アリールおよび(5〜10員)ヘテロアリールからなる群から選択される置換基であり、ここで、(C3〜C8)シクロアルキル、(4〜10員)ヘテロシクロアルキル、(C6〜C10)アリールおよび(5〜10員)ヘテロアリールは、1から5個のR5で置換されていてもよく、
R2およびR3は、水素、置換されていてもよい(C1〜C6)アルキル、(C3〜C8)シクロアルキル、(4〜10員)ヘテロシクロアルキル、(C6〜C10)アリールおよび(5〜10員)ヘテロアリールからなる群からそれぞれ独立して選択され、ここで、(C3〜C8)シクロアルキル、(4〜10員)ヘテロシクロアルキル、(C6〜C10)アリールおよび(5〜10員)ヘテロアリールは、1から5個のR6で置換されていてもよく、または
R2およびR3は、それらが結合した窒素と一緒になって、(4〜10員)ヘテロシクロアルキルまたは(5〜10員)ヘテロアリールを形成し、ここで、(4〜10員)ヘテロシクロアルキルおよび(5〜10員)ヘテロアリールは、1から5個のR6で置換されていてもよく、
存在する場合、R4は、各出現において、ハロゲン、シアノ、ヒドロキシ、−SF5、ニトロ、置換されていてもよい(C1〜C6)アルキル、置換されていてもよい(C2〜C6)アルケニル、置換されていてもよい(C2〜C6)アルキニル、置換されていてもよい(C1〜C6)アルキルチオ、置換されていてもよい(C1〜C6)アルコキシ、−N(R7)(R8)、−N(R7)(C=(O)R8)、−C(=O)N(R7)(R8)、−O−C(=O)−N(R7)(R8)、−C(=O)−R7および−C(=O)−OR7からなる群から独立して選択され、
存在する場合、R5およびR6は、各出現において、ハロゲン、オキソ、シアノ、ヒドロキシ、−SF5、ニトロ、置換されていてもよい(C1〜C6)アルキル、置換されていてもよい(C2〜C6)アルケニル、置換されていてもよい(C2〜C6)アルキニル、置換されていてもよい(C1〜C6)アルキルチオ、置換されていてもよい(C1〜C6)アルコキシ、−N(R7)(R8)、−N(R7)(C=(O)R8)、−C(=O)N(R7)(R8)、−O−C(=O)−N(R7)(R8)、−C(=O)−R7および−C(=O)−OR7からなる群から独立して選択され、
R7およびR8は、各出現において、水素および(C1〜C6)アルキルからなる群から独立して選択され、
aは、0、1、2または3から選択される整数によって表される]
の化合物または薬学的に許容できるその塩を対象とする。
特許請求の範囲を包含する本願全体を通して使用される場合、下記の用語は、具体的に別段の指示がない限り、以下で定義する意味を有する。複数形および単数形は、数の指示以外、交換可能なものとして扱われるべきである:
式Iの化合物は、上述した通り、6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジンコアを含有し、ここで、コアは、1から3個のR5で置換されていてもよいR1部分によって3位で置換されており、R4部分によって5、6および/または7位で置換されていてもよく、6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジンコアの2位と結合しているアミド部分の窒素は、R2およびR3で置換されている。
R2およびR3は、水素、置換されていてもよい(C1〜C6)アルキルおよび(C3〜C8)シクロアルキルからなる群からそれぞれ独立して選択され、ここで、(C3〜C8)シクロアルキルは、1から3個のR6で置換されていてもよく、または
R2およびR3は、それらが結合した窒素と一緒になって、1から3個のR6で置換されていてもよい(4〜6員)ヘテロシクロアルキルを形成し、
存在する場合、各R4は、ハロゲンまたは置換されていてもよい(C1〜C6)アルキルから独立して選択され、
存在する場合、R5およびR6は、各出現において、ハロゲン、シアノ、置換されていてもよい(C1〜C6)アルキルおよび置換されていてもよい(C1〜C6)アルコキシからなる群から独立して選択され、
aは、0、1または2から選択される整数である]
の化合物または薬学的に許容できるその塩を対象とする。
PDE4ファミリーのホスホジエステラーゼ(PDE)は、第二のメッセンジャー環状ヌクレオチド、アデノシン3’,5’−環状一リン酸(cAMP)の選択的高親和性加水分解を特徴とする。PDE4A、PDE4BおよびPDE4Dサブタイプは、脳の全体にわたって広く発現され、PDE4A、PDE4BおよびPDE4Dサブタイプの局部的な細胞内分布が明確であることが公知であるのに対し、PDE4Cサブタイプは、中枢神経系の全体にわたってより低レベルで発現される(Siuciak,J.A.ら、Antipsychotic profile of rolipram:efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase−4B(PDE4B)enzyme、Psychopharmacology(2007)192:415〜424を参照)。PDE4サブタイプの位置により、PDE4サブタイプは、中枢神経系疾患および障害のための新たな治療を探索するための興味深い標的となる。例えば、PDE4Bは、統合失調症の遺伝的感受性因子として同定されている(Millar,J.K.ら、Disrupted in schizophrenia 1 and phosphodiesterase 4B:towards an understanding of psychiatric illness、J.Physiol.584(2007)401〜405頁を参照)。
本発明の化合物は、経口的に投与され得る。経口投与には、化合物が胃腸管に入るような嚥下が関与し得、または化合物が口から血流に直接入る口腔もしくは舌下投与を用いてもよい。
(i)ドネペジル塩酸塩(ARICEPT、MEMAC)、サリチル酸フィゾスチグミン(ANTILIRIUM)、硫酸フィゾスチグミン(ESERINE)、メトリホネート、ネオスチグミン、ガンスチグミン、ピリドスチグミン(MESTINON)、アンベノニウム(MYTELASE)、デメカリウム、デビオ9902(ZT−1としても公知である;Debiopharm)、リバスチグミン(EXELON)、ラドスチギル、NP−0361、ガランタミン臭化水素酸塩(RAZADYNE、RIMINYL、NIVALIN)、タクリン(COGNEX)、トルセリン、マレイン酸ベルナクリン、メモキン、ヒューペルジンA(HUP−A;NeuroHitech)、フェンセリン、エドロホニウム(ENLON、TENSILON)およびINM−176等の、アセチルコリンエステラーゼ阻害剤;
(ii)汎HLA DR結合エピトープとコンジュゲートしているAβ1〜15(PADRE)、ACC−001(Elan/Wyeth)、ACI−01、ACI−24、AN−1792、Affitope AD−01、CAD106、およびV−950等の、アミロイド−β(または、そのフラグメント);
(iii)ポネズマブ、ソラネズマブ、バピネオズマブ(AAB−001としても公知である)、AAB−002(Wyeth/Elan)、ACI−01−Ab7、BAN−2401、静脈内Ig(GAMMAGARD)、LY2062430(ヒト化m266;Lilly)、R1450(Roche)、ACU−5A5、huC091、および国際特許公開第WO04/032868号、同第WO05/025616号、同第WO06/036291号、同第WO06/069081号、同第WO06/118959号に、米国特許公開第US2003/0073655号、同第US2004/0192898号、同第US2005/0048049号、同第US2005/0019328号に、欧州特許公開第EP0994728号および同第1257584号に、ならびに米国特許第5,750,349号に開示されているもの等の、アミロイド−βに対する抗体(または、それらのフラグメント);
(iv)ディメボン、ダブネチド、エプロジセート、ロイプロリド、SK−PC−B70M、セレコキシブ、ロバスタチン、アナプソス、オキシラセタム、プラミラセタム、バレニクリン、ニセルゴリン、コロストリニン、ビスノルシムセリン(BNCとしても公知である)、NIC5−15(Humanetics)、E−2012(エーザイ株式会社)、ピオグリタゾン、クリオキノール(PBT1としても公知である)、PBT2(Prana Biotechnology)、フルルビプロフェン(ANSAID、FROBEN)およびそのR−エナンチオマータレンフルビル(FLURIZAN)、ニトロフルルビプロフェン、フェノプロフェン(FENOPRON、NALFON)、イブプロフェン(ADVIL、MOTRIN、NUROFEN)、イブプロフェンリシネート、メクロフェナム酸、メクロフェナム酸ナトリウム(MECLOMEN)、インドメタシン(INDOCIN)、ジクロフェナクナトリウム(VOLTAREN)、ジクロフェナクカリウム、スリンダク(CLINORIL)、スリンダク硫化物、ジフルニサル(DOLOBID)、ナプロキセン(NAPROSYN)、ナプロキセンナトリウム(ANAPROX、ALEVE)、ARC031(Archer Pharmaceuticals)、CAD−106(Cytos)、LY450139(Lilly)、インスリン分解酵素(インスリシンとしても公知である)、イチョウ(gingko biloba)抽出物EGb−761(ROKAN、TEBONIN)、トラミプロセート(CEREBRIL、ALZHEMED)、エプロジセート(FIBRILLEX、KIACTA)、化合物W[3,5−ビス(4−ニトロフェノキシ)安息香酸]、NGX−96992、ネプリライシン(中性エンドペプチダーゼ(NEP)としても公知である)、シロイノシトール(シリトールとしても公知である)、アトルバスタチン(LIPITOR)、シンバスタチン(ZOCOR)、KLVFF−(EEX)3、SKF−74652、メシル酸イブタモレン、ASP−1702、SCH−745966、JNJ−715754、AMG−0683、AZ−12304146、BMS−782450、GSK−188909、NB−533、E2609およびTTP−854等のBACE阻害剤;ELND−007等のガンマセクレターゼモジュレーター;ならびに、TTP488(Transtech)およびTTP4000(Transtech)、およびPTI−777を包含する米国特許第7,285,293号において記述されているもの等のRAGE(糖化最終産物の受容体)阻害剤等の、アミロイド低下または阻害剤(アミロイド産生、蓄積および線維化を低減させるものを包含する);
(v)グアンファシン(INTUNIV、TENEX)、クロニジン(CATAPRES)、メタラミノール(ARAMINE)、メチルドパ(ALDOMET、DOPAMET、NOVOMEDOPA)、チザニジン(ZANAFLEX)、フェニレフリン(ネオシネフリンとしても公知である)、メトキサミン、シラゾリン、グアンファシン(INTUNIV)、ロフェキシジン、キシラジン、モダフィニル(PROVIGIL)、アドラフィニルおよびアルモダフィニル(NUVIGIL)等の、アルファ−アドレナリン受容体アゴニスト;
(vi)カルテオロール、エスモロール(BREVIBLOC)、ラベタロール(NORMODYNE、TRANDATE)、オクスプレノロール(LARACOR、TRASACOR)、ピンドロール(VISKEN)、プロプラノロール(INDERAL)、ソタロール(BETAPACE、SOTALEX、SOTACOR)、チモロール(BLOCADREN、TIMOPTIC)、アセブトロール(SECTRAL、PRENT)、ナドロール(CORGARD)、酒石酸メトプロロール(LOPRESSOR)、コハク酸メトプロロール(TOPROL−XL)、アテノロール(TENORMIN)、ブトキサミンおよびSR59230A(Sanofi)等の、ベータ−アドレナリン受容体遮断剤(ベータ遮断薬);
(vii)アミトリプチリン(ELAVIL、ENDEP)、ブトリプチリン、メシル酸ベンズトロピン(COGENTIN)、トリヘキシフェニジル(ARTANE)、ジフェンヒドラミン(BENADRYL)、オルフェナドリン(NORFLEX)、ヒヨスチアミン、アトロピン(ATROPEN)、スコポラミン(TRANSDERM−SCOP)、臭化メチルスコポラミン(PARMINE)、ジシクロベリン(BENTYL、BYCLOMINE、DIBENT、DILOMINE)、トルテロジン(DETROL)、オキシブチニン(DITROPAN、LYRINEL XL、OXYTROL)、臭化ペンチエネート、プロパンテリン(PRO−BANTHINE)、シクリジン、イミプラミン塩酸塩(TOFRANIL)、イミプラミンマレイン酸塩(SURMONTIL)、ロフェプラミン、デシプラミン(NORPRAMIN)、ドキセピン(SINEQUAN、ZONALON)、トリミプラミン(SURMONTIL)およびグリコピロレート(ROBINUL)等の、抗コリン薬;
(viii)カルバマゼピン(TEGRETOL、CARBATROL)、オクスカルバゼピン(TRILEPTAL)、フェニトインナトリウム(PHENYTEK)、フォスフェニトイン(CEREBYX、PRODILANTIN)、バルプロ酸ナトリウム(DEPAKOTE)、ガバペンチン(NEURONTIN)、プレガバリン(LYRICA)、トピラメート(TOPAMAX)、バルプロ酸(DEPAKENE)、バルプロ酸ナトリウム(DEPACON)、1−ベンジル−5−ブロモウラシル、プロガビド、ベクラミド、ゾニサミド(TRERIEF、EXCEGRAN)、CP−465022、レチガビン、タランパネルおよびプリミドン(MYSOLINE)等の、抗けいれん薬;
(ix)ルラシドン(LATUDA、SM−13496としても公知である;大日本住友製薬株式会社)、アリピプラゾール(ABILIFY)、クロルプロマジン(THORAZINE)、ハロペリドール(HALDOL)、イロペリドン(FANAPTA)、デカン酸フルペンチキソール(DEPIXOL、FLUANXOL)、レセルピン(SERPLAN)、ピモジド(ORAP)、デカン酸フルフェナジン、塩酸フルフェナジン、プロクロルペラジン(COMPRO)、アセナピン(SAPHRIS)、ロキサピン(LOXITANE)、モリンドン(MOBAN)、パーフェナジン、チオリダジン、チオチキセン、トリフルオロペラジン(STELAZINE)、ラメルテオン、クロザピン(CLOZARIL)、ノルクロザピン(ACP−104)、リスペリドン(RISPERDAL)、パリペリドン(INVEGA)、メルペロン、オランザピン(ZYPREXA)、クエチアピン(SEROQUEL)、タルネタント、アミスルピリド、ジプラシドン(GEODON)、ブロナンセリン(LONASEN)およびACP−103(Acadia Pharmaceuticals)等の、抗精神病薬;
(x)ロメリジン、ジコノチド、ニルバジピン(ESCOR、NIVADIL)、ジペルジピン、アムロジピン(NORVASC、ISTIN、AMLODIN)、フェロジピン(PLENDIL)、ニカルジピン(CARDENE)、ニフェジピン(ADALAT、PROCARDIA)、MEM1003およびその親化合物ニモジピン(NIMOTOP)、ニソルジピン(SULAR)、ニトレンジピン、ラシジピン(LACIPIL、MOTENS)、レルカニジピン(ZANIDIP)、リファリジン、ジルチアゼム(CARDIZEM)、ベラパミル(CALAN、VERELAN)、AR−R18565(AstraZeneca)ならびにエネカジン等の、カルシウムチャネル遮断薬;
(xi)ニテカポン、トルカポン(TASMAR)、エンタカポン(COMTAN)およびトロポロン等の、カテコールO−メチルトランスフェラーゼ(COMT)阻害剤;
(xii)アトモキセチン、レボキセチン、ヨヒンビン、カフェイン、フェンメトラジン、フェンジメトラジン、ペモリン、フェンカムファミン(GLUCOENERGAN、REACTIVAN)、フェネチリン(CAPTAGON)、ピプラドロール(MERETRAN)、デアノール(ジメチルアミノエタノールとしても公知である)、メチルフェニデート(DAYTRANA)、塩酸メチルフェニデート(RITALIN)、デクスメチルフェニデート(FOCALIN)、アンフェタミン(単独で、または他のCNS刺激物質、例えば、ADDERALL(アスパラギン酸アンフェタミン、硫酸アンフェタミン、デキストロアンフェタミンサッカレートおよび硫酸デキストロアンフェタミン)と組み合わせて)、硫酸デキストロアンフェタミン(DEXEDRINE、DEXTROSTAT)、メタンフェタミン(DESOXYN)、リスデキサンフェタミン(VYVANSE)およびベンズフェタミン(DIDREX)等の、中枢神経系刺激物質;
(xiii)プレドニゾン(STERAPRED、DELTASONE)、プレドニゾロン(PRELONE)、酢酸プレドニゾロン(OMNIPRED、PRED MILD、PRED FORTE)、プレドニゾロンリン酸ナトリウム(ORAPRED ODT)、メチルプレドニゾロン(MEDROL);酢酸メチルプレドニゾロン(DEPO−MEDROL)およびコハク酸メチルプレドニゾロンナトリウム(A−METHAPRED、SOLU−MEDROL)等の、コルチコステロイド;
(xiv)アポモルヒネ(APOKYN)、ブロモクリプチン(PARLODEL)、カベルゴリン(DOSTINEX)、ジヒドレキシジン、ジヒドロエルゴクリプチン、フェノルドパム(CORLOPAM)、リスリド(DOPERGIN)、テルグリド、ペルゴリド(PERMAX)、ピリベジル(TRIVASTAL、TRASTAL)、プラミペキソール(MIRAPEX)、キンピロール、ロピニロール(REQUIP)、ロチゴチン(NEUPRO)、SKF−82958(GlaxoSmithKline)、カリプラジン、パルドプルノックスおよびサリゾタン等の、ドーパミン受容体アゴニスト;
(xv)クロルプロマジン、フルフェナジン、ハロペリドール、ロキサピン、リスペリドン、チオリダジン、チオチキセン、フルオロペラジン、テトラベナジン(NITOMAN、XENAZINE)、7−ヒドロキシアモキサピン、ドロペリドール(INAPSINE、DRIDOL、DROPLETAN)、ドンペリドン(MOTILIUM)、L−741742、L−745870、ラクロプリド、SB−277011A、SCH−23390、エコピパム、SKF−83566およびメトクロプラミド(REGLAN)等の、ドーパミン受容体アンタゴニスト;
(xvi)ブプロピオン、サフィナミド、マレイン酸ノミフェンシン(MERITAL)、バノキセリン(GBR−12909としても公知である)およびそのデカン酸エステルDBL−583ならびにアミネプチン等の、ドーパミン再取り込み阻害剤;
(xvii)バクロフェン(LIORESAL、KEMSTRO)、サクロフェン、ペントバルビタール(NEMBUTAL)、プロガビド(GABRENE)およびクロメチアゾール等の、ガンマ−アミノ−酪酸(GABA)受容体アゴニスト;
(xviii)シプロキシファン、チプロリサント(tiprolisant)、S−38093、イルダビサント、ピトリサント、GSK−239512、GSK−207040、JNJ−5207852、JNJ−17216498、HPP−404、SAR−110894、trans−N−エチル−3−フルオロ−3−[3−フルオロ−4−(ピロリジン−1−イルメチル)フェニル]−シクロブタンカルボキサミド(PF−3654746、ならびに、米国特許公開第US2005−0043354号、同第US2005−0267095号、同第US2005−0256135号、同第US2008−0096955号、同第US2007−1079175号および同第US2008−0176925号;国際特許公開第WO2006/136924号、同第WO2007/063385号、同第WO2007/069053号、同第WO2007/088450号、同第WO2007/099423号、同第WO2007/105053号、同第WO2007/138431号および同第WO2007/088462号;ならびに米国特許第7,115,600号において開示されているもの)等の、ヒスタミン3(H3)アンタゴニスト;
(xix)酢酸グラチラマー(コポリマー−1としても公知である;COPAXONE)、MBP−8298(合成ミエリン塩基性タンパク質ペプチド)、フマル酸ジメチル、フィンゴリモド(FTY720としても公知である)、ロキニメクス(LINOMIDE)、ラキニモド(ABR−215062およびSAIK−MSとしても公知である)、ABT−874(ヒト抗−IL−12抗体;Abbott)、リツキシマブ(RITUXAN)、アレムツズマブ(CAMPATH)、ダクリズマブ(ZENAPAX)およびナタリズマブ(TYSABRI)等の、免疫モジュレーター;
(xx)メトトレキサート(TREXALL、RHEUMATREX)、ミトキサントロン(NOVANTRONE)、ミコフェノール酸モフェチル(CELLCEPT)、ミコフェノール酸ナトリウム(MYFORTIC)、アザチオプリン(AZASAN、IMURAN)、メルカプトプリン(PURI−NETHOL)、シクロホスファミド(NEOSAR、CYTOXAN)、クロラムブシル(LEUKERAN)、クラドリビン(LEUSTATIN、MYLINAX)、アルファ−フェトプロテイン、エタネルセプト(ENBREL)、および4−(ベンジルオキシ)−5−[(5−ウンデシル−2H−ピロール−2−イリデン)メチル]−1H,1’H−2,2’−ビピロール(PNU−156804としても公知である)等の、免疫抑制薬;
(xxi)インターフェロンベータ−1a(AVONEX、REBIF)およびインターフェロンベータ−1b(BETASERON、BETAFERON)を包含する、インターフェロン;
(xxii)単独であるか、またはDOPAデカルボキシラーゼ阻害剤(例えば、カルビドパ(SINEMET、CARBILEV、PARCOPA)、ベンセラジド(MADOPAR)、α−メチルドパ、モノフルオロメチルドパ、ジフルオロメチルドパ、ブロクレシンまたはm−ヒドロキシベンジルヒドラジン)と組み合わせた、レボドパ(または、そのメチルもしくはエチルエステル);
(xxiii)メマンチン(NAMENDA、AXURA、EBIXA)、アマンタジン(SYMMETREL)、アカンプロセート(CAMPRAL)、ベソンプロジル、ケタミン(KETALAR)、デルセミン、デキサナビノール、デキセファロキサン、デキストロメトルファン、デキストロルファン、トラキソプロジル、CP−283097、ヒマンタン、インダンタドール、イペノキサゾン、L−701252(Merck)、ランシセミン、レボルファノール(DROMORAN)、LY−233536およびLY−235959(いずれもLilly)、メタドン、(DOLOPHINE)、ネラメキサン、ペルジンホテル、フェンシクリジン、チアネプチン(STABLON)、ジゾシルピン(MK−801としても公知である)、EAB−318(Wyeth)、イボガイン、ボアカンギン、チレタミン、リルゾール(RILUTEK)、アプチガネル(CERES0TAT)、ガベスチネルならびにレマセミド等の、N−メチル−D−アスパラギン酸(NMDA)受容体アンタゴニスト;
(xxiv)セレギリン(EMSAM)、塩酸セレギリン(l−デプレニール、ELDEPRYL、ZELAPAR)、ジメチルセレギリン、ブロファロミン、フェネルジン(NARDIL)、トラニルシプロミン(PARNATE)、モクロベミド(AURORIX、MANERIX)、ベフロキサトン、サフィナミド、イソカルボキサジド(MARPLAN)、ニアラミド(NIAMID)、ラサギリン(AZILECT)、イプロニアジド(MARSILID、IPROZID、IPRONID)、CHF−3381(Chiesi Farmaceutici)、イプロクロジド、トロキサトン(HUMORYL、PERENUM)、ビフェメラン、デソキシペガニン(desoxypeganine)、ハルミン(テレパシンまたはバナステリン(banasterine)としても公知である)、ハルマリン、リネゾリド(ZYVOX、ZYVOXID)およびパージリン(EUDATIN、SUPIRDYL)等の、モノアミンオキシダーゼ(MAO)阻害剤;
(xxv)セビメリン、レベチラセタム、塩化ベタネコール(DUVOID、URECHOLINE)、イタメリン、ピロカルピン(SALAGEN)、NGX267、アレコリン、L−687306(Merck)、L−689660(Merck)、ヨウ化フルトレトニウム(FURAMON、FURANOL)、ベンゼンスルホン酸フルトレトニウム、p−トルエンスルホン酸フルトレトニウム、McN−A−343、オキソトレモリン、サブコメリン、AC−90222(Acadia Pharmaceuticals)およびカルバコール(CARBASTAT、MIOSTAT、CARBOPTIC)等の、ムスカリン様受容体(特に、M1サブタイプ)アゴニスト;
(xxvi)ボスチニブ、コンドリアーゼ、アリモクロモル(airmoclomol)、ラモトリジン、ペランパネル、アニラセタム、ミナプリム(minaprime)、リルゾール、N−ヒドロキシ−1,2,4,9−テトラヒドロ−3H−カルバゾール−3−イミン、デスモテプラーゼ、アナチバント、アスタキサンチン、ニューロペプチドNAP(例えば、AL−108およびAL−208;いずれもAllon Therapeutics)、ニューロストロール(neurostrol)、ペランパネル(perampenel)、イスプロニクリン、ビス(4−β−D−グルコピラノシルオキシベンジル)−2−β−D−グルコピラノシル−2−イソブチルタルトレート(ダクチロリン(dactylorhin)BまたはDHBとしても公知である)、ホルモバクチン、キサリプロデン(XAPRILA)、ラクタシスチン、ジメボリン塩酸塩(DIMEBON)、ジスフェントン(CEROVIVE)、アルンジン酸(ONO−2506、PROGLIA、CEREACT)、シチコリン(シチジン5’−ジホスホコリンとしても公知である)、エダラボン(RADICUT)、AEOL−10113およびAEOL−10150(いずれもAeolus Pharmaceuticals)、AGY−94806(SA−450およびMsc−1としても公知である)、顆粒球コロニー刺激因子(AX−200としても公知である)、BAY−38−7271(KN−387271としても公知である;Bayer AG)、アンクロド(VIPRINEX、ARWIN)、DP−b99(D−Pharm Ltd)、HF−0220(17−β−ヒドロキシエピアンドロステロン;Newron Pharmaceuticals)、HF−0420(オリゴトロピン(oligotropin)としても公知である)、ピリドキサール5’−リン酸(MC−1としても公知である)、マイクロプラスミン、S−18986、ピクロゾタン、NP031112、タクロリムス、L−セリル−L−メチオニル−L−アラニル−L−リシル−L−グルタミル−グリシル−L−バリン、AC−184897(Acadia Pharmaceuticals)、ADNF−14(National Institutes of Health)、スチルバズレニルトロン、SUN−N8075(第一サントリー生物医学研究所)ならびにゾナンパネル等の、神経保護薬;
(xxvii)エピバチジン、ブプロピオン、CP−601927、バレニクリン、ABT−089(Abbott)、ABT−594、AZD−0328(AstraZeneca)、EVP−6124、R3487(MEM3454としても公知である;Roche/Memory Pharmaceuticals)、R4996(MEM63908としても公知である;Roche/Memory Pharmaceuticals)、TC−4959およびTC−5619(いずれもTargacept)ならびにRJR−2403等の、ニコチン性受容体アゴニスト;
(xxviii)アトモキセチン(STRATTERA)、ドキセピン(APONAL、ADAPIN、SINEQUAN)、ノルトリプチリン(AVENTYL、PAMELOR、NORTRILEN)、アモキサピン(ASENDIN、DEMOLOX、MOXIDIL)、レボキセチン(EDRONAX、VESTRA)、ビロキサジン(VIVALAN)、マプロチリン(DEPRILEPT、LUDIOMIL、PSYMION)、ブプロピオン(WELLBUTRIN)およびラダキサフィン(radaxafine)等の、ノルエピネフリン(ノルアドレナリン)再取り込み阻害剤;
(xxix)(a)PDE1阻害剤(例えば、ビンポセチン(CAVINTON、CERACTIN、INTELECTOL)および米国特許第6,235,742号において開示されているもの)、(b)PDE2阻害剤(例えば、エリスロ−9−(2−ヒドロキシ−3−ノニル)アデニン(EHNA)、BAY60−7550および米国特許第6,174,884号において開示されているもの)、(c)PDE3阻害剤(例えば、アナグレリド、シロスタゾール、ミルリノン、オルプリノン、パログレリルおよびピモベンダン)、(d)PDE4阻害剤(例えば、アプレミラスト、イブジラスト、ロフルミラスト、ロリプラム、Ro20−1724、イブジラスト(KETAS)、ピクラミラスト(RP73401としても公知である)、CDP840、シロミラスト(ARIFLO)、ロフルミラスト、トフィミラスト、オグレミラスト(GRC3886としても公知である)、テトミラスト(OPC−6535としても公知である)、リリミラスト(lirimifast)、テオフィリン(UNIPHYL、THEOLAIR)、アロフィリン(LAS−31025としても公知である)、ドキソフィリン、RPR−122818またはメセンブリン)ならびに(e)PDE5阻害剤(例えば、シルデナフィル(VIAGRA、REVATIO)、タダラフィル(CIALIS)、バルデナフィル(LEVITRA、VIVANZA)、ウデナフィル、アバナフィル、ジピリダモール(PERSANTINE)、E−4010、E−4021、E−8010、ザプリナスト、イオデナフィル(iodenafil)、ミロデナフィル、DA−8159、ならびに国際特許出願第WO2002/020521号、同第WO2005/049616号、同第WO2006/120552号、同第WO2006/126081号、同第WO2006/126082号、同第WO2006/126083号および同第WO2007/122466号において開示されているもの)、(f)PDE7阻害剤;(g)PDE8阻害剤;(h)PDE9阻害剤(例えば、BAY73−6691(Bayer AG)、ならびに米国特許公開第US2003/0195205号、同第US2004/0220186号、同第US2006/0111372号、同第US2006/0106035号、およびUSSN12/118,062(2008年5月9日出願)において開示されているもの)、(i)2−({4−[1−メチル−4−(ピリジン−4−イル)−1H−ピラゾール−3−イル]フェノキシ}メチル)キノリン−3(4H)−オンおよびSCH−1518291等のPDE10阻害剤;ならびに(j)PDE11阻害剤を包含するがこれらに限定されない、ホスホジエステラーゼ(PDE)阻害剤;
(xxx)キニーネ(その塩酸塩、二塩酸塩、硫酸塩、重硫酸塩およびグルコン酸塩を包含する)、クロロキン、サントキン、ヒドロキシクロロキン(PLAQUENIL)、メフロキン(LARIAM)およびアモジアキン(CAMOQUIN、FLAVOQUINE)等の、キノリン;
(xxxi)ASP−1702、SCH−745966、JNJ−715754、AMG−0683、AZ−12304146、BMS−782450、GSK−188909、NB−533、LY−2886721、E−2609、HPP−854、(+)−酒石酸フェンセリン(POSIPHEN)、LSN−2434074(LY−2434074としても公知である)、KMI−574、SCH−745966、Ac−rER(N2−アセチル−D−アルギニル−L−アルギニン)、ロキシスタチン(E64dとしても公知である)およびCA074Me等の、β−セクレターゼ阻害剤;
(xxxii)BMS−708163(Avagacest)、WO20060430064(Merck)、DSP8658(大日本住友製薬株式会社)、ITI−009、L−685458(Merck)、ELAN−G、ELAN−Z、4−クロロ−N−[(2S)−3−エチル−1−ヒドロキシペンタン−2−イル]ベンゼンスルホンアミド等の、γ−セクレターゼ阻害剤およびモジュレーター;
(xxxiii)スピペロン、レボ−ピンドロール、BMY7378、NAD−299、S−(−)−UH−301、NAN190、レコゾタン等の、セロトニン(5−ヒドロキシトリプタミン)1A(5−HT1A)受容体アンタゴニスト;
(xxxiv)バビカセリンおよびジクロナピン等の、セロトニン(5−ヒドロキシトリプタミン)2C(5−HT2c)受容体アゴニスト;
(xxxv)PRX−03140(Epix)等の、セロトニン(5−ヒドロキシトリプタミン)4(5−HT4)受容体アゴニスト;
(xxxvi)A−964324、AVI−101、AVN−211、ミアンセリン(TORVOL、BOLVIDON、NORVAL)、メチオテピン(メチテピンとしても公知である)、リタンセリン、ALX−1161、ALX−1175、MS−245、LY−483518(SGS518としても公知である;Lilly)、MS−245、Ro04−6790、Ro43−68544、Ro63−0563、Ro65−7199、Ro65−7674、SB−399885、SB−214111、SB−258510、SB−271046、SB−357134、SB−699929、SB−271046、SB−742457(GlaxoSmithKline)、Lu AE58054(Lundbeck A/S)およびPRX−07034(Epix)等の、セロトニン(5−ヒドロキシトリプタミン)6(5−HT6)受容体アンタゴニスト;
(xxxvii)アラプロクレート、シタロプラム(CELEXA、CIPRAMIL)、エスシタロプラム(LEXAPRO、CIPRALEX)、クロミプラミン(ANAFRANIL)、デュロキセチン(CYMBALTA)、フェモキセチン(MALEXIL)、フェンフルラミン(PONDIMIN)、ノルフェンフルラミン、フルオキセチン(PROZAC)、フルボキサミン(LUVOX)、インダルピン、ミルナシプラン(IXEL)、パロキセチン(PAXIL、SEROXAT)、セルトラリン(ZOLOFT、LUSTRAL)、トラゾドン(DESYREL、MOLIPAXIN)、ベンラファキシン(EFFEXOR)、ジメリジン(NORMUD、ZELMID)、ビシファジン、デスベンラファキシン(PRISTIQ)、ブラソフェンシン、ビラゾドン、カリプラジン、ニューラルステムおよびテソフェンシン等の、セロトニン(5−HT)再取り込み阻害剤;
(xxxviii)神経成長因子(NGF)、塩基性線維芽細胞成長因子(bFGF;ERSOFERMIN)、ニューロトロフィン−3(NT−3)、カルディオトロフィン−1、脳由来神経栄養因子(BDNF)、ニューブラスチン、メテオリンおよびグリア由来神経栄養因子(GDNF)等の栄養因子、ならびに、プロペントフィリン、イデベノン、PYM50028(COGANE;Phytopharm)およびAIT−082(NEOTROFIN)等の栄養因子の産生を刺激する薬剤;
(xxxix)パリフルチン(paliflutine)、ORG−25935、JNJ−17305600およびORG−26041等の、グリシン輸送体−1阻害剤;
(xl)ペランパネル、ミバンパトル(mibampator)、セルランパネル(selurampanel)、GSK−729327、N−{(3S,4S)−4−[4−(5−シアノチオフェン−2−イル)フェノキシ]テトラヒドロフラン−3−イル}プロパン−2−スルホンアミド等の、AMPA型グルタミン酸受容体モジュレーター;
(xli)トファシチニブ、ルキソリチニブ、バリシチニブ、CYT387、GLPG0634、レスタウルチニブ、パクリチニブおよびTG101348等であるがこれらに限定されない、ヤヌスキナーゼ阻害剤(JAK);
(xlii)PF−06650833等であるがこれに限定されない、インターロイキン−1受容体関連キナーゼ4阻害剤(IRAK4)。
下記は、本発明の種々の化合物の合成を例証するものである。本発明の範囲内にある追加の化合物は、単独で、または当技術分野において概して公知である技術と組み合わせてのいずれかで、これらの実施例において例証されている方法を使用して調製され得る。
エチル3−ブロモ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキシレート(P1)
酢酸(150mL)を、トルエン(150mL)中のナトリウム1,4−ジエトキシ−1,4−ジオキソブタ−2−エン−2−オレート(30.0g、0.143mol)の溶液に滴下添加し、混合物を室温で30分間にわたって攪拌したら直ぐに、ヒドラジン一塩酸塩(85%、17g、0.29mol)を添加した。反応混合物を室温でさらに30分間にわたって攪拌し、その後、100℃で終夜加熱した。次いで、これを真空で濃縮し、酢酸エチル(500mL)で抽出し、有機層を、飽和重炭酸ナトリウム水溶液(200mL)および飽和塩化ナトリウム水溶液(200mL)で順次に洗浄し、硫酸ナトリウムで乾燥させ、濾過し、減圧下で濃縮して、生成物を黄色固体として提供した。収量:17g、0.11mol、77%。1H NMR (400 MHz, DMSO-d6) δ 12.75 (br s, 1H), 5.91 (br s, 1H), 4.24
(q, J=7 Hz, 2H), 1.27 (t, J=7 Hz, 3H).
炭酸カリウム(48.3g、349mmol)を、アセトニトリル(250mL)中のC1(13.65g、87.42mmol)の溶液に添加した。混合物を室温で15分間にわたって攪拌したら直ぐに、1,3−ジブロモプロパン(10mL、98mmol)を滴下添加し、反応混合物を16時間にわたって加熱還流した。次いで、これを室温に冷却させ、濾過し、濾過した固体をアセトニトリル(2×100mL)で洗浄した。濾液を真空で濃縮し、残留物を、シリカゲル上のクロマトグラフィー(勾配:ヘプタン中50%から95%酢酸エチル)を介して精製して、生成物を橙色油状物として得た。収量:10.48g、53.4mmol、61%。LCMS m/z 197.0[M+H]+. 1H NMR (400 MHz, CDCl3)
δ 6.03 (s, 1H), 4.39 (q, J=7.1
Hz, 2H), 4.34-4.30 (m, 2H), 4.26 (t, J=6.2 Hz, 2H), 2.33-2.26 (m, 2H), 1.39 (t,
J=7.1 Hz, 3H).
N−ブロモコハク酸イミド(6.00g、33.7mmol)を、アセトニトリル(100mL)中のC2(6.00g、30.6mmol)の溶液に小分けにして添加した。反応混合物を50℃で1時間にわたって攪拌した後、これを室温に冷却させ、真空で濃縮し、酢酸エチル(200mL)と水(150mL)とに分配した。有機層を、水(150mL)でおよび飽和塩化ナトリウム水溶液(100mL)で洗浄し、硫酸マグネシウムで乾燥させ、濾過し、真空で濃縮した。シリカゲルクロマトグラフィー(勾配:ヘプタン中20%から80%酢酸エチル)により、残留コハク酸イミドを含有する材料を提供し、これを酢酸エチル(100mL)に溶解し、水(2×100mL)でおよび飽和塩化ナトリウム水溶液(100mL)で洗浄し、硫酸マグネシウムで乾燥させ、濾過し、減圧下で濃縮した。得られた黄色固体をペンタンで粉砕して、生成物を白色粉末として得た。収量:6.00g、21.8mmol、71%。LCMS m/z 276.9 (臭素同位体パターンが観察された) [M+H]+.
1H NMR (400 MHz, CDCl3) δ 4.44-4.40 (m, 2H), 4.42 (q, J=7.1 Hz, 2H), 4.26 (t, J=6.2 Hz, 2H),
2.36-2.29 (m, 2H), 1.41 (t, J=7.1 Hz, 3H).
アゼチジン−1−イル(3−ブロモ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−イル)メタノン(P2)
J=5.3, 5.3 Hz, 2H), 4.22-4.13 (m, 4H), 2.37-2.26 (m, 4H).
3−ブロモ−N−シクロプロピル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド(P3)
2H), 4.16 (t, J=6.2 Hz, 2H), 2.89-2.81 (m, 1H), 2.35-2.27 (m, 2H), 0.86-0.79
(m, 2H), 0.64-0.58 (m, 2H).
エチル(6S)−6−フルオロ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキシレート(P4)およびエチル(6R)−6−フルオロ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキシレート(P5)
水素化アルミニウムリチウム(テトラヒドロフラン中1M溶液;53.3mL、53.3mmol)を、テトラヒドロフラン(210mL)中のジメチルフルオロプロパンジオエート(5.00g、33.3mmol)の0℃溶液に10分間かけて添加した。0℃で2分の攪拌後、氷浴を除去し、反応混合物を2時間かけて室温に加温させたら直ぐに、これを再度0℃に冷却した。L(+)−酒石酸、カリウムナトリウム塩の水溶液(ロッシェル塩;2N、100mL)を慎重に添加し、得られた混合物を室温で終夜攪拌した。酢酸エチルを添加し、水性層を酢酸エチルで3回抽出し、合わせた有機層を硫酸ナトリウムで乾燥させ、濾過し、真空で濃縮して、生成物を得た。収量:2.31g、24.6mmol、74%。1H NMR (400 MHz, CD3CN) δ 4.48 (五重線のd,
J=48.9, 4.7 Hz, 1H), 3.72-3.59 (m, 4H), 2.95 (br s, 2H).
4−メチルベンゼンスルホン酸無水物(16.8g、51.5mmol)を、ジクロロメタン(120mL)中のC3(2.31g、24.6mmol)の0℃溶液に添加した。次いで、トリエチルアミン(7.87mL、56.5mmol)を1分間かけて添加し、反応混合物を0℃で1時間にわたって攪拌したら直ぐに、これを飽和重炭酸ナトリウム水溶液および1M塩酸で順次に洗浄し、硫酸ナトリウムで乾燥させ、濾過し、真空で濃縮した。残留物をエタノール(50mL)で処理し、加熱還流し、次いで、氷浴中で冷却した。混合物を0℃で20分間にわたって攪拌した後、これを濾過し、収集した材料を冷エタノールで洗浄して、生成物を固体として得た。収量:8.42g、20.9mmol、85%。1H NMR (400 MHz, CDCl3) δ 7.78 (br d, J=8.2 Hz, 4H), 7.38 (br d,
J=8.3 Hz, 4H), 4.82 (五重線のd, J=46.5, 4.4 Hz, 1H), 4.18
(br dd, J=20, 4.4 Hz, 4H), 2.48 (s, 6H).
N,N−ジメチルホルムアミド(150mL)中の、C4(20g、50mmol)、C1(8.2g、52mmol)、炭酸セシウム(48.5g、149mmol)およびヨウ化ナトリウム(7.5g、50mmol)の混合物を、100℃で2時間にわたって加熱した。水(1L)および酢酸エチル(500mL)を添加し、有機層を真空で濃縮し、シリカゲルクロマトグラフィー(勾配:石油エーテル中1%から50%酢酸エチル)により、生成物を白色固体として提供した。収量:8.0g、37mmol、74%。1H NMR (400 MHz, CDCl3) δ 6.10 (s, 1H), [5.32-5.27 (m)および5.21-5.16 (m), JHF=46 Hz, 1H], 4.67-4.54 (m, 2H),
4.48-4.32 (m, 1H), 4.39 (q, J=7.1 Hz, 2H), 4.22 (br dd, J=36.6, 12.4 Hz, 1H),
1.39 (t, J=7.1 Hz, 3H).
P4およびP5のラセミ混合物(833mg)を、超臨界流体クロマトグラフィー(カラム:Phenomenex Lux Cellulose−4、5μm;移動相:4:1 二酸化炭素/メタノール)を使用して分離した。第一溶離エナンチオマーは、P4であり、この材料は、負(−)回転を呈した。分離のための収量:250mg、30%。第二溶離エナンチオマーは、P5であり、この材料は、正(+)回転を呈した。分離のための収量:241mg、29%。P4およびP5について示されている絶対配置は、P4のX線構造分析(以下を参照)に基づいて割り当てられ、結晶は、酢酸エチルおよびヘキサンからのP4の再結晶を介して得られた。
データ収集は、Bruker APEX回折計で室温において実施した。データ収集は、オメガおよびファイ走査からなるものであった。
SHELXTL、バージョン5.1、Bruker AXS、1997。
PLATON, A. L. Spek, J. Appl. Cryst. 2003,
36, 7-13.
MERCURY, C. F. Macrae, P. R. Edington, P.
McCabe, E. Pidcock, G. P. Shields, R. Taylor, M. TowlerおよびJ. van de Streek, J. Appl. Cryst. 2006, 39, 453-457.
OLEX2, O. V. Dolomanov, L. J. Bourhis, R.
J. Gildea, J. A. K. HowardおよびH.
Puschmann, J. Appl. Cryst. 2009, 42, 339-341.
R. W. W. Hooft, L. H. StraverおよびA. L. Spek, J. Appl. Cryst. 2008, 41,
96-103.
H. D. Flack, Acta Cryst. 1983, A39,
867-881.
エチル(6S)−3−ブロモ−6−フルオロ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキシレート(P6)およびエチル(6R)−3−ブロモ−6−フルオロ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキシレート(P7)
N−ブロモコハク酸イミド(7.3g、41mmol)を、ジクロロメタン(120mL)中のC5(8.0g、37mmol)および酢酸(0.5mL)の溶液に添加し、反応混合物を室温で3時間にわたって攪拌した。真空での溶媒の除去後、残留物を、シリカゲルクロマトグラフィー(勾配:石油エーテル中9%から50%酢酸エチル)を介して精製して、生成物を白色固体として得た。収量:8.5g、29mmol、78%。LCMS m/z 294.8 (臭素同位体パターンが観察された) [M+H]+.
1H NMR (400 MHz, CDCl3) δ [5.37-5.31 (m)および5.25-5.20 (m), JHF=45
Hz, 1H], 4.79-4.70 (m, 1H), 4.66-4.55 (m, 1H), 4.48-4.32 (m, 1H), 4.43 (q,
J=7.2 Hz, 2H), 4.29 (br dd, J=36.8, 12.9 Hz, 1H), 1.42 (t, J=7.2 Hz, 3H).
P6およびP7のラセミ混合物(1.0g)を、超臨界流体クロマトグラフィー(カラム:Phenomenex Lux Cellulose−3、5μm;移動相:4:1 二酸化炭素/メタノール)を使用して分離した。第一溶離エナンチオマーは、P6であり、この材料は、負(−)回転を呈した。分離のための収量:約500mg、約50%。1H NMR (400 MHz, CDCl3) δ [5.36-5.32 (m)および5.25-5.21
(m), JHF=45 Hz, 1H], 4.79-4.70 (m, 1H), 4.67-4.56 (m, 1H), 4.48-4.33
(m, 1H), 4.43 (q, J=7.1 Hz, 2H), 4.29 (br dd, J=36.9, 12.9 Hz, 1H), 1.42 (t,
J=7.1 Hz, 3H).第二溶離エナンチオマーは、P7であり、この材料は、正(+)回転を呈した。分離のための収量:約500mg、約50%。1H NMR (400 MHz, CDCl3) δ [5.36-5.32 (m)および5.25-5.20
(m), JHF=45 Hz, 1H], 4.79-4.70 (m, 1H), 4.67-4.56 (m, 1H), 4.49-4.32
(m, 1H), 4.43 (q, J=7.1 Hz, 2H), 4.29 (br dd, J=36.8, 12.8 Hz, 1H), 1.42 (t,
J=7.1 Hz, 3H).P6およびP7の絶対配置は、P5との相関関係を介して割り当てられた(以下のP7の代替合成を参照)。
N−ブロモコハク酸イミド(229mg、1.29mmol)を、ジクロロメタン(5mL)中のP5(250mg、1.17mmol)の溶液に添加した。数滴の酢酸を添加し、反応混合物を室温で終夜攪拌した。次いで、これを、ジクロロメタンで希釈し、重炭酸ナトリウム水溶液で洗浄し、硫酸マグネシウムで乾燥させ、濾過し、真空で濃縮した。シリカゲル上のクロマトグラフィー(勾配:ヘプタン中0%から100%酢酸エチル)により、生成物を固体として得た。この材料は、正(+)回転を呈し、それがP7であることを確認した。収量:259mg、0.884mmol、76%。LCMS m/z 315.1 (臭素同位体パターンが観察された) [M+Na+].1H
NMR (400 MHz, CDCl3) δ [5.36-5.32 (m)および5.25-5.20 (m), JHF=45
Hz, 1H], 4.78-4.68 (m, 1H), 4.65-4.54 (m, 1H), 4.48-4.32 (m, 1H), 4.41 (q,
J=7.1 Hz, 2H), 4.29 (br dd, J=37.1, 12.8 Hz, 1H), 1.40 (t, J=7.1 Hz, 3H).
エチル5−メチル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキシレート(P8)およびエチル7−メチル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキシレート(P9)
4.42-4.14 (m, 5H), 2.25-2.17 (m, 1H), 2.15-2.06 (m, 1H), 1.48 (d, J=6.3 Hz,
3H), 1.39 (t, J=7.1 Hz, 3H); P9と推定される主成分: δ 6.00 (s, 1H), 4.49-4.22 (m, 5H), 2.37
(dddd, J=14.4, 7.4, 5.6, 3.1 Hz, 1H), 2.01 (dddd, J=14.4, 7.8, 6.6, 3.1 Hz,
1H), 1.64 (d, J=6.5 Hz, 3H), 1.38 (t, J=7.1 Hz, 3H).この混合物を、シリカゲルクロマトグラフィー(勾配:石油エーテル中17%から67%酢酸エチル)に供して、生成物を得た。示されている位置化学は、ブロモ誘導体C7およびC9に対して行われたNMR研究に基づいて割り当てられた(以下を参照)。P8の収量:0.9g、4mmol、15%。P9の収量:1.7g、8.1mmol、31%。
3−(4−クロロフェニル)−5−メチル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボン酸(P10)
テトラクロロメタン(30mL)中のP8(0.84g、4.0mmol)およびN−ブロモコハク酸イミド(0.86g、4.8mmol)の溶液を、60℃で3時間にわたって攪拌したら直ぐに、これを水(30mL)とジクロロメタン(50mL)とに分配した。有機層を飽和塩化ナトリウム水溶液(30mL)で洗浄し、硫酸ナトリウムで乾燥させ、濾過し、真空で濃縮した。シリカゲルクロマトグラフィー(勾配:石油エーテル中9%から50%酢酸エチル)により、生成物を黄色固体として得た。収量:0.80g、2.8mmol、70%。メチル基の位置は、C9の13C NMRおよびDEPTスペクトルと比較したC7の13C NMRスペクトルの調査を介して確立した。1H NMR (400 MHz, CDCl3) δ 4.52-4.43 (m, 1H), 4.42 (q, J=7.1 Hz, 2H),
4.32 (ddd, ABXYパターンの半分, J=12.9, 5.8, 2.9 Hz, 1H), 4.19
(ddd, ABXYパターンの半分, J=12.8, 11.0, 5.4 Hz, 1H), 2.29-2.21
(m, 1H), 2.19-2.05 (m, 1H), 1.55 (d, J=6.3 Hz, 3H), 1.41 (t, J=7.1 Hz, 3H).
1,4−ジオキサン(10mL)および水(2.5mL)中のC7(332mg、1.15mmol)の溶液に、(4−クロロフェニル)ボロン酸(187mg、1.20mmol)、炭酸セシウム(560mg、1.72mmol)およびジクロロビス(トリシクロヘキシルホスフィン)パラジウム(II)(39mg、53μmol)を添加した。反応混合物を、窒素でスパージすることによって脱気し、次いで、110℃で終夜攪拌したら直ぐに、これを水(10mL)と酢酸エチル(60mL)とに分配した。有機層を飽和塩化ナトリウム水溶液(20mL)で洗浄し、硫酸ナトリウムで乾燥させ、濾過し、真空で濃縮し、シリカゲルクロマトグラフィー(勾配:石油エーテル中9%から50%酢酸エチル)により、生成物を黄色固体として得た。この材料は、1H NMR分析によって評価される通り、不純であった。収量: 0.38 g, 約60%純度,
0.7 mmol, 60%. 1H NMR (400 MHz, CDCl3), 特徴的ピーク: δ 7.38 (br AB四重線, JAB=8.6 Hz, ΔνAB=33.7 Hz, 4H), 4.35 (q, J=7.1 Hz,
2H), 1.49 (d, J=6.3 Hz, 3H), 1.34 (t, J=7.2 Hz, 3H).
メタノール(6mL)中のC8(前ステップから、およそ60%純度のもの;250mg、0.47mmol)の溶液に、水酸化リチウム一水和物(79mg、1.9mmol)を添加し、反応混合物を60℃で終夜攪拌した。次いで、これを、濃塩酸の添加を介しておよそ6のpHに酸性化した。真空での揮発物の除去により、粗生成物(350mg)を得、これを、追加の精製なしに実施例9において使用した。LCMS m/z 292.7 (塩素同位体パターンが観察された) [M+H]+.
3−(4−クロロフェニル)−7−メチル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボン酸(P11)
P9からC9への変換は、調製P10においてC7の合成について記述されている方法を使用して行い、生成物は、黄色固体として単離された。メチル基の位置は、C7の13C NMRスペクトルと比較したC9の13C NMRおよびDEPTスペクトルの調査を介して確立した。収量:1.1g、3.8mmol、76%。1H NMR (400 MHz, CDCl3) δ 4.51-4.40 (m, 2H), 4.42 (q, J=7.2 Hz, 2H),
4.36 (ddd, J=11.3, 7.9, 3.1 Hz, 1H), 2.40 (dddd, J=14.6, 7.4, 5.4, 3.1 Hz, 1H),
2.10-2.00 (m, 1H), 1.64 (d, J=6.4 Hz, 3H), 1.41 (t, J=7.1 Hz, 3H).
C9から生成物への変換は、調製P10においてC8の合成について記述されている方法を使用して行った。生成物は、1H NMR分析を介しておよそ60%純度の黄色固体として得られた。収量:1.2g、約60%純度、2mmol、50%。1H NMR (400 MHz, CDCl3), 特徴的な生成物ピークのみ: δ 7.36 (br AB四重線, JAB=8.7 Hz, ΔνAB=24.2 Hz, 4H), 4.34 (q, J=7.2 Hz,
2H), 1.68 (d, J=6.5 Hz, 3H), 1.31 (t, J=7.2 Hz, 3H).
メタノール(6mL)中のC10(前ステップから、およそ60%純度のもの;320mg、0.6mmol)の溶液に、水酸化リチウム一水和物(126mg、3.00mmol)を添加し、反応混合物を60℃で終夜攪拌した。次いで、これを、濃塩酸の添加を介しておよそ6のpHに酸性化した。真空での揮発物の除去により、粗生成物(500mg)を得、これを、追加の精製なしに実施例10において使用した。LCMS m/z 292.8 (塩素同位体パターンが観察された) [M+H]+.
3−ブロモ−N−シクロプロピル−6,6−ジフルオロ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド(P12)
p−トルエンスルホニルクロリド(747g、3.92mol)を、ピリジン(400mL)およびジクロロメタン(1.5L)中のプロパン−1,2,3−トリオール(180g、1.95mol)および4−(ジメチルアミノ)ピリジン(24g、0.20mol)の0℃溶液に小分けにして添加した。反応混合物を室温で終夜攪拌した後、これを氷水で処理し、濃塩酸の添加を介してpHを3に調整した。混合物をジクロロメタン(3×1L)で抽出し、合わせた有機層を乾燥させ、濾過し、真空で濃縮した。シリカゲルクロマトグラフィー(勾配:石油エーテル中9%から33%酢酸エチル)により、生成物を無色油状物として提供し、これは、1H NMR分析により、不純であった。収量:280g、699mmol未満、36%未満。1H NMR (400 MHz, CDCl3), 生成物ピークのみ: δ 7.77 (d, J=8.3
Hz, 4H), 7.36 (d, J=8.0 Hz, 4H), 4.10-4.01 (m, 5H), 2.47 (s, 6H).
デス・マーチン・ペルヨージナン[1,1,1−トリス(アセチルオキシ)−1,1−ジヒドロ−1,2−ベンズヨードキソール−3−(1H)−オン](9.50g、22.4mmol)を、ジクロロメタン(100mL)中のC11(3.0g、7.5mmol)の溶液に添加し、反応混合物を室温で終夜攪拌した。飽和重炭酸ナトリウム水溶液および飽和チオ硫酸ナトリウム水溶液を添加し、得られた混合物をジクロロメタンで抽出した。合わせた有機層を乾燥させ、濾過し、真空で濃縮し、シリカゲルクロマトグラフィー(勾配:石油エーテル中9%から50%酢酸エチル)により、生成物を白色固体として得た。収量:2.0g、5.0mmol、67%。1H NMR (400 MHz, CDCl3) δ 7.81 (d, J=8.3 Hz, 4H), 7.39 (d, J=8.1 Hz,
4H), 4.71 (s, 4H), 2.48 (s 6H).
ジクロロメタン(30mL)中のC12(1.2g、3.0mmol)の溶液を、(ジエチルアミノ)硫黄トリフルオリド(2.4g、15mmol)に0℃でゆっくりと添加した。反応混合物を40℃で6時間にわたって攪拌したら直ぐに、これを飽和重炭酸ナトリウム水溶液でゆっくりと処理した。得られた混合物をジクロロメタンで抽出し、有機層を乾燥させ、濾過し、真空で濃縮した。残留物を、シリカゲルクロマトグラフィー(勾配:石油エーテル中9%から50%酢酸エチル)を介して精製して、生成物を薄黄色固体として提供した。収量:550mg、1.3mmol、43%。LCMS m/z 442.9 [M+Na+].1H NMR (400 MHz, CDCl3)
δ 7.78 (br d, J=8.3 Hz, 4H),
7.39 (br d, J=8.0 Hz, 4H), 4.18 (t, JHF=11.4 Hz, 4H), 2.48 (s, 6H).
N,N−ジメチルホルムアミド(13mL)中の、C13(460mg、1.1mmol)、C1(600mg、3.8mmol)、炭酸セシウム(1.1g、3.4mmol)およびヨウ化ナトリウム(140mg、0.93mmol)の混合物を、100℃に3時間にわたって加熱した。次いで、反応混合物を水(30mL)で希釈し、酢酸エチル(3×15mL)で抽出した。合わせた有機層を減圧下で濃縮し、シリカゲルクロマトグラフィー(勾配:石油エーテル中0%から50%酢酸エチル)を介して精製し、生成物は、白色固体として単離された。収量:220mg、0.95mmol、86%。1H NMR (400 MHz, CDCl3) δ 6.15 (s, 1H), 4.59 (br t, JHF=12.4
Hz, 2H), 4.40 (q, J=7.2 Hz, 2H), 4.36 (br t, JHF=10.4 Hz, 2H), 1.40
(t, J=7.2 Hz, 3H).
ジクロロメタン(30mL)中のC14(200mg、0.86mmol)およびN−ブロモコハク酸イミド(178mg、1.00mmol)の混合物を、室温で16時間にわたって攪拌した。次いで、反応混合物をジクロロメタン(50mL)で希釈し、飽和塩化ナトリウム水溶液で洗浄し、硫酸ナトリウムで乾燥させ、濾過し、真空で濃縮して、生成物を黄色固体として得た。収量:230mg、0.74mmol、86%。
メタノール(20mL)中の、C15(290mg、0.93mmol)、シクロプロパンアミン(2mL)および塩化カルシウム(100mg、0.90mmol)の混合物を、50℃に3時間にわたって加熱した。次いで、反応混合物を減圧下で濃縮し、残留物をジクロロメタン(80mL)で希釈し、水(15mL)および飽和塩化ナトリウム水溶液で順次に洗浄し、硫酸ナトリウムで乾燥させ、濾過し、真空で濃縮して、生成物を黄色固体として提供した。収量:250mg、0.78mmol、84%。1H NMR (400 MHz, CDCl3) δ 4.50 (t, JHF=11.9 Hz, 2H), 4.43
(t, JHF=10.4 Hz, 2H), 2.90-2.81 (m, 1H), 0.89-0.80 (m, 2H),
0.66-0.58 (m, 2H).
アゼチジン−1−イル[3−(4−クロロ−2−メチルフェニル)−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−イル]メタノン(1)
4.34-4.28 (m, 2H), 4.28-4.17 (m, 4H), 4.11-4.04 (m, 2H), 2.37-2.28 (m, 2H),
2.27-2.17 (m, 2H), 2.20 (s, 3H).
3−(4−クロロ−2−メチルフェニル)−N−シクロプロピル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド(2)
1H NMR (400 MHz, CDCl3) δ 7.20 (br s, 1H), 7.15 (AB四重線, 高磁場二重線が広がっている, JAB=8.2 Hz, ΔνAB=10.7 Hz, 2H), 6.79 (br s, 1H), 4.27
(dd, J=5.1, 5.1 Hz, 2H), 4.20 (t, J=6.2 Hz, 2H), 2.79-2.70 (m, 1H), 2.33-2.24
(m, 2H), 2.17 (s, 3H), 0.78-0.71 (m, 2H), 0.56-0.49 (m, 2H).
アゼチジン−1−イル[3−(4−クロロ−2,5−ジフルオロフェニル)−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−イル]メタノン(3)
1,4−ジオキサン(80mL)中の、1−ブロモ−4−クロロ−2,5−ジフルオロベンゼン(9.00g、39.6mmol)、4,4,4’,4’,5,5,5’,5’−オクタメチル−2,2’−ビ−1,3,2−ジオキサボロラン(15.1g、59.5mmol)および酢酸カリウム(7.8g、80mmol)の混合物を、窒素でのスパージを介して2分間にわたって脱気した。次いで、[1,1’−ビス(ジフェニルホスフィノ)フェロセン]ジクロロパラジウム(II)(1.5g、2.0mmol)を添加し、反応混合物を100℃で18時間にわたって攪拌した。次いで、これを濾過し、濾液を真空で濃縮し、シリカゲルクロマトグラフィー(勾配:石油エーテル中0%から10%酢酸エチル)に供して、生成物を黄色固体として得た。収量:6.1g、2.2mmol、56%。1H NMR (400 MHz, CDCl3) δ 7.48 (dd, J=8.8, 4.9 Hz, 1H), 7.12 (dd,
J=8.0, 5.6 Hz, 1H), 1.36 (s, 12H).
1,4−ジオキサン(20mL)中の、P2(1.8g、6.3mmol)、C16(4.32g、15.7mmol)および炭酸セシウム(4.10g、12.6mmol)の混合物を、窒素でのスパージを介して2分間にわたって脱気した。次いで、[1,1’−ビス(ジフェニルホスフィノ)フェロセン]ジクロロパラジウム(II)(460mg、0.63mmol)を添加し、反応混合物を100℃で18時間にわたって攪拌した。水(60mL)およびジクロロメタン(60mL)を添加した後、混合物を濾過し、濾液をジクロロメタン(3×40mL)で抽出した。合わせた有機層を飽和塩化ナトリウム水溶液で洗浄し、硫酸ナトリウムで乾燥させ、濾過し、真空で濃縮し、逆相HPLC(カラム:Phenomenex Gemini、10μm;移動相A:0.05%塩酸水溶液;移動相B:アセトニトリル;勾配:30%から70%B)により、生成物を薄黄色固体として提供した。収量:700mg、2.0mmol、32%。LCMS m/z 354.1 (塩素同位体パターンが観察された) [M+H]+.
1H NMR (400 MHz, CDCl3) δ 7.26 (dd, J=9.4, 6.4 Hz, 1H), 7.13 (dd, J=8.8, 6.3 Hz, 1H), 4.41
(br dd, J=7.8, 7.5 Hz, 2H), 4.36 (dd, J=5.3, 5.3 Hz, 2H), 4.22 (t, J=6.3 Hz,
2H), 4.14 (br dd, J=7.8, 7.8 Hz, 2H), 2.38-2.25 (m, 4H).
アゼチジン−1−イル[3−(4−クロロ−2,3−ジフルオロフェニル)−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−イル]メタノン(4)
1,4−ジオキサン(8mL)および水(2mL)中の2−(4−クロロ−2,3−ジフルオロフェニル)−4,4,5,5−テトラメチル−1,3,2−ジオキサボロラン(C17;この材料は、粗製および過剰で使用したことを除き、実施例3においてC16の合成について記述されている方法を使用して調製した)の溶液に、P1(150mg、0.545mmol)、ジクロロビス(トリシクロヘキシルホスフィン)パラジウム(II)(20mg、27μmol)および炭酸セシウム(355mg、1.09mmol)を添加した。反応混合物を100℃で終夜攪拌したら直ぐに、これを真空で濃縮し、シリカゲルクロマトグラフィーを介して精製して、生成物を黄色固体として提供した。収量:24.1mg、70.3μmol、13%。LCMS m/z 342.9 (塩素同位体パターンが観察された) [M+H]+.
アゼチジン塩酸塩(37.6mg、0.402mmol)、N,N−ジイソプロピルエチルアミンおよび塩化カルシウム(22.2mg、0.200mmol)を、メタノール(10mL)中のC18(35mg、0.10mmol)の溶液に添加し、反応混合物を50℃で終夜攪拌した。真空での溶媒の除去後、残留物を、逆相HPLC(カラム:Phenomenex Synergi C18、4μm;移動相A:水中0.225%ギ酸;移動相B:メタノール;勾配:40%から60%B)を使用して精製して、生成物を白色固体として得た。収量:11.2mg、31.6μmol、32%。LCMS m/z 354.2 (塩素同位体パターンが観察された) [M+H]+. 1H NMR (400 MHz, CDCl3) δ 7.21-7.10 (m, 2H), 4.46-4.37 (m, 2H), 4.36
(dd, J=5.4, 4.9 Hz, 2H), 4.23 (t, J=6.2 Hz, 2H), 4.18-4.10 (m, 2H), 2.39-2.25
(m, 4H).
3−(4−シアノ−5−フルオロ−2−メチルフェニル)−N−シクロプロピル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド(5)
4−ブロモ−2−フルオロ−5−メチルベンゾニトリル(600mg、2.8mmol)を、実施例3においてC16の合成について記述されている方法を使用して、生成物に変換した。この場合、シリカゲルクロマトグラフィーは、石油エーテル中0%から30%酢酸エチルの勾配を使用して行い、生成物は、白色固体として得られた。収量:500mg、1.9mmol、68%。1H NMR (400 MHz, CDCl3) δ 7.56 (d, J=9.4 Hz, 1H), 7.38 (d, J=5.9 Hz,
1H), 2.51 (s, 3H), 1.36 (s, 12H).
[1,1’−ビス(ジフェニルホスフィノ)フェロセン]ジクロロパラジウム(II)(96mg、0.13mmol)を、1,4−ジオキサン(20mL)および水(2mL)中の、P3(750mg、2.62mmol)、C19(1.03g、3.94mmol)および炭酸セシウム(723mg、2.22mmol)の混合物に添加した。反応物を100℃で16時間にわたって攪拌した後、これを真空で濃縮し、酢酸エチル(10mL)に溶解し、水(5mL)で洗浄した。有機層を硫酸ナトリウムで乾燥させ、濾過し、減圧下で濃縮し、シリカゲルクロマトグラフィー(勾配:石油エーテル中20%から40%酢酸エチル)により、生成物を白色固体として得た。収量:381.4mg、1.120mmol、43%。LCMS m/z 340.9 [M+H]+. 1H NMR (400 MHz, CDCl3)
δ 7.43 (d, J=6.5 Hz, 1H), 7.11
(d, J=9.7 Hz, 1H), 6.90 (br s, 1H), 4.34 (dd, J=5.3, 5.1 Hz, 2H), 4.22 (dd,
J=6.3, 6.2 Hz, 2H), 2.79-2.72 (m, 1H), 2.39-2.30 (m, 2H), 2.18 (s, 3H),
0.82-0.75 (m, 2H), 0.61-0.54 (m, 2H).
(6S)−3−(4−クロロ−2−メチルフェニル)−N−シクロプロピル−6−フルオロ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド(6)
1,4−ジオキサン(5mL)および水(0.5mL)の脱気した混合物に、P6(2.50g、8.53mmol)、(4−クロロ−2−メチルフェニル)ボロン酸(1.60g、9.39mmol)、炭酸セシウム(5.56g、17.1mmol)および[1,1’−ビス(ジ−tert−ブチルホスフィノ)フェロセン]ジクロロパラジウム(II)(278mg、0.426mmol)を添加した。反応ベッセルを排気し、窒素を投入した。この排気サイクルを2回繰り返し、次いで、反応を室温で3時間にわたって進行させた。溶媒を真空で除去し、残留物をシリカゲル上でクロマトグラフ(溶離液:1:1 酢酸エチル/ヘプタン)して、生成物を提供した。収量:2.1g、6.2mmol、73%。LCMS m/z 339.4 (塩素同位体パターンが観察された) [M+H]+.
1H NMR (400 MHz, CDCl3), 特徴的ピーク: δ 7.24 (br s, 1H), 7.17 (br dd, ABXパターンの半分, J=8.2, 2.0 Hz, 1H), 7.13 (br d, AB四重線の半分,
J=8.2 Hz, 1H), [5.34-5.29 (m)および5.23-5.18 (m), JHF=45
Hz, 1H], 4.30-4.13 (m, 3H), 2.16 (s, 3H), 1.23 (t, J=7.1 Hz, 3H).
水酸化カリウム(13mmol)を、メタノール(10mL)中のC20(2.2g、6.5mmol)の溶液に添加し、反応混合物を室温で終夜攪拌した。次いで、これを氷浴中で冷却し、塩化水素溶液の添加を介して4〜5のpHに酸性化し、真空で濃縮した。この材料を、精製することなく後続のステップにおいて使用した。LCMS m/z 311.3 (塩素同位体パターンが観察された) [M+H]+.
ジクロロメタン(50mL)中のC21(前ステップから、6.5mmol以下)およびシクロプロパンアミン(600mg、10.5mmol)の溶液を、N,N−ジイソプロピルエチルアミン(2.49mL、14.3mmol)で処理した。次いで、2,4,6−トリプロピル−1,3,5,2,4,6−トリオキサトリホスフィナン2,4,6−三酸化物(4.55g、14.3mmol、酢酸エチル中50%溶液として)を添加し、反応混合物を室温で終夜攪拌した。次いで、これを、飽和重炭酸ナトリウム水溶液(10mL)および飽和塩化ナトリウム水溶液(10mL)で順次に洗浄し、乾燥させ、濾過し、真空で濃縮した。得られた材料の一部を、超臨界流体クロマトグラフィー(カラム:Princeton 4−Ethylpyridine、5μm;移動相:4:1 二酸化炭素/エタノール)に供して、生成物を白色固体(0.89g)として得た。この材料は、粉末X線回折を介して結晶性であった。残りをメタノールから再結晶させて、追加の生成物(0.97g)を得た。2ステップにわたって合わせた収量:1.86g、5.32mmol、82%。LCMS m/z 350.4 (塩素同位体パターンが観察された) [M+H]+.
1H NMR (400 MHz, CDCl3) δ 7.24 (br s, 1H), 7.21 (d, AB四重線の半分, J=8.2
Hz, 1H), 7.17 (br dd, ABXパターンの半分, J=8.2, 1.4 Hz, 1H),
6.75 (br s, 1H), [5.34-5.29 (m)および5.23-5.18 (m), JHF=45
Hz, 1H], 4.65-4.49 (m, 2H), 4.40 (ddd, ABXYパターンの半分,
J=36.7, 14.2, 3.3 Hz, 1H), 4.21 (dd, J=36.9, 12.7 Hz, 1H), 2.81-2.72 (m, 1H),
2.19 (s, 3H), 0.80-0.73 (m, 2H), 0.57-0.50 (m, 2H).
(6S)−3−(4−クロロ−2,5−ジフルオロフェニル)−N−シクロプロピル−6−フルオロ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド(7)
トリメチルアルミニウム(トルエン中2M溶液;8mL、16mmol)を、トルエン(50mL)中のP6(2.5g、8.5mmol)およびシクロプロパンアミン(8mL)の溶液に添加し、反応混合物を80℃に2時間にわたって加熱した。水(200mL)を添加し、得られた混合物を酢酸エチル(3×100mL)で抽出し、合わせた有機層を乾燥させ、濾過した。濾液をシリカゲルで処理した後、これを濾過し、濾液を真空で濃縮して、生成物を黄色固体として提供した。収量:2.30g、7.56mmol、89%。1H NMR (400 MHz, CDCl3) δ 6.81 (br s, 1H), [5.36-5.30 (m)および5.25-5.18 (m), JHF=45.2 Hz, 1H], 4.77-4.67 (m, 1H),
4.53-4.42 (m, 1H), 4.42-4.21 (m, 2H), 2.88-2.80 (m, 1H), 0.86-0.79 (m, 2H),
0.64-0.58 (m, 2H).
1,4−ジオキサン(15mL)および水(1.5mL)中の、C22(600mg、1.97mmol)、C16(850mg、3.10mmol)および炭酸セシウム(1.3g、4.0mmol)の混合物を、窒素でのスパージを介して2分間にわたって脱気したら直ぐに、[1,1’−ビス(ジ−tert−ブチルホスフィノ)フェロセン]ジクロロパラジウム(II)(30mg、46μmol)を添加した。反応混合物を100℃で3時間にわたって加熱した後、これを濾過し、真空で濃縮した。逆相HPLC(カラム:YMC−Triart C18、5μm;移動相A:水中0.225%ギ酸;移動相B:アセトニトリル;勾配:42%から62%B)を使用する精製により、生成物を黄色固体として得た。収量:257mg、0.691mmol、35%。LCMS m/z 371.9 (塩素同位体パターンが観察された) [M+H]+.
1H NMR (400 MHz, CDCl3) δ 7.28 (dd, J=9.0, 6.5 Hz, 1H, 推定; 溶媒ピークにより一部不明確), 7.15 (dd, J=8.6, 6.4 Hz, 1H), 6.87 (br s, 1H), [5.37-5.29 (m)および5.25-5.18 (m), JHF=44.9 Hz, 1H], 4.69-4.59 (m, 1H), 4.51
(br dd, J=16.5, 15 Hz, 1H), 4.37 (ddd, ABXYパターンの半分,
J=36.5, 14.6, 3.0 Hz, 1H), 4.25 (dd, J=36.9, 12.8 Hz, 1H), 2.83-2.74 (m, 1H),
0.84-0.76 (m, 2H), 0.63-0.56 (m, 2H).
3−(4−クロロ−2−メチルフェニル)−N−シクロプロピル−6,6−ジフルオロ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド(8)
s, 1H), 4.57 (t, JHF=12.0 Hz, 2H), 4.34 (t, JHF=10.4 Hz,
2H), 2.81-2.72 (m, 1H), 2.17 (s, 3H), 0.81-0.74 (m, 2H), 0.58-0.51 (m, 2H).
3−(4−クロロフェニル)−N−シクロプロピル−5−メチル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド(9)
1H NMR (400 MHz, CDCl3) δ 7.57 (br d, J=8.3 Hz, 2H), 7.31 (br d, J=8.5 Hz, 2H), 6.90 (br s,
1H), 4.47-4.35 (m, 1H), 4.29-4.09 (m, 2H), 2.86-2.75 (m, 1H), 2.30-2.20 (m,
1H), 2.20-2.06 (m, 1H), 1.49 (d, J=6.0 Hz, 3H), 0.85-0.76 (m, 2H), 0.63-0.55
(m, 2H).
3−(4−クロロフェニル)−N−シクロプロピル−7−メチル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド(10)
1H NMR (400 MHz, CDCl3) δ 7.56 (d, J=8.5 Hz, 2H), 7.31 (d, J=8.3 Hz, 2H), 7.00 (br s, 1H),
4.46-4.33 (m, 2H), 4.33-4.25 (m, 1H), 2.85-2.76 (m, 1H), 2.45-2.34 (m, 1H),
2.11-2.01 (m, 1H), 1.64 (d, J=6.3 Hz, 3H), 0.84-0.77 (m, 2H), 0.65-0.58 (m,
2H).
3−(4−シアノ−3−フルオロフェニル)−N−シクロプロピル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド(11)
1,4−ジオキサン(10mL)および水(1mL)中の、P1(200mg、0.73mmol)、(4−シアノ−3−フルオロフェニル)ボロン酸(160mg、0.97mmol)および炭酸セシウム(400mg、1.23mmol)の混合物を、窒素でのスパージを介して2分間にわたって脱気した。ジクロロビス(トリシクロヘキシルホスフィン)パラジウム(II)(10mg、14μmol)を添加し、反応混合物を100℃で16時間にわたって攪拌した。次いで、これを水(50mL)で希釈し、得られた混合物を酢酸エチル(3×100mL)で抽出し、合わせた有機層を飽和塩化ナトリウム水溶液で洗浄し、硫酸ナトリウムで乾燥させ、濾過し、真空で濃縮した。分取薄層クロマトグラフィーにより、生成物を黄色油状物として得た。収量:200mg、0.63mmol、86%。
メタノール(2mL)中の、C23(150mg、0.476mmol)、塩化カルシウム(50mg、0.45mmol)およびシクロプロパンアミン(0.5mL)の混合物を、50℃で2時間にわたって攪拌したら直ぐに、反応混合物を濾過した。濾液を減圧下で濃縮し、逆相HPLC(カラム:Phenomenex Gemini C18、8μm;移動相A:アンモニア水、pH10;移動相B:アセトニトリル;勾配:36%から56%B)に供して、生成物を白色固体として提供した。収量:47.4mg、0.145mmol、30%。LCMS m/z 327.1 [M+H]+. 1H NMR (400 MHz, CDCl3)
δ 7.68-7.60 (m, 2H), 7.55 (dd,
J=7.8, 7.0 Hz, 1H), 6.99 (br s, 1H), 4.41 (dd, J=5.3, 5.0 Hz, 2H), 4.21 (t,
J=6.3 Hz, 2H), 2.86-2.79 (m, 1H), 2.40-2.33 (m, 2H), 0.87-0.81 (m, 2H),
0.65-0.59 (m, 2H).
P1からの3−置換−N−置換−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミドの2ステップ合成
ヒトPDE4A3コード配列(受託番号NP_001104779を持つ配列からの配列2から825)を、精製を補助するためのN末端His6親和性タグおよびC末端FLAG親和性タグを包含するように操作されたバキュロウイルス発現ベクターpFastBac(Invitrogen)にクローン化した。組換えバクミドを単離し、昆虫細胞をトランスフェクトしてウイルスストックを生成するために使用した。精製用の細胞ペーストを生成するために、昆虫細胞をウイルスストックに感染させ、感染72時間後に細胞を採取した。昆虫細胞ペーストを溶解し、遠心分離後、上清をNi−NTAアガロース(GE Healthcare)とバッチ結合(batch bound)させ、250mMのイミダゾールで溶離した。この溶離物をFLAG緩衝液(50mMのトリスHCL pH7.5、100mMのNaCl、5%グリセロール、1mMのTCEPにプロテアーゼ阻害剤を加えたもの)で希釈し、抗FLAG M2アガロース(Sigma)と4℃で終夜バッチ結合させた。アガロースをカラムに詰め、緩衝液で洗浄し、溶離物を含有する緩衝液で、250ug/mlのFlagペプチドを使用して溶離した。SDS−PAGEクマシーブルー染色を使用して画分を分析し、純度に基づいてプールした。プールした画分を、50mMのトリスHCL pH7.5、150mMのNaCl、10%グリセロール、2mMのTCEPにプロテアーゼ阻害剤を加えたもの中、S200 120mlカラム(GE Healthcare)でクロマトグラフした。PDE4A3画分を、SDS−PAGEクマシーブルー染色によって分析し、純度に基づいてプールし、50mMのトリスHCL pH7.5、100mMのNaCl、20%グリセロール、2mMのTCEPに対して透析し、凍結させ、−80℃で貯蔵した。
Claims (36)
- 式I:
R1は、(C3〜C8)シクロアルキル、(4〜10員)ヘテロシクロアルキル、(C6〜C10)アリールおよび(5〜10員)ヘテロアリールからなる群から選択される置換基であり、ここで、前記(C3〜C8)シクロアルキル、(4〜10員)ヘテロシクロアルキル、(C6〜C10)アリールおよび(5〜10員)ヘテロアリールは、1から5個のR5で置換されていてもよく、
R2およびR3は、水素、置換されていてもよい(C1〜C6)アルキル、(C3〜C8)シクロアルキル、(4〜10員)ヘテロシクロアルキル、(C6〜C10)アリールおよび(5〜10員)ヘテロアリールからなる群からそれぞれ独立して選択され、ここで、前記(C3〜C8)シクロアルキル、(4〜10員)ヘテロシクロアルキル、(C6〜C10)アリールおよび(5〜10員)ヘテロアリールは、1から5個のR6で置換されていてもよく、または
R2およびR3は、それらが結合した窒素と一緒になって、(4〜10員)ヘテロシクロアルキルまたは(5〜10員)ヘテロアリールを形成し、ここで、前記(4〜10員)ヘテロシクロアルキルおよび(5〜10員)ヘテロアリールは、1から5個のR6で置換されていてもよく、
存在する場合、R4は、各出現において、ハロゲン、シアノ、ヒドロキシ、−SF5、ニトロ、置換されていてもよい(C1〜C6)アルキル、置換されていてもよい(C2〜C6)アルケニル、置換されていてもよい(C2〜C6)アルキニル、置換されていてもよい(C1〜C6)アルキルチオ、置換されていてもよい(C1〜C6)アルコキシ、−N(R7)(R8)、−N(R7)(C=(O)R8)、−C(=O)N(R7)(R8)、−O−C(=O)−N(R7)(R8)、−C(=O)−R7および−C(=O)−OR7からなる群から独立して選択され、
存在する場合、R5およびR6は、各出現において、ハロゲン、オキソ、シアノ、ヒドロキシ、−SF5、ニトロ、置換されていてもよい(C1〜C6)アルキル、置換されていてもよい(C2〜C6)アルケニル、置換されていてもよい(C2〜C6)アルキニル、置換されていてもよい(C1〜C6)アルキルチオ、置換されていてもよい(C1〜C6)アルコキシ、−N(R7)(R8)、−N(R7)(C=(O)R8)、−C(=O)N(R7)(R8)、−O−C(=O)−N(R7)(R8)、−C(=O)−R7および−C(=O)−OR7からなる群から独立して選択され、
R7およびR8は、各出現において、水素および(C1〜C6)アルキルからなる群から独立して選択され、
aは、0、1、2または3から選択される整数によって表される]
の化合物または薬学的に許容できるその塩。 - R1が、フェニルまたはナフチルから選択される、置換されていてもよい(C6〜C10)アリールである、請求項1に記載の化合物、または薬学的に許容できるその塩。
- R1が、置換されていてもよい(C6〜C10)アリールであり、前記アリールは、フェニルである、請求項2に記載の化合物、または薬学的に許容できるその塩。
- R1が、置換されていてもよい(5〜10員)ヘテロアリールである、請求項1に記載の化合物、または薬学的に許容できるその塩。
- R1が、トリアゾリル、イミダゾリル、フラニル、イソオキサゾリル、イソチアゾリル、1,2,3−オキサジアゾリル、1,2,4−オキサジアゾリル、1,2,5−オキサジアゾリルまたは1,3,4−オキサジアゾリル、オキサゾリル、チオフェニル、チアゾリル、イソチアゾリル、ピラゾリル、ピリジニル、ピラジニル、ピリミジニル、ピリダジニル、インドリル、インダゾリル、ベンゾフラニル、ベンズイミダゾリル、ベンゾチエニル、ベンズオキサジアゾリル、ベンゾチアゾリル、イソベンゾチオフラニル、ベンゾチオフラニル、ベンズイソオキサゾリル、ベンゾオキサゾリル、ベンゾジオキソリル、フラノピリジニル、プリニル、イミダゾピリジニル、イミダゾピリミジニル、ピロロピリジニル、ピラゾロピリジニル、ピラゾロピリミジニル、チエノピリジニル、トリアゾロピリミジニル、トリアゾロピリジニル、キノリニル、イソキノリニル、シンノリニル、キナゾリニル、オキソクロメニルおよび1,4−ベンゾオキサジニルからなる群から選択される、置換されていてもよい(5〜10員)ヘテロアリールであり、そのそれぞれは、1から3個のR5で置換されていてもよい、請求項4に記載の化合物、または薬学的に許容できるその塩。
- R1が、置換されていてもよい(5〜10員)ヘテロアリールであり、前記ヘテロアリールは、ピリジニル、トリアゾロピリジニル、ピラゾロピリジニルおよびベンゾオキサゾリルからなる群から選択される、請求項5に記載の化合物、または薬学的に許容できるその塩。
- R1が、置換されていてもよい(5〜6員)ヘテロアリールであり、前記ヘテロアリールは、ピリジニルである、請求項5に記載の化合物、または薬学的に許容できるその塩。
- R1が、1から3個のR5で置換されており、ここで、各R5は、ハロゲン、シアノ、置換されていてもよい(C1〜C6)アルキルおよび置換されていてもよい(C1〜C6)アルコキシからなる群から独立して選択される、請求項1から7のいずれか一項に記載の化合物、または薬学的に許容できるその塩。
- R5が、フルオロまたはクロロから選択されるハロゲンである、請求項8に記載の化合物、または薬学的に許容できるその塩。
- R5が、置換されていてもよい(C1〜C6)アルキルであり、前記アルキルは、メチル、エチルまたはプロピルから選択され、前記メチル、エチルおよびプロピルは、1から3個のフッ素原子で置換されていてもよい、請求項8に記載の化合物、または薬学的に許容できるその塩。
- R5が、置換されていてもよい(C1〜C6)アルコキシであり、前記アルコキシは、メトキシ、エトキシまたはプロポキシから選択され、前記メトキシ、エトキシおよびプロポキシは、1から3個のフッ素原子で置換されていてもよい、請求項8に記載の化合物、または薬学的に許容できるその塩。
- R2およびR3が、水素、置換されていてもよい(C1〜C6)アルキル、(C3〜C8)シクロアルキルおよび(5〜6員)ヘテロアリールからなる群からそれぞれ独立して選択され、化学的に容認できる場合、前記(C3〜C8)シクロアルキルおよび(5〜6員)ヘテロアリールは、1から3個のR6で置換されていてもよい、請求項1から11のいずれか一項に記載の化合物、または薬学的に許容できるその塩。
- R2およびR3の一方が、水素であり、他方が、置換されていてもよい(C1〜C6)アルキルである、請求項12に記載の化合物、または薬学的に許容できるその塩。
- 前記置換されていてもよい(C1〜C6)アルキルが、メチル、エチル、プロピルおよびイソプロピルからなる群から選択される、請求項13に記載の化合物、または薬学的に許容できるその塩。
- R2およびR3の一方が、水素であり、他方が、1から3個のR6で置換されていてもよい(C3〜C8)シクロアルキルである、請求項12に記載の化合物、または薬学的に許容できるその塩。
- 前記置換されていてもよい(C3〜C8)シクロアルキルが、シクロプロピル、シクロブチルおよびシクロペンチルからなる群から選択される、請求項15に記載の化合物、または薬学的に許容できるその塩。
- 前記置換されていてもよい(C3〜C8)シクロアルキルが、シクロプロピルである、請求項16に記載の化合物、または薬学的に許容できるその塩。
- R2およびR3が、それらが結合した窒素と一緒になって、1から3個のR6で置換されていてもよい、(4〜6員)ヘテロシクロアルキルを形成する、請求項1から11のいずれか一項に記載の化合物、または薬学的に許容できるその塩。
- 前記(4〜6員)ヘテロシクロアルキルが、アゼチジニル、テトラヒドロピラゾリル、テトラヒドロオキサジニル、テトラヒドロピリミジニル、イミダゾリジニル、ピペリジニル、ピペラジニル、オキサゾリジニルおよびピロリジニルからなる群から選択される、請求項18に記載の化合物、または薬学的に許容できるその塩。
- 前記(4〜6員)ヘテロシクロアルキルが、アゼチジニルである、請求項19に記載の化合物、または薬学的に許容できるその塩。
- R6が、ハロゲン、オキソ、シアノ、ヒドロキシ、置換されていてもよい(C1〜C6)アルキルおよび置換されていてもよい(C1〜C6)アルコキシからなる群から独立して選択される、請求項12から20のいずれか一項に記載の化合物、または薬学的に許容できるその塩。
- 各R4が、存在する場合、ハロゲン、シアノ、ヒドロキシ、−SF5、ニトロ、置換されていてもよい(C1〜C6)アルキルおよび置換されていてもよい(C1〜C6)アルコキシからなる群から独立して選択される、請求項1から21のいずれか一項に記載の化合物、または薬学的に許容できるその塩。
- R4が、ハロゲンであり、前記ハロゲンは、フルオロまたはクロロから選択される、請求項22に記載の化合物、または薬学的に許容できるその塩。
- R4が、置換されていてもよい(C1〜C6)アルキルである、請求項22に記載の化合物、または薬学的に許容できるその塩。
- aが、0、1または2から選択される整数である、請求項1から24のいずれか一項に記載の化合物、または薬学的に許容できるその塩。
- 式II:
R2およびR3は、水素、置換されていてもよい(C1〜C6)アルキルおよび(C3〜C8)シクロアルキルからなる群からそれぞれ独立して選択され、ここで、前記(C3〜C8)シクロアルキルは、1から3個のR6で置換されていてもよく、または
R2およびR3は、それらが結合した窒素と一緒になって、1から3個のR6で置換されていてもよい(4〜6員)ヘテロシクロアルキルを形成し、
存在する場合、各R4は、ハロゲンまたは置換されていてもよい(C1〜C6)アルキルから独立して選択され、
存在する場合、R5およびR6は、各出現において、ハロゲン、シアノ、置換されていてもよい(C1〜C6)アルキルおよび置換されていてもよい(C1〜C6)アルコキシからなる群から独立して選択され、
aは、0、1または2から選択される整数である]
の化合物または薬学的に許容できるその塩。 - R2およびR3の一方が、水素であり、他方が、置換されていてもよい(C1〜C6)アルキルであり、前記(C1〜C6)アルキルは、メチル、エチル、プロピルおよびイソプロピルからなる群から選択される、請求項26に記載の化合物、または薬学的に許容できるその塩。
- R2およびR3の一方が、水素であり、他方が、(C3〜C8)シクロアルキルであり、ここで、前記(C3〜C8)シクロアルキルは、シクロプロピルである、請求項26に記載の化合物、または薬学的に許容できるその塩。
- R2およびR3が、それらが結合した窒素と一緒になって、1から3個のR6で置換されていてもよい(4〜6員)ヘテロシクロアルキルを形成する、請求項26に記載の化合物、または薬学的に許容できるその塩。
- 前記(4〜6員)ヘテロシクロアルキルが、アゼチジニルである、請求項29に記載の化合物、または薬学的に許容できるその塩。
- アゼチジン−1−イル[3−(4−クロロ−2−メチルフェニル)−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−イル]メタノン;
3−(4−クロロ−2−メチルフェニル)−N−シクロプロピル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
アゼチジン−1−イル[3−(4−クロロ−2,5−ジフルオロフェニル)−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−イル]メタノン;
アゼチジン−1−イル[3−(4−クロロ−2,3−ジフルオロフェニル)−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−イル]メタノン;
3−(4−シアノ−5−フルオロ−2−メチルフェニル)−N−シクロプロピル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
(6S)−3−(4−クロロ−2−メチルフェニル)−N−シクロプロピル−6−フルオロ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
(6S)−3−(4−クロロ−2,5−ジフルオロフェニル)−N−シクロプロピル−6−フルオロ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
3−(4−クロロ−2−メチルフェニル)−N−シクロプロピル−6,6−ジフルオロ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
3−(4−クロロフェニル)−N−シクロプロピル−5−メチル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
3−(4−クロロフェニル)−N−シクロプロピル−7−メチル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
3−(4−シアノ−3−フルオロフェニル)−N−シクロプロピル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
3−(4−クロロフェニル)−N−シクロプロピル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
3−(4−クロロ−3−フルオロフェニル)−N−シクロプロピル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
アゼチジン−1−イル[3−(3,4−ジクロロフェニル)−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−イル]メタノン;
アゼチジン−1−イル[3−(4−クロロ−3−フルオロフェニル)−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−イル]メタノン;
3−(4−クロロ−2,5−ジフルオロフェニル)−N−シクロプロピル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
3−(4−クロロ−5−フルオロ−2−メチルフェニル)−N−シクロプロピル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
4−[2−(アゼチジン−1−イルカルボニル)−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−3−イル]−2−フルオロ−5−メチルベンゾニトリル;
3−(4−クロロフェニル)−N−シクロプロピル−6,6−ジフルオロ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
アゼチジン−1−イル[3−(4−クロロフェニル)−5−メチル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−イル]メタノン、塩酸塩;
N−シクロプロピル−3−(3,4−ジクロロフェニル)−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
アゼチジン−1−イル[3−(4−クロロフェニル)−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−イル]メタノン;
4−[2−(アゼチジン−1−イルカルボニル)−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−3−イル]−2,6−ジフルオロベンゾニトリル;
アゼチジン−1−イル[3−(3,5−ジフルオロ−4−メトキシフェニル)−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−イル]メタノン;
N−シクロプロピル−3−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド、塩酸塩;
3−(4−シアノ−2−メチルフェニル)−N−シクロプロピル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
N−シクロプロピル−3−[2−(ジフルオロメトキシ)ピリジン−4−イル]−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
3−(5−シアノ−2−フルオロフェニル)−N−シクロプロピル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
N−シクロプロピル−3−(ピラゾロ[1,5−a]ピリジン−6−イル)−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
3−(4−シアノ−2,5−ジフルオロフェニル)−N−シクロプロピル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
3−(6−シアノピリジン−3−イル)−N−シクロプロピル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
アゼチジン−1−イル[3−(3−クロロフェニル)−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−イル]メタノン;
3−(3−クロロフェニル)−N−シクロプロピル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
3−(4−クロロ−3−フルオロフェニル)−N−(プロパン−2−イル)−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
3−(4−クロロ−3−フルオロフェニル)−N−メチル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
3−(4−シアノ−5−フルオロ−2−メチルフェニル)−N−エチル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
3−(4−クロロ−5−フルオロ−2−メチルフェニル)−N−メチル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
3−(4−クロロ−5−フルオロ−2−メチルフェニル)−N−エチル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
3−(4−クロロ−2,5−ジフルオロフェニル)−N−エチル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
3−(4−クロロ−3−フルオロフェニル)−N−シクロプロピル−6−フルオロ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
アゼチジン−1−イル[3−(4−クロロ−2−フルオロフェニル)−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−イル]メタノン;
3−(4−クロロ−2−フルオロフェニル)−N−シクロプロピル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
3−(4−クロロフェニル)−N−シクロプロピル−6−フルオロ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
3−(4−クロロ−2−メチルフェニル)−N−シクロプロピル−6−フルオロ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
3−(3−クロロ−4−フルオロフェニル)−N−シクロプロピル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
3−(4−クロロ−2,3−ジフルオロフェニル)−N−シクロプロピル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
3−(4−クロロ−3,5−ジフルオロフェニル)−N−シクロプロピル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
アゼチジン−1−イル[3−(4−クロロ−5−フルオロ−2−メチルフェニル)−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−イル]メタノン;
アゼチジン−1−イル[3−(4−クロロ−3,5−ジフルオロフェニル)−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−イル]メタノン;
4−[2−(アゼチジン−1−イルカルボニル)−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−3−イル]−2,5−ジフルオロベンゾニトリル;
3−(4−シアノ−5−フルオロ−2−メチルフェニル)−N−シクロプロピル−6−フルオロ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
(6R)−3−(4−シアノ−5−フルオロ−2−メチルフェニル)−N−シクロプロピル−6−フルオロ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
(6S)−3−(4−シアノ−5−フルオロ−2−メチルフェニル)−N−シクロプロピル−6−フルオロ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
(6S)−3−(4−シアノ−5−フルオロ−2−メチルフェニル)−N−シクロプロピル−6−フルオロ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
(6S)−3−(4−クロロフェニル)−N−シクロプロピル−6−フルオロ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
(6R)−3−(4−クロロフェニル)−N−シクロプロピル−6−フルオロ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
(6R)−3−(4−クロロ−5−フルオロ−2−メチルフェニル)−N−シクロプロピル−6−フルオロ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;
(6S)−3−(4−クロロ−5−フルオロ−2−メチルフェニル)−N−シクロプロピル−6−フルオロ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド;および
3−(4−クロロ−2,5−ジフルオロフェニル)−N−シクロプロピル−6,6−ジフルオロ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド
からなる群から選択される、請求項1に記載の化合物、または薬学的に許容できるその塩。 - (6S)−3−(4−クロロ−2−メチルフェニル)−N−シクロプロピル−6−フルオロ−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド、または薬学的に許容できるその塩。
- 4−[2−(アゼチジン−1−イルカルボニル)−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−3−イル]−2−フルオロ−5−メチルベンゾニトリル、または薬学的に許容できるその塩。
- 3−(4−シアノ−5−フルオロ−2−メチルフェニル)−N−シクロプロピル−6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド、または薬学的に許容できるその塩。
- PDE4A、PDE4BおよびPDE4Cアイソフォームによって媒介される疾患または状態に罹患している患者を治療する方法であって、前記治療を必要とする前記患者に、治療有効量の、請求項1から34のいずれか一項に記載の化合物または薬学的に許容できるその塩を投与するステップを含み、ここで、前記疾患または状態が、統合失調症、うつ病、不安神経症、物質乱用、アルツハイマー病、パーキンソン病、多発性硬化症、筋萎縮性側索硬化症、慢性閉塞性肺疾患、炎症、脳卒中、喘息、脳血管疾患およびアレルギー性結膜炎からなる群から選択される、方法。
- 請求項1から34のいずれか一項に記載の化合物、または薬学的に許容できるその塩と、薬学的に許容できる添加剤とを含む、医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662298657P | 2016-02-23 | 2016-02-23 | |
US62/298,657 | 2016-02-23 | ||
PCT/IB2017/050844 WO2017145013A1 (en) | 2016-02-23 | 2017-02-15 | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019505558A true JP2019505558A (ja) | 2019-02-28 |
JP2019505558A5 JP2019505558A5 (ja) | 2020-03-26 |
JP6837072B2 JP6837072B2 (ja) | 2021-03-03 |
Family
ID=58347718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018544154A Active JP6837072B2 (ja) | 2016-02-23 | 2017-02-15 | 6,7−ジヒドロ−5H−ピラゾロ[5,1−b][1,3]オキサジン−2−カルボキサミド化合物 |
Country Status (19)
Country | Link |
---|---|
US (2) | US10323042B2 (ja) |
EP (1) | EP3419979B1 (ja) |
JP (1) | JP6837072B2 (ja) |
KR (1) | KR102148587B1 (ja) |
CN (2) | CN108699080B (ja) |
AU (1) | AU2017223132B2 (ja) |
BR (1) | BR112018015191B1 (ja) |
CA (1) | CA3015166C (ja) |
DK (1) | DK3419979T3 (ja) |
ES (1) | ES2775674T3 (ja) |
HU (1) | HUE048658T2 (ja) |
IL (1) | IL260536B (ja) |
MX (1) | MX2018010177A (ja) |
PL (1) | PL3419979T3 (ja) |
PT (1) | PT3419979T (ja) |
RU (1) | RU2719599C2 (ja) |
SG (1) | SG11201806383TA (ja) |
WO (1) | WO2017145013A1 (ja) |
ZA (1) | ZA201804619B (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3766885T3 (da) * | 2015-06-17 | 2022-08-01 | Pfizer | Tricykliske forbindelser og deres anvendelse som phoshodiesteraseinhibitorer |
BR112020017541A2 (pt) | 2018-03-01 | 2020-12-22 | Board Of Regents, The University Of Texas System | Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, método para inibição de prmt, método para modular expressão de gene, e método para tratamento de uma doença mediada por prmt |
BR112021001608A2 (pt) | 2018-09-10 | 2021-04-27 | Kaken Pharmaceutical Co., Ltd. | derivado de amida heteroaromático inovador e medicamento contendo o mesmo |
JP2022518292A (ja) * | 2019-01-23 | 2022-03-14 | パス セラピューティクス,インク. | ホスホジエステラーゼ4(pde4)阻害によるてんかんの治療方法 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69432629T3 (de) | 1993-01-25 | 2008-01-17 | Takeda Pharmaceutical Co. Ltd. | Antikörper gegen beta-amyloid oder derivative davon und seine verwendung |
DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
EP2305709A1 (en) | 1997-04-09 | 2011-04-06 | Intellect Neurosciences, Inc. | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods for use thereof |
US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
US6929808B2 (en) | 2000-11-03 | 2005-08-16 | Proteotech, Inc. | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants |
GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
WO2001058869A2 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
EP3070100B1 (en) | 2000-02-24 | 2021-07-07 | Washington University St. Louis | Humanized antibodies that sequester amyloid beta peptide |
DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
JP2005503789A (ja) | 2001-08-17 | 2005-02-10 | イーライ・リリー・アンド・カンパニー | 抗Aβ抗体 |
FR2831536A1 (fr) | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr |
US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
AR039774A1 (es) | 2002-05-01 | 2005-03-02 | Wyeth Corp | 6-alquiliden-penems biciclicos como inhibidores de beta-lactamasas |
US20040132708A1 (en) | 2002-05-01 | 2004-07-08 | Wyeth | Process for preparing 6-alkylidene penem derivatives |
DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
MXPA05003621A (es) | 2002-10-09 | 2005-10-19 | Rinat Neuroscience Corp | Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos. |
US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
WO2004110996A1 (en) | 2003-06-19 | 2004-12-23 | Pfizer Products Inc. | Nk1 antagonist |
CA2538220A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
JP2007519707A (ja) | 2004-02-02 | 2007-07-19 | ファイザー・プロダクツ・インク | ヒスタミン−3受容体モジュレーター |
US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
RU2007103816A (ru) * | 2004-07-01 | 2008-08-10 | Мерк энд Ко., Инк. (US) | Ингибиторы митотического кинезина |
BRPI0513959A (pt) | 2004-07-30 | 2008-05-20 | Rinat Neuroscience Corp | anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos |
GB0423356D0 (en) | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
WO2006069081A2 (en) | 2004-12-22 | 2006-06-29 | Washington University In St. Louis | USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY |
PE20061323A1 (es) | 2005-04-29 | 2007-02-09 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos |
ATE493413T1 (de) | 2005-05-12 | 2011-01-15 | Pfizer | Wasserfreie kristalline formen von n-ä1,2- ethoxyethyl)-5-(n-ethyl-n-methylaminoü-7-(4- methylpyridin-2-yl-aminoü-1h-pyrazoloä4,3- |
WO2006126081A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors |
WO2006126082A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
WO2006126083A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors |
TW200716102A (en) | 2005-06-01 | 2007-05-01 | Wyeth Corp | Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors |
WO2006136924A1 (en) | 2005-06-22 | 2006-12-28 | Pfizer Products Inc. | Histamine-3 receptor antagonists |
US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
JP2009514846A (ja) | 2005-11-04 | 2009-04-09 | ファイザー・リミテッド | テトラヒドロナフチリジン誘導体 |
WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
EP2007749A2 (en) | 2006-03-13 | 2008-12-31 | Pfizer Products Inc. | Tetralines antagonists of the h-3 receptor |
RS51885B (en) | 2006-04-21 | 2012-02-29 | Pfizer Products Inc. | PYRIDIN [3,4-b] PYRAZINNES |
WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
CN101631545B (zh) | 2007-01-22 | 2013-03-13 | 辉瑞产品公司 | 治疗性化合物的甲苯磺酸盐及其药物组合物 |
BRPI0912103A2 (pt) * | 2008-05-27 | 2021-04-20 | Astrazeneca Ab | derivados de fenoxipiridinilamida e seu uso no tratamento de estados de doenças mediados por pde4 |
US20110039873A1 (en) | 2009-06-08 | 2011-02-17 | Gaeta Federico C A | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY |
AR079967A1 (es) | 2010-01-26 | 2012-02-29 | Sanofi Aventis | Derivados de acido 3-heteroaroilamino-propionico sustituidos con oxigeno y su uso como productos farmaceuticos |
MD20150071A2 (ro) * | 2013-02-19 | 2016-02-29 | Pfizer Inc. | Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni |
JP6506833B2 (ja) * | 2014-08-06 | 2019-04-24 | ファイザー・インク | イミダゾピリダジン化合物 |
-
2017
- 2017-02-15 AU AU2017223132A patent/AU2017223132B2/en active Active
- 2017-02-15 CN CN201780013020.4A patent/CN108699080B/zh active Active
- 2017-02-15 WO PCT/IB2017/050844 patent/WO2017145013A1/en active Application Filing
- 2017-02-15 PT PT177113305T patent/PT3419979T/pt unknown
- 2017-02-15 US US16/074,290 patent/US10323042B2/en active Active
- 2017-02-15 EP EP17711330.5A patent/EP3419979B1/en active Active
- 2017-02-15 SG SG11201806383TA patent/SG11201806383TA/en unknown
- 2017-02-15 HU HUE17711330A patent/HUE048658T2/hu unknown
- 2017-02-15 ES ES17711330T patent/ES2775674T3/es active Active
- 2017-02-15 CN CN202110445183.8A patent/CN113332292A/zh active Pending
- 2017-02-15 PL PL17711330T patent/PL3419979T3/pl unknown
- 2017-02-15 CA CA3015166A patent/CA3015166C/en active Active
- 2017-02-15 RU RU2018128781A patent/RU2719599C2/ru active
- 2017-02-15 JP JP2018544154A patent/JP6837072B2/ja active Active
- 2017-02-15 KR KR1020187023853A patent/KR102148587B1/ko active IP Right Grant
- 2017-02-15 DK DK17711330.5T patent/DK3419979T3/da active
- 2017-02-15 MX MX2018010177A patent/MX2018010177A/es unknown
- 2017-02-15 BR BR112018015191-2A patent/BR112018015191B1/pt active IP Right Grant
-
2018
- 2018-07-11 IL IL260536A patent/IL260536B/en active IP Right Grant
- 2018-07-11 ZA ZA2018/04619A patent/ZA201804619B/en unknown
-
2019
- 2019-05-31 US US16/427,627 patent/US10738063B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
PL3419979T3 (pl) | 2020-06-29 |
ZA201804619B (en) | 2020-12-23 |
WO2017145013A1 (en) | 2017-08-31 |
US10738063B2 (en) | 2020-08-11 |
CN108699080B (zh) | 2021-05-14 |
HUE048658T2 (hu) | 2020-07-28 |
BR112018015191A2 (pt) | 2018-12-18 |
US10323042B2 (en) | 2019-06-18 |
AU2017223132B2 (en) | 2019-12-05 |
DK3419979T3 (da) | 2020-03-23 |
AU2017223132A1 (en) | 2018-07-26 |
US20190055262A1 (en) | 2019-02-21 |
EP3419979B1 (en) | 2020-01-29 |
SG11201806383TA (en) | 2018-09-27 |
CN108699080A (zh) | 2018-10-23 |
RU2018128781A3 (ja) | 2020-03-24 |
KR102148587B1 (ko) | 2020-08-26 |
RU2018128781A (ru) | 2020-03-24 |
PT3419979T (pt) | 2020-03-26 |
KR20180101568A (ko) | 2018-09-12 |
US20190300546A1 (en) | 2019-10-03 |
MX2018010177A (es) | 2019-01-21 |
IL260536B (en) | 2020-10-29 |
CA3015166A1 (en) | 2018-08-31 |
CN113332292A (zh) | 2021-09-03 |
EP3419979A1 (en) | 2019-01-02 |
BR112018015191B1 (pt) | 2023-10-17 |
ES2775674T3 (es) | 2020-07-27 |
CA3015166C (en) | 2021-08-03 |
JP6837072B2 (ja) | 2021-03-03 |
RU2719599C2 (ru) | 2020-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10669279B2 (en) | Imidazopyridazine compounds | |
US10131669B2 (en) | Pyrazolopyrimidine compounds | |
US10738063B2 (en) | 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | |
OA19120A (en) | Imidazopyridazine compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20181030 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20181112 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200217 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200217 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210115 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210114 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210208 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6837072 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |